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fluorescence intensity at the center (as indicated by arrow) of 3D- plot (E) suggests that CA IXRhoda oligomer is highly efficient to reach deep into the core of the tumor spheroid. (F) Z-stacking
of the spheroid at different sections from 10-100 m with CA IX targeted formulations also reveals
similar findings as noted for the 40-60 µm that had superior fluorescence intensity. Figure (G)
shows the untreated control experiments in comparison with CA IX-Rhoda oligomer and Figure
(H) shows the overall shape of the spheroid from along the three dimensions (x, y, and z)…….102

Figure 5.5. C-4.16 inhibits growth of RCC cell lines derived from WT and Everolimusresistant cells. Cell cultures studies and in vitro cytotoxicity assay of C-4.16, sorafenib,
Everolimus on (WT and Evr-Res) A498 and UOK-262 RCC cell lines. (A, B, and C) Cytotoxicity
data indicates C-4.16 was more potent than FDA approved drugs (sorafenib and everolimus) in
WT A498 and (D, E, and F) WT UOK262. Also, cell cultures studies result on EV-res A498 RCC
cell lines (G and H) indicates that C-4.16 was more effective in inhibiting growth of Evr-res A498
RCC cell lines than sorafenib; however, Everolimus is not inhibiting the growth of Evr-res A498
and UOK262 RCC cell lines as previously published [14]. The data in the GI50 columns represent
mean of three independent experiments. Indicated parental and their respective drug resistant RCC
cells were either untreated (Control) or treated with noted doses of C-4.16 and sorafenib for
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Figure 5.6. High synergistic CI value of C-4.16 with sorafenib combination supports the
hypothesis of selecting the combination to RCC treatment using hypoxia targeting OMs. (A)
Combining very low doses of both drugs will lower the IC50 value significantly as in (D) which
shows the combination index plot for C-4.16 plus sorafenib in the cells for both types A498 RCC
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cell lines indicates very strong synergism between sorafenib and C-4.16. (B) The results also show
that CA IX-C-4.16 was more effective in inhibiting growth of A498 (WT and Ev-res) and to less
extent (C) UOK262 (WT and Ev-res) RCC cell lines than sorafenib and Ev and support that C4.16 was more potent than FDA approved drugs (sorafenib and everolimus). (D) We summarized
IC50 value table for all drugs with all the above mentioned RCC cell lines. (E) In vitro cytotoxicity
assay of CA IX-C4.16 (500 nM) in combination with different doses of sorafenib on Ev-res A498
RCC cell lines indicates that low dose of C-4.16-OMs sensitize sorafenib for inhibiting growth of
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Figure 5.7. (A) Western Blot data indicates that C-4.16 stimulates apoptosis in WT and Evresistant RCC cells in part by upregulating pro-apoptotic CARP-1 and activating SAPKs as
previously shown in [14], and in here P-AKT is indicated as the a protein which is affected much
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Figure 5.8. Reprogramming macrophages with CA IX-C4.16+Sorafenib treatment. (A) Schematic
diagram of the procedure. Raw-264.7 cells were placed into the insert. Then, cells were polarized
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1. CHAPTER 1: LITERATURE REVIEW
1.1.Renal Cell Carcinoma (RCC)
Urologic malignancies of the kidney are responsible for 1.62 % of all cancer deaths in the
United States 2. Also, an age-adjusted incidence rates have elevated approximately 2-3% annually
over the past 30 years 3–6. In 2018, there will be an estimated 65,340 new cases of RCC and over
14,970 deaths 7. Kidney cancer incidence increased from 1997 to 2008 before leveling off 8. The
increase in incidence since late 1990s reflects a rapid increase in early stage disease that has been
associated in part with incidental diagnosis during abdominal imaging and may not represent a real
increase in cancer occurrence 9. The overall mortality rate has fallen an average of 0.6 percent each
year since 2001 as shown in Figure 1.1. The expected RCC incidence and mortality rates in 2018
are double as high in men (42,680 cases) versus women ( 22,660 cases) 7. Kidney cancer is now
the 6th highest occurring cancer in the US and has been continually increasing with over 14,970
patients expected to die from this disease in 2018 7. The fivefold rise in incidence is because of
many factors, such as smoking, obesity, exposure to some environmental agents, renal failure, and
hypertension. The advances in detection technology are likely a result of the widespread utilization
of sensitive imaging such as ultrasonography and computed tomography (CT) for diagnosis of
abdominal or gastrointestinal complaints8.
The most common cancer of the kidney with 72% of all cases is the renal cell carcinoma
(RCC). RCC is heterogeneous in nature and progression of the disease has been difficult to monitor
despite the existence of prognostic scoring systems based on conventional clinical and pathological
indices

10

. RCC is derived from renal tubular epithelial cells and considered as one of the ten

highest common cancers worldwide

11,12

. RCC is lethal urologic malignancy as approximately

third of patients would have developed visceral metastasis during the diagnosis and half of the

2

remaining patients would eventually progress to distant metastases

13

. Survival data of a

population-based cancer indicated that more than 40% of patients with RCC would die from the
disease 14–16, in comparison with bladder and prostate cancers which have approximately half the
mortality rates 17–20.

Figure 1.1. US kidney cancer incidence and mortality. Estimated age-standardized rates of incidence for
both sexes (per 100,000 people) between 1990-2011. Rates are generally higher in males with the higher
mortality rates. Reproduced with permission from Surveillance, Epidemiology, and End Results (SEER)
Program and the National Center for Health Statistics.
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1.1.1. Histological Types of RCCs
since 1990s, significant efforts from researchers and clinicians have been devoted to
promoting the understanding of how molecular genetics drive RCC pathogenesis. The
advancement of research in the histopathological and molecular characterization of RCC disease
over the past few years have resulted into major revisions in its subtype classification

11,12,21,22

.

RCC is a heterogeneous malignancy and involves many different histological subtypes 23, each of
which is distinguished from the other subtypes by the (i) location of the renal tubular epithelium
from which it originates, (ii) the genetic mutations involved in its occurrence, and (iii) the
particular clinical options and outcome of the disease

24,25

as shown in Table 1.1. As shown in

Figure 1.2 , Primary RCC subtypes with ≥5% incidence are clear cell RCC (ccRCC) , papillary
RCC (pRCC), and Chromophobe RCC (chRCC)

26

. Along with ccRCC, other recognized

histological sub-classifications are Type 1 (5%) and Type 2 (10%) papillary RCC, chromophobe
tumors (4-5%) and collecting duct/medullary cell tumors (<1%) as shown in Figure 1.2 21,27. The
other subtypes are very rare (each with total incidence ≤1%)

22

. Also, other known familial

syndromes that might lead to renal tumors have been identified alongside RCC that arise
sporadically. These hereditary subtypes of RCC have a meager rate (approximately 5%) of
occurrence and that involve: (i) Von Hippel-Lindau (VHL) disease; (ii) hereditary papillary renal
cell carcinoma (HPRC); (iii) hereditary leiomyomatosis renal cancer (HLRC); and (iv) Birt-HoggDube (BHD) syndrome 28. Each genetic subtype has characteristic molecular changes, which are
often indicated development of specific histopathological features

29

. Molecular genetic

understanding of hereditary cases contributes a significant insight into the molecular mechanisms
causing cancer initiation and progression. This knowledge particularly would improve the

4

understanding of sporadic RCC and can possibly be converted into the more promising therapeutic
approach for RCC.
1.1.2. Clear Cell Renal Cell Carcinoma
Clear cell RCC is the most common class, and the majority of deaths from kidney cancer
are from this type, and ccRCC will be the focus of this Dissertation

30

. Indeed, considering the

predominance of ccRCC histological manifestations in metastatic disease (83–88%) 31,32, tumors
with non-clear cell histology have been named as non-clear renal cell carcinoma ‘nccRCC’ (Table
1.1) 33–35. Likewise, recent cancer genome reports have explained an apparent complexity of intratumor

36–38

and inter-tumor

27,39

heterogeneity in ccRCC, which could contribute to the

heterogeneous clinical outcomes observed

21,28,40

. Approximately 75% of all clear cell RCC is

correlated with the inactivating VHL gene mutation. Papillary RCC often correlated with the
activation of the Met proto-oncogene and chromosome trisomy while the other histological types
do not have well-defined genetic mutation. Table 1.1 and Figure 1.2 provide a summary of tumor
suppressor genes and oncogenes that might be the leading cause for development of familial and
sporadic RCC 23,41–44. Recently, five new frequently mutated genes associated with the clear cell
RCC were identified. These genes encode four other proteins; KDM6A/UTX, SETD2,
KDM5C/JARID1C and MLL229 which are essential for the methylation and demethylation
process of histone residues and consequently control gene transcription.
Table 1.1. Classification of renal cell carcinoma (RCC) and their associated molecular alterations in
hereditary syndromes associated with renal cell carcinoma. Adapted with permission from 8.
Syndrome
(phenotype
OMIM
reference)

Gene
(position)

Clear cell renal cell carcinoma*

Protein

Incidence of
developing a
kidney tumor
(%)

Median age at
diagnosis
(years)

Other phenotypic
features

5
von Hippel–
Lindau disease
(193300)

VHL (3p25–
26)

pVHL

25–45

40

BAP1 mutant
disease (also
known as tumor
predisposition
disease;
614327)

BAP1
(3p21)

BRCA-associated
protein

No data

SDH-associated
kidney cancer
(185470,
602413, 602690
and 115310)

SDHB
(1p36),
SDHC
(1q23) and
SDHD
(11q23)

Succinate
dehydrogenase
subunits B, C and D

5–15

Fumarate
hydratase

2–21

Hepatocyte growth
factor receptor

No data

<60

Folliculin

34

50

Hemangioblastoma
Pancreatic
neuroendocrine
tumors
Pheochromocytoma
Renal Cysts
Pancreatic Cysts
Ovary cystadenoma
Epididymal
cystadenoma
No data
Breast cancer
Uveal melanoma
Mesothelioma
Other cutaneous
melanocytic tumors
30
Paraganglioma
Carotid body tumors
Pheochromocytoma
Gastrointestinal
stromal tumor

Papillary renal cell carcinoma
Hereditary
leiomyomatosis
and renal cell
cancer (150800)
‡

FH (1q43)

Hereditary
papillary kidney
cancer (605074)
§

MET (7q31)

46
Uterine
leiomyosarcomas
Breast cancer
Bladder cancer
Cutaneous
leiomyomas
Uterine leiomyomas
No additional
features

Multiple tumor types
Birt–Hogg–Dubé
syndrome
(135150)||

FLCN
(17p11.2)

Fibrofolliculomas
and trichodiscomas
Pulmonary cysts
Pneumothorax

6
Tuberous
sclerosis
complex
(191100 and
191092) ¶

TSC1
(9q34) and
TSC2
(16p13)

Hamartin and
tuberin

2–4

Cowden
syndrome (also
known as
multiple
hamartoma
syndrome;
158350) #

PTEN
(10q23)

Phosphatase and
tensin homologue

34

Hyperparathyroi
dism jaw tumor
syndrome
(145001) **

HRPT2
(1q31)

Parafibromin

No data

30
Subependymal giant
cell astrocytomas
Angiomyolipomas
Renal Cysts
Facial angiofibroma
Ungual and
periungual fibromas
Hypomelanotic
macule
Forehead plaque
Cardiac
rhabdomyomas
Connective tissue
naevus
40
Breast cancer
Endometrial cancer
Thyroid cancer
Prostate cancer
Macrocephaly
Intestinal
hamartomatous
polyps
Benign skin tumors
(multiple
trichilemmomas,
papillomatous
papules, and acral
keratoses)
Dysplastic
gangliocytoma of the
cerebellum
No data
Parathyroid
carcinomas
Uterine carcinomas
Renal cysts and
hamartomas
Hyperparathyroidis
m
Parathyroid gland
tumors
Jaw fibromas
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Figure 1.2. Distinct subtypes and distribution of common histological subtypes of renal cell carcinoma
(RCCs). Different types of RCC have different histology and clinical courses and caused by a different
gene profiles. Tumors are accompanied with a significantly poorer prognosis. BHD=Birt-Hogg-Dubé;
FH=fumarate hydratase; VHL=von Hippel-Lindau. Approximately 75% of RCCs are clear cell RCC.
Papillary RCCs make up ~15% of all kidney Cancers and are divided into two types based on staining
features: type 1 (basophilic) and type 2 (eosinophilic). Chromophobe RCCs make up ~5% of kidney tumors.
Additional minor subtypes include medullary RCC, clear cell papillary RCC, acquired cystic diseaseassociated RCC, tubulocystic RCC, mucinous tubular and spindle RCC, succinate dehydrogenase-deficient
RCC, hereditary leiomyomatosis, RCC-associated RCC, and Oncocytoma. Tumors not fitting into any of
these categories are designated as unclassified RCC. Adapted from 25.

1.1.3. Clear Cell-RCC and Von Hippel-Lindau (VHL) Gene Mutation
The most common form of RCC (more than 95%) is clear cell RCC (ccRCC). The mutation
and inactivation of tumor suppressor VHL gene is frequently presented in this malignancy. The
VHL gene is positioned on chromosome 3p25-26 and composed of three exons 35,38,45. It yields 2
transcripts that translate to three proteins (pVHL). The common product (VHL30) is made up of
213 amino acids with a molecular weight of approximately 24 to 30 kDa 46. A second isoform of
pVHL (VHL19) contains 160 amino acids and is approximately 19 kDa

47–50

. The two isoforms

show tumor suppressor activity. Exon 2 is not existed in the second mRNA transcript due to
another splicing and has been recognized to encode a defective protein with no tumor suppressor
activity

51

. Studies had shown that pVHL locates between the nucleus and cytoplasm

52–55

and

8

VHL30 is located mainly in the cytoplasm; however, VHL19 is located mainly inside the nucleus,
revealing that the activities of both isoforms might overlap but are not similar 48,55.
1.1.3.1. Functions of VHL
The function of VHL and the ability to regulate and control protein expression at the posttranscriptional level has been studied extensively. VHL works as substrate recognition component
of an E3 ubiquitin ligase complex and it forms a stable complex and functions as a binding and
substrate recognition component

56,57

for the ubiquitination of targeted proteins. As a result,

covalent binding of polyubiquitin residues onto the specific site of substrate protein promotes
proteasomal degradation of the target protein

58

. For example, ligase-E3 complex ubiquitylates

HIF1α and HIF2α for proteasome-mediated degradation 59–61. As shown in Figure 1.3, both HIF1α and HIF-1β subunits which are the heterodimeric HIF-1 are a sequence-specific DNA-binding
transcription factor

62,63

. The modulation of the expression of HIF-1α regulates the transcription

function of HIF-1 as the subunit HIF-1β is expressed genetically in cells

64

. The HIF subunits

respond to changes in oxygen in the cellular environment and are unstable in normoxic
microenvironments. Under normoxic conditions, the highly conserved proline residues inside the
oxygen-dependent degradation (ODD) domain of HIF-1α subunit are hydroxylated

65–68

. The

asparagine sites at the COOH-terminal transactivation domain (CAD) of HIF-1α are further
hydroxylated by an enzyme called asparaginyl hydroxylase, Factor Inhibiting HIF1 (FIH-1)

69

.

Hydroxylation of HIF-1α by FIH-1 inhibits the association of HIFs with the transcriptional
coactivator CREB-binding protein (CBP)/p300; therefore, suppressing transcription activation.
Alternately, HIF-1 binds to the β domain of pVHL, goes through polyubiquitination and
subsequent degradation by the proteasome

70–72

. Under hypoxic conditions, the pVHL-HIF

interaction is disordered due to the lack of oxygen-dependent hydroxylation of particular proline

9

and asparagine residues on HIF-1α; as a result, leading to active stabilization and translocation of
HIF-1 to the nucleus. The HIF-1 complex binds to hypoxia response elements (HREs) in the target
gene promoter origins and activates transcription as shown in Figure 1.3.

Figure 1.3. Schematic role of pVHL in Hypoxia-inducible factors (HIF) pathway. pVHL is the crucial
part of an ubiquitin ligase protein complex that involves elongin C (EloC) and other partners. Under
normoxic conditions HIFα is hydroxylated on two proline residues by prolyl hydroxylase 2 (PHD2), then
conjugates to pHVL that targets it for ubiquitylation and proteasomal degradation. Under hypoxic
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condition, HIF 1α is stabilized, binds to HIF1β and lead to expression of several downstream genes
including VEGF, PDGFβ, TGFα and EPO. pVHL/HIF oxygen sensing pathway. HIFs are transcription
factors that are affected by the changes in available oxygen in the cellular microenvironment. In conditions
of physiologic oxygen availability and normal VHL gene function, pVHL is the substrate recognition
component of an ubiquitin ligase complex that targets HIFs for proteolysis. In conditions of cellular
hypoxia, the pVHL-HIF interaction is disrupted due to the loss of oxygen-dependent hydroxylation of
specific proline residues on HIF, thus leading to active stabilization and translocation of HIF to the nucleus.
When the VHL gene is defective, this interaction is dysfunctional even in the presence of adequate oxygen.
As such, HIF is not subjected to proteolysis and this leads to constitutive activation of the hypoxia response
pathway and transcriptional activation of genes involved in tumor proliferation. Adapted with permission
from 73.

1.1.3.2. VHL Inactivation
VHL has the mutations in α- and β- domain which is responsible for abrogation of protein
binding and degradation because of malfunction in assembly of the VHL ubiquitin complex. In
RCC, all familial VHL-related, and around 75% of occasional cases, harbor the biallelic VHL
functional inactivation through lack of heterozygosity, promoter methylation or intragenic deletion
74–76

. Because of the malfunction of VHL gene, the interaction between VHL-HIF-1 becomes

defective despite the presence of adequate oxygen. Intrinsically, HIF-1 is not required for
proteolysis, and this induces consequent activation of the hypoxia responsive pathway and genes
transcriptional activation associated with tumor proliferation. Genes linked to short-term hypoxic
condition involve inducible nitric oxide synthase (iNOS) to amplify vasodilation, glycolytic
enzymes to elevate glycolysis, glucose transporter-1 (GLUT-1) to have more glucose uptake,
pyruvate dehydrogenase kinase (PDK1) to block mitochondrial respiration, and cyclin-dependent
kinase inhibitors p21 and p27 to minimize cell proliferation. When cells lack functional VHL gene,
chronic cellular adaption is attained via the help of hypoxic condition by promoting angiogenesis.
These pro-angiogenic genes are majorly controlled by HIF and involve vascular endothelial
growth factor (VEGF) and its receptors (VEGFR), platelet-derived growth factor (PDGF), and
basic fibroblast growth factor (bFGF).

11

The tumor suppressor function of VHL regulates the activity of hypoxia-inducible factor
(HIF). As a result, lack of VHL gene will lead to the abnormal accumulation of HIF proteins even
insufficiently oxygenated tissue microenvironment, which consequently results in uncontrolled
activation of HIF target genes that control angiogenesis, glycolysis and apoptosis (Figure. 1.3).
Subsequently, human ccRCC tumors are rich in lipids and glycogens, and are greatly vascular 77,78
which makes anticancer agents that primarily block VEGF and its receptor VEGFR therapeutically
active for metastatic ccRCC 33,34,79. VHL loss alone however is inadequate to produce ccRCC, as
demonstrated by the long latency (>30 years) in patients who harbor VHL mutations to develop
ccRCC

80

and by the fact that lack of VHL in mice does not cause ccRCC

81

. These outcomes

indicate that additional genetic and epigenetic events are apparently required for ccRCC to occur
82

. To recognize these events, large-scale RCC genomic research has thus far indicated multiple

new prevalent mutations in ccRCC. Complete molecular characterization of more than 400 clear
cell RCC tumors identified more than 19 genes with extensive mutations, some of which changed
cell metabolism and correlated with poor survival, suggesting new opportunities for therapeutic
targets 83.
1.1.4. Therapy Models of RCCs
RCC is tough to treat as the cells are largely resistant to many current therapies. Surgery
continues to be the best treatment choice 8, although 20-30% of patients progress to develop
metastatic disease. In case of early diagnosis, there is a high chance of the cancer going into
remission but if the cancer does not respond to first-line therapies there are very limited secondary
options

8,32,35,84,85

. The most important treatment for many years has been cytokine therapy with

interferon alpha (IFN-αa) and interleukin-2 (IL-2). There has been a host of new FDA approved
chemotherapeutic agents now approved for treatment of metastatic RCC including tyrosine kinase

12

inhibitors, mTOR inhibitors, and monoclonal antibodies 86. Currently, FDA approved treatments
for metastatic RCC include (i) tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, and
cabozantinib; (ii) mammalian target of rapamycin (mTOR) inhibitors such as temsirolimus and
everolimus; and (iii) immunotherapeutic agents as PD-1/PD-L1 inhibitors.
1.1.4.1.Surgery
In some early stages of RCC, surgery by radical nephrectomy remains the best treatment
choice for localized RCC, provided tumors can be excised with an appropriate surgical margin.
Under this stage, the prognosis is excellent and hence, it is considered as the “gold standard”
among treatment models. The surgery involves early ligation of the renal vessels, removing the
kidney outside the Gerota's fascia, with or without removing of the adrenal gland depending on
tumor sites and invasiveness score

87,88

. Data and reports indicated that 5-year survival rate of

75% or more after radical nephrectomy for stage I tumors are achieved 89,90. Even though, about
third of the RCC cases that were treated with radical nephrectomy eventually experience a local
recurrence or distant metastasis 91, with the incidence based on tumor stage and grade 92,93. If the
kidney cancer is contained within the kidney, the cancer can be surgically removed with robotic
partial nephrectomy. This surgery cuts out the cancer, and saves 50-75% of the remaining kidney,
which can function sufficiently to keep the patient off hemodialysis. As reported earlier, about
third of cases exhibit visceral metastasis at diagnosis time 94. The overall clinical prognosis differs
from less than 1 year for approximately half of the cases to more than 5 years for 10% of the
patients 95.
1.1.4.2.Chemotherapy and Radiotherapy
Treatment options for metastatic RCC are insufficient because it is unresponsive to usual
chemotherapeutic agents and radiotherapies; therefore, it remains one of the most difficult tumors

13

to treat

96,97

. Over 30% of people who are diagnosed with renal cancers will have cancer spread

outside the kidney to the lymph nodes or distant metastases. With new FDA approved
chemotherapeutic agents now approved for treatment of metastatic RCC, the survival has still been
low. Unfortunately, renal cancers cells are usually resistant to chemotherapy; therefore, chemo
drugs are not a standard treatment option for RCC. Some chemo drugs, such as vinblastine,
floxuridine, 5-fluorouracil (5-FU), capecitabine, and gemcitabine have been utilized and shown to
benefit a small population of patients. Importantly, chemo is often only used for kidney cancer
after targeted drugs and/or immunotherapy have already been tried and failed. In the last few
years, cytokine-based immunotherapy using interleukin (IL)-2 or interferon (IFN)-α have been the
only therapy that have shown efficacy for metastatic RCC cases. However, it is still unsatisfactory
option as only a low percentage of patients (10-15%) respond to this treatment type but often with
severe side effects 98–101.
1.1.4.3. Molecular targeted therapy for RCC
VHL inactivation leads to higher intracellular level of hypoxia-inducible factors 1α and 2α
(HIF1α and HIF2α). The increased level of HIF-1α in RCC effectively regulates the tumorigenesis
by secreting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF),
modifying the cellular metabolism, inhibiting apoptosis pathway, acclimatizing to acidic pH, and
up-regulating metastasis associated proteins. All these factors promote RCC to develop resistance
against radiotherapy and conventional chemotherapy

2,32,85,102

. Several receptor tyrosine kinase

inhibitors (RTKIs), mammalian target of rapamycin inhibitors (mTOR) and serine-threonine
kinase (STK) inhibitors are clinically approved for treatment of RCC 2,32, although the benefit of
overall progression-free survival continues to be very poor (5-year survival rate of <10%).Thus,
there is an urgent need for targeted combination therapies with novel mechanisms

85

. RCC is
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generally difficult to treat since the cancer cells are largely resistant to currently available
therapies. When RCC fails to respond to first-line therapies there are very limited secondary
options. For example, everolimus (inhibitor of mTOR) is the first drug that was recently developed
as a secondary treatment option for resistant RCC. It is very clear that newer and more effective
treatment strategies for RCC are needed. In patients with an advanced form of RCC, targeted
therapies including the ones using Everolimus resulted in improved clinical outcomes. However,
patients ultimately develop resistance to this targeted therapy as well 103.
It is known that the pVHL/HIF molecular pathway is a crucial factor in the pathogenesis
of cc-RCC

104–106

. As previously also reported, biallelic VHL mutation or inactivation by

methylation occurs in majority of cases (~75%) of sporadic clear cell RCC

74,75

. Importantly,

multiple strategies are being investigated to target the various aspects of this hypoxic sensing
pathway and its associated molecules and growth factors. One strategy which has proven to be
highly effective is the activity of agents that specifically target angiogenesis. RCC is manifested
with highly vascular nature in both the primary and metastatic origins of the disease. This is
because of the continuous overexpression of pro-angiogenic factors, VEGF 107 and PDGF, which
are the most important factor in RCC tumor angiogenesis. The molecular association between
VHL, VEGF, and hypoxia signaling pathway in the biology of cc-RCC has revealed the
angiogenesis pathway as an important therapeutic approach. Moreover, the introduction of agents
that target angiogenesis has advanced the treatment strategies and effectively improvise the
management of patients with metastatic RCC. Significant advantages to patients include
management of the cancer, improvement in the quality of life and increase the overall duration of
survival 101,108–110.
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Now, there are more than six molecular targeted therapeutic agents that have been
approved by the US Food and Drug Administration (FDA) for treatment of metastatic RCC. They
are (i) tyrosine kinase inhibitors (TKIs); sunitinib, sorafenib, pazopanib, and cabozantinib which
inhibit the tyrosine kinase activation domain of vascular endothelial growth factor receptor
(VEGFR) and platelet-derived growth factor receptor (PDGFR), (ii) mammalian target of
rapamycin (mTOR) inhibitors temsirolimus and everolimus, and (iii) a monoclonal VEGF
antibody, bevacizumab in combination with IFN-α (Figure 1.4 and 1.5). A summary of the clinical
efficacies of these approved therapeutic agents is listed in Table 1.3.

Figure 1.4. VHL inactivation in clear cell RCC and its implication in targeted therapy. Loss of VHL
(which encodes pVHL) is the most frequent genetic feature of ccRCC. Its loss relieves the cell of negative
regulation of the hypoxia-inducible factors (HIFs), which results in increased HIF target gene expression
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and ensuing changes in cellular metabolism and signaling that enhance cell survival. For example, increased
vascular endothelial growth factor (VEGF) expression increases angiogenesis in concert with increased
growth factor signaling in endothelial cells in the tumor microenvironment (including fibroblast growth
factor (FGF) and hepatocyte growth factor (HGF)). Consequently, these changes provide the targets for
therapeutic agents to impede tumor growth, as shown. The dashed inhibitory line indicates indirect
inhibition shown in limited reports. EIF4EBP1, eukaryotic translation initiation factor 4E‑binding protein
1; FGFR, FGF receptor; HRE, HIF response element; MET, hepatocyte growth factor receptor; mTORC,
mechanistic target of rapamycin complex; PI3K, phosphoinositide 3‑kinase; PTEN, phosphatase and tensin
homologue; RHEB, GTP-binding protein Rheb; S6K1, ribosomal protein S6 kinase; TSC, tuberous
sclerosis complex; VEGFR, VEGF receptor. Adapted with permission from 8

Figure 1.5. Selected current targeted therapies in metastatic RCC. Modified from 111.

1.1.4.4.Anti-Angiogenesis therapy
Antiangiogenic drugs that block the vascular endothelial growth factor receptor (VEGFR)
pathway are now standard first-line treatment in metastatic RCC. They are also used sequentially
to prolong clinical benefit in patients with recurrent disease 8,112,113. However, resistance to therapy
ultimately emerges in most patients, and further understanding of the underlying biology and
potential therapeutic targets are urgently needed for clinical translation 8. Everolimus is one such
drug that was recently developed as a secondary treatment option for resistant RCCs

85,96,114

.
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However, resistance to newer drugs (including Everolimus) continues to emerge. Therefore, newer
drug molecules with a different mechanism of action and novel targeted drug delivery approaches
are needed to address the safety and efficacy of newer therapies. In addition, the introduction of
several anticancer small molecule drugs (e.g., sunitinib, pazopanib, axitinib, temsirolimus, and
everolimus) has rapidly changed the treatment of metastatic RCC 8,96,113. Although the impact on
RCC progression is encouraging, a substantial proportion of patients do not respond sufficiently,
and resistance to therapy almost inevitably occurs

102

. Possibly combination treatments aimed at

different, non-related pathways may be advantageous

85,115,116

. Due to their increase in vascular

nature and high level of vascular permeability factor or vascular endothelial growth factor (VEGF)
expression, ccRCC patients show promising success with anti-VEGF cancer therapy.
Unfortunately, most of cancer patients ultimately develop a refractory response to anti-VEGFR
treatment over time.
1.1.4.5.Immunotherapy for RCC
On November of 2015, the FDA approved Nivolumab (Opdivo®) for the treating of
patients with advanced metastatic RCC and who already have received a specific prior antiangiogenic cancer treatment. The FDA approval was based in part on an open-label, randomized
clinical trial including 821 cases with advanced metastatic RCC. The trial included those whose
disease status had deteriorated after or while on therapeutic plan with an anti-angiogenic
medications. A certain percentage of cases received Nivolumab, while the rest took everolimus
(Afinitor®). The Nivolumab group had an overall survival rate of more than 25 months compared
to 19.6 months in Everolimus group. Furthermore, complete or partial tumor growth suppression
lasting an average of 23 months was seen in 21.5% RCC patients of the Nivolumab treatment arm,
compared to 13.7 months in 3.9% of the Everolimus treatment arm 117.
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Table 1.2. (A) A summary of approved targeted therapies for metastatic RCC. Modified from Hutson et
al., 2011. Adapted with permission. (B) Clinical trials leading to newly approved drugs for advanced renal
cell carcinoma.
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1.1.5. Disadvantages and Limitations of Current Targeted Therapy
Despite the treatment advantages of agents targeting anti-angiogenic pathways, mostly
60% of the cases are non-responsive to these medications. Anti-angiogenic targeted agents are
estimated to have less toxicity than conventional chemo and radiotherapy approach due to the
higher dependence of cancerous cells on this pathway as compared to healthy cells. Also, they
might cause significant side effects that need to minimize the dose; therefore, restricting its clinical
utility and efficacy

118,119

. For instance, up to third of cancer patients on sorafenib needed dose

reduction and of these, 50% stopped treatment because of the side effects. Another disadvantage
of anti-angiogenic targeted therapy is that many active oncogenic pathways is mostly involved in
oncogenesis. The utilization of a single treatment class will invariably stimulate tumor cell
adaption by releasing higher amount of the many targeted growth factors.

120

. In view of the

existing limitations of the current molecular single targeted therapy, sequential treatment with
various targeted medications is advanced to be the standard strategy for the treatment. The efficacy
of combination treatment strategy thus urgently need a better understanding of the biology of the
cancer disease development, and mechanisms of action of the anticancer agents for effective
utilization in combination.
1.1.6. Combinations and Sequential Treatment for RCC
Anticancer agents that are synergistic or additive would ensure higher inhibition of
abnormal molecular target and their related signaling pathways. Moreover, combination therapy
can bypass or hinder the development of resistance. In addition to finding molecular targets for
RCC and anticancer agents that can work on these targets, another important need is to find a
molecular biomarker that can predict therapeutic outcomes in RCC. Currently, classical clinical
and pathologic indices provide reasonable evaluations of cancer patient response and disease

20

development

10

but are inadequate for patients’ disease management given the heterogeneous

nature of RCC. In essence, there is a crucial need for potential molecular biomarker which can be
used to detect disease remission after therapeutic intervention and improve the accuracy of current
prognostic indices. Also, the biomarkers will complement classical pathological and clinical
indices utilized in monitoring tumor progression and the disease status. Therefore, the need for a
suitable therapeutic target and an ideal molecular biomarker to predict responses of treatment in
RCC remain critical and unmet need. Importantly, a patient-derived RCC xenograft or PDX model
can be utilized for preclinical drug evaluation to find molecular targeted biomarkers capable of
estimating therapeutic efficacy response to the new agents

121

. This approach will save time for

finding new strategy and further pave the way into clinical translation.
1.2. Carbonic Anhydrase IX Targeting in Renal Cell Carcinoma
Carbonic anhydrase IX (CA IX) is a membrane-bound protein overexpressed on the surface
of many cancer cells in a hypoxic environment

122

. Carbonic anhydrase enzymes tightly control

the acid-base balance in the kidney 122. CA IX is involved in tumor cell survival and metastasis,
and increased expression correlates with poor clinical outcome. As shown in Figure 1.6 the overexpression of CA IX has been demonstrated in 93-97% of ccRCC with limited expression in
normal tissues/organs
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tissues and malignancies
the ccRCC subtype

. Numerous studies have confirmed the CA IX distribution in normal
124–129

84,111,124–129

. For renal cancer, CA IX is almost homogeneously expressed in

. Given the favorable tissue distribution, the potential of CA IX

targeting of RCC for diagnosis or therapy has been studied extensively 130,131. Due to the unique
molecular basis of ccRCC, CA IX is regarded as an excellent target for diagnosis and possibly for
therapy 111,126–128,132. Clinical trials have unambiguously demonstrated that CA IX can be targeted
in RCC tissues without damage to normal tissues133,134 However, there are no approved therapies
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against CA IX 135. Monoclonal antibodies have been used to target CA IX, but their large molecular
weight limits penetration throughout a poorly vascularized tumor and their slow blood clearance
minimize their utilization as tumor imaging agents or radiotherapeutics because of high
background and toxicity 134,132. Finally, the new therapeutic options have led to investigations that
examine whether small molecule CA IX-inhibitors can be used in serum assays or as an imaging
target to study whether CA IX monitoring can be useful to predict responses

127–129

. The future

will show whether the conjugation of CA IX as a targeting moiety can be helpful in the treatment
and clinical management of metastatic RCC.
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Figure 1.6. CA IX Expression and its role in cancer. Carbonic anhydrase IX (CA IX) which is a zinc
containing metalloproteinase is efficiently catalyzes the reversible hydration of carbon dioxide. It is upregulated in several cancer types. It has an important role in tumor progression, acidification and metastasis.
Figures modified and adapted from many references as shown above 136.

1.3. CARP-1 Functional Mimetics as a promising molecule to target Everolimus
Resistant Renal Cell Carcinoma Therapy
CARP-1 (Cell cycle and apoptosis regulator 1, aka CCAR1) is a peri-nuclear phosphoprotein and a regulator of cell growth and apoptosis signaling CARP-1 (Cell cycle and apoptosis
regulator 1, CCAR1) is a peri-nuclear phospho-protein and a regulator of cell growth and apoptosis
signaling

137–140

. CARP-1 not only works as a transcriptional co-activator of steroid family of

nuclear receptors and a regulator of adipogenesis through the glucocorticoid receptor (GR), it also
regulates Adriamycin (ADR)-dependent apoptosis in part through co-activation of p53

141,142

.

CARP-1 expression is often elevated in cells experiencing stress due to growth factor withdrawal
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or chemotherapy-induced cell cycle arrest and apoptosis 137,138,141. Knockdown of CARP-1 resulted
in resistance to apoptosis by ADR or EGFR tyrosine kinase inhibitors demonstrating the
requirement of CARP-1 in cell growth inhibitory and apoptosis signaling by these agents 137,138,141.
CARP-1 as shown in Figure 1.7 also works as a co-activator of the APC/C E3 ligase

139

. APC/C

is a multi-subunit ubiquitin E3 ligase protein that plays a distinct role in cell cycle transitions, and
misregulation of APC/C substrates such as securin, polo-like kinase (Plk) has been demonstrated
to correlate with tumor progression

143,144

. A chemical biology-based high-throughput screening

of a chemical library resulted in the identification of some novel, small molecule inhibitors (SMIs)
of CARP-1 binding with APC/C subunit APC2. These compounds, termed CARP-1 functional
mimetic (CFMs), inhibit cell growth by inducing apoptosis in various cancer types as the NCI 60panel screening indicated including non-small cell lung cancers (NSCLC), triple negative breast
cancers (TNBC) and RCC

145

. Recently, a promising library of a novel class of anticancer

compounds termed CARP-1 functional mimetics (CFMs) that inhibit cell growth by various
mechanisms such as inducing apoptosis has been developed for resistant RCC. In the case of renal
cell carcinoma (RCC), antiangiogenic drugs that block the vascular endothelial growth factor
receptor (VEGFR) pathway are now standard first-line treatment in metastatic RCC. They are also
used sequentially to prolong clinical benefit in patients with recurrent disease

30

. However,

resistance to therapy ultimately emerges in most patients, and further understanding of the
underlying biology and potential therapeutic targets are urgently needed for clinical translation 102.
Everolimus is one such drug that was recently developed as a secondary treatment option for
resistant RCCs

96,114

. However, resistance to Everolimus continues to emerge. Therefore, newer

drug molecules with a different mechanism of action and novel targeted drug delivery approaches
need to be developed to address the safety and efficacy of newer therapies. Also, the molecular
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complications of cancer manifestations and therapy-associated adverse effects often hinder the
effectiveness of many therapies and warrant discovery of effective alternative therapy for certain
molecular targets while minimizing the off-target effects. Therefore, the objective of most research
worldwide is to develop novel, safe and effective anti-cancer therapies and that is the focus of this
dissertation. One of these targets for drug discovery is CARP-1 that is an inhibitor of cell growth
and survival, as well as an inducer of apoptosis signaling.

Figure 1.7. A Schematic representation of CARP-1/CCAR1 Apoptosis Signaling. Adapted from 140.

1.3.1. Combination therapy advantage of CARP-1 Functional Mimetics with TKIs
The introduction of several anticancer small molecule drugs (e.g., sunitinib, pazopanib,
axitinib, temsirolimus, and everolimus) has rapidly changed the treatment of metastatic RCCs
112,113,146,147

. Although the impact on disease progression is encouraging, a substantial proportion

of patients do not respond adequately, and therapy resistance almost inevitably occurs 103. Possibly
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combination treatment aimed at different, non-related pathways may be advantageous

112,113,146

.

Due to their increase in vascular nature and high level of vascular permeability factor or vascular
endothelial growth factor (VEGF) expression, ccRCC patients show promising success with antiVEGF cancer therapy. Unfortunately, most of cancer patients ultimately develop a refractory
response to anti-VEGF treatment over time. In this regard, novel therapeutic strategies for
nonresponsive, highly aggressive tumor types to tackle the current clinical challenges are needed.
Concurrently, we would like to perceive the molecular mechanism of these untreatable tumor types
by using patient samples and utilizing different approaches. We speculate that the proposed
experimental plan will be supportive to design new treatment options for lasting and sensitizing
anti-angiogenic effects and better clinical management with the help of novel anticancer agents as
CFMs. Also, we will work on different models of RCC, with a poor prognosis and because of their
modest or non-response to systemic therapy. We will pursue different combination regimens,
including drugs that work on the mTOR inhibition (everolimus), inhibit VEGFR (cabozantinib or
sorafenib), because elevation in VEGF and CA IX levels are expected to happen in response to the
hypoxic tumor environment. Escape from sorafenib and cabozantinib blockade of the VEGFR and
mTOR inhibition of everolimus may also occur if levels of VEGF exceed a threshold that can
circumvent the blockade. Toxicity was shown to be variable, and that will be taken into
consideration. Even though in some combinations, both agents seem to be tolerable when utilized
in full doses (Temsirolimus or everolimus with bevacizumab). In many instances the combination
has shown not to be safe or feasible as a singular agent because combinations have required dose
reductions (sorafenib with bevacizumab, Temsirolimus with sorafenib) or are not safe to be
administered together (Temsirolimus with sunitinib, bevacizumab with sunitinib) 85,116,147–149.
1.4. Can Nanotechnology help improve drug delivery for RCC?
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When cancer metastasizes outside of the kidney, it becomes even more complicated to treat
and control. One challenge to overcome is delivery of agents targeted to metastatic cancer.
Nanotechnology can combine the drug delivery system with anticancer drugs to target cancer and
augment the cellular kill with higher concentrations to deliver drugs to cancer will need to be
tested. One challenge to overcome is the delivery of these medications to metastatic cancer which
has spread outside the kidney. Nanotechnology is the engineering of novel small molecules to
direct treatment. To let cancer agents interact with cells and molecules, these drugs and carriers
should have uniform particle size. One property is the high surface area to volume ratio, meaning
one can encapsulate drugs to the nanoparticle in high concentrations. Therefore, the concentration
of the delivery of the drug to cancer can be increased many folds 150.
One such solution is the use of nano-sized micelles as delivery vehicles for cancer
therapeutics. Amphiphilic polymers self-assemble under aqueous conditions to form water-soluble
micelles with a hydrophobic core. Hydrophobic drugs can then be chemically or physically
incorporated into the micelle core for parenteral administration. This micelle drug delivery strategy
has been applied to a variety of medical conditions, from hepatic fibrosis to knee osteoarthritis
151,152

. However, the micelle technique renders itself particularly relevant for the treatment of

different types of solid tumor because of selective accumulation at the target site resulting from an
enhanced permeability and retention (EPR) effect

153–156

. EPR is a phenomenon by which

macromolecules, notably nanoparticles (NPs) and micelles, are delivered to, and accumulate at the
tumor site in higher concentrations than are observed in healthy tissue because of anatomical and
pathophysiological abnormalities or the leaky tumor vasculature of the tumor tissues

153–155

.

However, angiogenesis is not always uniform throughout a tumor, leading to disproportional drug
distribution by EPR; additionally, in some cases, tumors can exist with little or no evidence of EPR
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153,155

. Passive targeting by the EPR effect is a promising means of overcoming the specificity

challenge of modern chemotherapeutic agents in many cases. Furthermore, newer active targeting
strategies have been developed and can add to the selectivity of the EPR effect to overcome above
noted limitations.
Moreover, there is a critical need to develop safe and effective delivery vehicles that can
carry the payload to the specific target tissue and cell. Different types of nanoparticles recently
emerged as an excellent delivery system. The CFM compounds have poor aqueous solubility and
consequently poor bioavailability for their use and development as potential anti-cancer agents157–
160

. To address this issue, nanolipid formulations (NLFs) of CFM-4 and CFM-4.16 compounds

were generated using chemically conjugated SMA-TPGS block polymer, then addition of DMSO
contained the drug to the aqueous phase of polymer, followed by stirring, separation of
unencapsulated drugs using Tangential Flow Filtration

161,162

. The NLFs caused in a significant

enhancement in overall bioavailabilities of CFM-4 and CFM-4.16 when compared with respective
free compound. Nanoparticles that encapsulate CFMs also protect them from premature clearance
and degradation.
1.4.1. Rationale Novel Designed Theranostics Nano-platforms Utilizing Multiple
Linkers with Click chemistry
In the proposed studies we will utilize a nanotechnology-based approach to address the
poor aqueous solubility of a potent CFM compound (CFM-4.16) that has restricted its clinical
development as a therapeutic agent. Our preliminary data thus far revealed that we have been
successful in overcoming the solubility concerns of CFM-4.16 by encapsulating it in water-soluble
vitamin E TPGS based nano-formulation that enabled high drug loading (up to 30% w/w of drug
equivalent) and afforded its intravenous administration for animal testing. Since there is a critical
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need to develop safe and effective delivery vehicles that can carry the payload to the specific target
tissue and cell, different types of nanoparticles have been developed to deliver a variety of
therapeutic agents. They have recently emerged as an excellent delivery system. Nanoparticles
need to encapsulate CFMs and protect them from premature clearance and degradation. Ideally,
they need to be loaded and functionalized with targeting ligands such as CA IX, which may
potentially improve the delivery, specificity, and efficacy.
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2. CHAPTER 2. RESEARCH OBJECTIVES
2.1.Introduction
Cancer remains the second cause of mortality worldwide. Throughout the last decade, cancer
incidence has constantly and sharply increased all over the world. The molecular complications
of cancer manifestations and therapy-associated adverse effects often hinder effectiveness of many
therapies and warrant discovery of alternative effective therapy for certain molecular targets while
minimizing the off-target effects. Therefore, the objective of most research worldwide is to
develop novel, safer and more effective anti-cancer therapies. One of these targets for drug
discovery works based on cell growth and survival inhibiting functions of an apoptosis regulatory
protein, termed CARP-1. CARP-1 (Cell cycle and apoptosis regulator 1, aka CCAR1) is a perinuclear phospho-protein and a regulator of cell growth and apoptosis signaling 137–140 CARP-1 not
only functions as a transcriptional co-activator of steroid family of nuclear receptors and a
regulator of adipogenesis through the glucocorticoid receptor (GR), it also regulates Adriamycin
(ADR)-dependent apoptosis in part through co-activation of p53

141,142

. CARP-1 expression is

often elevated in cells experiencing stress due to growth factor withdrawal or chemotherapyinduced cell cycle arrest and apoptosis 137,138,141. Knockdown of CARP-1 resulted in resistance to
apoptosis by ADR or EGFR tyrosine kinase inhibitors, demonstrating requirement of CARP-1 in
cell growth inhibitory and apoptosis signaling by these agents 137,138,141.
2.2.Significance
Renal cell carcinoma (RCC) is one of the most common and lethal of all kidney cancers. RCC
is tough to treat as the cells are largely resistant to many current therapies. In patients with an
advanced form of RCC, targeted therapies including the ones using the new drug, Everolimus
resulted in improved clinical outcomes. However, patients ultimately develop resistance to

30

targeted therapies as well. Thus, newer therapies including better ways of delivery system such as
by targeting CA IX and using novel approaches are urgently needed to effectively fight this
malignant disease. Our current project for uses a nanotechnology-based approach as well as
clinically relevant RCC tumor model and directed address the current challenges of treating
resistant RCCs. This project will be an important step forward in the development of novel drug
delivery technologies and therapies for treating clinically relevant RCC. Besides that, identifying
TKIs such as sorafenib or cabozantinib that can work synergistically in combination with CFMs
using targeted nano-formulation will have a huge impact on kidney cancer treatment options. Our
robust and positive preliminary studies provide a rational approach to investigate our hypothesis
that CFMs and kinase inhibitors loaded in CA IX-PLNPs/OMs alone or combination will offer
better prospects for inhibiting resistant RCCs. In the research strategy as outlined before, we will
design experiments to maximize the success in overcoming naive and everolimus resistant RCC
in animal models.
2.3. Specific Aims
In the light of the preceding literature review, it is apparent that CARP-1 (CCAR-1) is a
potential molecular target whose functional mimetic analogs may lead to the suppression of tumor
growth, that of resistant ccRCC. It may also be useful to integrate a combination strategy with CA
IX targeted molecule as a predictive biomarker for patient survivability and treatment modalities,
as suggested in preliminary studies. To validate this hypothesis, the small molecule mimetic of
CARP-1 CFM-4.16, has been deployed. In this study, the initial step would be to elucidate the
effect of CFM-4.16 on RCC cell growth and survival. This would provide insight into the
molecular mechanisms by which CARP-1 is regulated in RCC. Once established, the next step
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would be to investigate the effect of CFM-4.16 on a panel of RCC cells and to determine if it is
inhibiting RCC cell lines growth.
In the specific aim 1, the CFM compounds will be investigated for (i) the molecular
mechanisms of RCC cell growth inhibition, and (ii) to the extent these compounds inhibit growth
of RCC cells. Collectively, these data would establish that CFMs inhibit growth of parental, wildtype RCC in part by promoting apoptosis signaling. However, CFM compounds suffer from an
inherent drawback of poor aqueous solubility and its dose escalation for systemic administration
and in vivo testing is highly challenging.
In Specific Aim 2, we will perform confirmatory studies to validate that the in vitro
anticancer activity of CFM-4.16 is maintained when loaded in vitamin E-TPGS based micellar
nano-formulation. Specifically, samples consisting of free CFM-4.16 and CFM-4.16 loaded in
vitamin E-TPG based micellar nano-formulation (abbreviated as SMA-TPGS-CFM) will be tested
in vitro and in vivo using parental, wild-type RCC cells as well as Everolimus-resistant RCC. The
objective for SA2 is to test the safety of intravenous administration of SMA-TPGS-CFM micellar
nano-formulation and the antitumor response in RCC mouse model. Our preliminary data thus far
revealed that we have been successful in overcoming the solubility concerns of CFM-4.16 by
encapsulating it in water-soluble vitamin E TPGS based nano-formulation that enabled high drug
loading and affords its intravenous administration for animal testing. Studies will be performed (i)
to test the in vitro efficacy of the CFM 4.16 loaded in vitamin E TPGS based nano-formulation in
parental, wild-type RCC and Everolimus-resistant RCC cells as well as (ii) perform proof-ofconcept studies to explore their antitumor response in a clinically relevant RCC mouse model.
Specifically, we aim to achieve (1) an increased serum bioavailability of CFM-4.16 nanoformulation following i.v administration; (2) increased nano-formulation accumulation and
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retention within the tumor (by the EPR effect) and therefore (3) an increased localized CFM-4.16
concentration in tumor tissues relative to free drug, thus producing a marked antitumor response.
In this regard, it is worthwhile to note that in an earlier study a polymeric nano-lipid formulation
resulted in enhanced serum bioavailability of CFM-4.16 when compared with the free CFM-4.
Oral administration of CFM-4 NLF resulted in reduced weights and volume of the xenograft
tumors derived from A549 NSCLC and MDA-MB-231 TNBC cells 160.
In Specific Aim 3, CA IX expression on the cell surface is associated with the induction
of tumor hypoxia through regulation of HIF1α. The clinicopathological analysis has supported the
fact that overexpression of CA IX in RCC is linked to poor disease prognosis and resistance to
therapy. The accumulated literature and clinical trial data indicate that CA IX expression is 9599% for both primary and metastatic RCC 129,132,133,163,164, whereas it has restricted expression in
healthy tissues (including non-cancerous renal tissue). Thus, CA IX is significantly overexpressed
in RCC tumor. These results signify that CA IX is an excellent target for site specific delivery of
therapeutic payloads to renal tumors. As reported earlier, a small molecule, Acetazolamide (ATZ),
has high affinity (Kd 8.3 nM) to CA IX 133,164 and ATZ-conjugated nanoformulations can deliver
the payload into the inner core (more than the periphery) of the tumor. Along these lines, for the
first time, development of an ATZ-conjugated polymeric lipid nanoformulations library for the
selective delivery of a drug cocktail to the hypoxic region of therapy resistant RCC was proposed.
It is well established that the hypoxic tumor (core) harbors aggressive and drug resistant stem-like
cells that can persist after initial drug therapy and have the ability to invade normal tissues and
metastasize to distant sites forming secondary tumors. Authenticated RCC cell lines such as WT
(A498, UOK262) and Evr-res (A498, UOK262) will be utilized as RCC cells, as well as Raw
264.7 (macrophage) for macrophage phenotyping studies. The following will be established (i) a
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synergistic anticancer effect of CFM-4.16 with TKIs, (ii) the role of M2-macrophages in tumor
immune evasion, and (iii) the mechanism of inhibiting tumorigenic cross-talk between RCC
epithelial cells and M2-macrophages using NPs. The tumor environment mimetic advance
spheroid and Transwell cell culture models will be used to establish efficacy.
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3. CHAPTER 3. A CARP-1 FUNCTIONAL MIMETIC AS A PROMISING
THERAPEUTIC ANTICANCER AGENT FOR EV-RESISTANT RENAL CELL
CARCINOMA
Results from the following studies have been published: Oncotarget Journal, Cheriyan, V. T. *,
Alsaab, H. O., *, et al., (2017). A CARP-1 functional mimetic loaded vitamin E-TPGS micellar
nano-formulation for inhibition of renal cell carcinoma. Oncotarget, 8(62), 104928. *Equal contribution.
3.1.Objectives:
In this chapter we investigated: (i) the molecular mechanisms of RCC cell growth
inhibition by the CFM compounds, (ii) the extent to which these compounds inhibit growth of drug
(Everolimus)-resistant RCC cells, and (iii) whether CFMs inhibit growth of parental as well as
Everolimus-resistant RCC cells.
3.2.Introduction
RCCs comprise of different types of renal epithelial tumors that include most commonly
occurring conventional (clear cell) renal cell carcinomas (ccRCCs) followed by the papillary renal
cell carcinomas, Chromophobe renal carcinoma, Oncocytoma, and Collecting-duct carcinoma 165.
Most RCCs seem to occur sporadically while 1-4% of the cases have an inherited predisposition.
Mutations in the Von Hippel-Lindau (VHL) tumor suppressor occur frequently in RCCs. RCC is
generally very difficult to treat as the cells are largely resistant to many conventional therapies.
Currently, surgery remains the best treatment option 165, although 20-30% of the patients progress
to develop metastatic disease. If diagnosed early, there is a better chance of the cancer going into
remission but if the cancer does not respond to first-line therapies there are very limited secondary
options

30,97

. FDA approved agents for treatment of metastatic RCC include tyrosine kinase

inhibitors (TKIs) such as sorafenib and sunitinib, and mammalian target of rapamycin (mTOR)
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inhibitors temsirolimus and everolimus

8,112,113,147

. These targeted therapies result in improved

clinical outcomes, and although everolimus is the first drug used as a secondary treatment option
for resistant RCCs, patients ultimately develop resistance to targeted therapies that correlates with
poor overall prognosis

96,166

. Dr. Rishi’s group at Wayne State University previously discovered

that CARP-1 also functions as a co-activator of the APC/C E3 ligase 139. APC/C is a multi-subunit
ubiquitin E3 ligase protein that plays a distinct role in cell cycle transitions. Misregulation of
APC/C substrates such as Securin, Polo-like kinase (Plk) correlate with tumor progression 143,167.
A chemical biology-based high-throughput screening of a chemical library as shown in Figure 3.1
resulted in identification of a number of novel, small molecule inhibitors (SMIs) of CARP-1
binding with APC/C subunit APC2

139

. These compounds, termed CARP-1 functional mimetics

(CFMs)159. CFMs bind with CARP-1 and block its interaction with APC2, cause G2M cell cycle
arrest, and inhibit cell growth by inducing apoptosis in various cancer types 139,140.

Figure 3.1 CFMs (Top Row) and CFM-4 analogs (Bottom Row) that inhibit CARP-1 binding with
APC-2. IC50 value for each compound was derived by conducting dose response assays. Adapted
from 1.
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CARP-1 (Cell cycle and apoptosis regulator 1, aka CCAR1) is a peri-nuclear phosphoprotein and a regulator of cell growth and apoptosis signaling 137,138,140. CARP-1 not only functions
as a transcriptional co-activator of steroid family of nuclear receptors and a regulator of
adipogenesis through the glucocorticoid receptor (GR), it also regulates Adriamycin (ADR)dependent apoptosis in part through co-activation of p53

140–142

. CARP-1 expression is often

elevated in cells experiencing stress due to growth factor withdrawal or chemotherapy-induced
cell cycle arrest and apoptosis. Knockdown of CARP-1 resulted in resistance to apoptosis by ADR
or EGFR tyrosine kinase inhibitors demonstrating requirement of CARP-1 in cell growth
inhibitory and apoptosis signaling by these agents 137,140.
3.3.Material and methods:
3.3.1. Chemicals and Reagents
Structure and synthesis of CFM compounds (CFM-4, -4.16, and -4.17) have been recently
described and their structures are shown in Figure 3.1. A stock solution of 50mM of each CFM
was prepared in dimethyl sulfoxide (DMSO) and stored at –20°C. 3-[4,5-Dimethylthiazol-2-yl]2,5diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich, St Louis, MO.
Everolimus was purchased from SelleckChem, Boston, MA and a 50mM stock solution was
prepared in DMSO and stored at –20°C, while clinical grade Adriamycin (ADR) was obtained
from Karmanos Cancer Institute pharmacy, Detroit, MI. We purchased all other analytical grade
reagents from Sigma-Aldrich (St Louis, MO) and used them without further purification.
3.3.2. Cell culture conditions and cell lines
DMEM, EMEM medium and antibiotics (penicillin and streptomycin) used in this study
were purchased from Invitrogen Co. (Carlsbad, CA). Fetal bovine serum (FBS) and DMSO were
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obtained from Denville Scientific Inc. (Metuchen, NJ), and Fisher Scientific (Fair Lawn, NJ),
respectively. The Protein Assay Kit was obtained from Bio-Rad Laboratories (Hercules, CA). The
mouse monoclonal antibodies for –actin was acquired from Sigma-Aldrich (St. Louis, MO). We
purchased rabbit polyclonal antibodies for α-tubulin, Cyclin B1, Cleaved Caspase-8, PARP,
phospho and total p38/, phospho- and total JNK1/2 SAPKs from Cell Signaling Technology
(Beverly, MA). We have previously described generation and characterization of the anti-CARP1 rabbit polyclonal antibodies 159,160,168,169.
The human RCC A498, CAKI-1, CAKI-2, and ACHN cells were from ATCC and kindly
provided by Dr. Rajvir Dahiya from Department of Urology, San Francisco Veterans Affairs
Medical Center and University of California San Francisco, San Francisco, CA (UCSF). The
HLRCC (UOK 268 and UOK 262) cells were kindly provided by Dr. Marston Linehan Urologic
Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of
Health, and Bethesda, MD. (NCI). All the cells were routinely maintained as described before.
All the cell culture media were containing 10% FBS, 100 units/ml of penicillin, and 100 μg/ml
of streptomycin, and the cells were kept at 37°C and 5% CO2. For cell growth and MTT studies,
the cells were cultured in fresh media with 10% FBS prior to their treatments with various agents.
The Caki-1 and Caki-2 were grown in RPMI 1640 medium, and UOK 262, UOK 268, and Huh7
were routinely cultured in DMEM medium.
3.3.3. Generation of Everolimus-resistant RCC cells
The human RCC A498, UOK262, and UOK268 cells were cultured in the chronic
presence (>6 months) of Everolimus. The parental A498 cells were initially treated with 500nM
Everolimus for 3-4 weeks, followed by escalation to 1.0, 2.0, 4.0 and 10.0μM doses for a period
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of three to four months till the resistant subline emerged. The cells were cultured in continuous
presence of each of the dose for 3-4 weeks till resistance developed and cells adapted to growth
in 2μM Everolimus. In the case of UOK262 and 268 RCC cells, the parental cells were initially
cultured in 10nM Everolimus for 3-4 weeks. For selection of the resistant cells, everolimus dose
was escalated to 20, 50, 100, 200, 500, 1000, and 2000nM. The UOK cells were cultured in
continuous presence of each of the dose for 2-3 weeks till resistance developed and cells adapted
to growth in 2μM Everolimus. Subsequent, routine maintenance of the resistant cells in the
presence of 2μM Everolimus was continued and multiple, resistant sublines for each of the RCC
cells were isolated and characterized for their growth inhibitory (GI50) dose of Everolimus by
the MTT-based viability assays as detailed below. Several resistant sublines of each cell line
were then isolated and maintained in respective culture media containing 2.0 µM everolimus.
3.3.4. Generation of CARP-1 knock-down RCC cells
The human RCC UOK262 parental cells were transfected with vector plasmid
pcDNA3/hygro or plasmid expressing CARP-1 anti-sense (Clone 1.6, ref 8). Multiple, stable
sublines for hygromycin resistance were selected in the presence of 400μg/ml hygromycin
(#10687010, Invitrogen Inc) following methods described before

159,160,168,169

. We determined

the levels of CARP-1 in the parental, and vector or CARP-1 antisense plasmid-transfected RCC
cells and their viabilities in the presence of CFM compounds by western blot and MTT assays,
respectively, as described below.
3.3.5. Cell viability assays (MTT assay)
The cell growth inhibition was assessed by using MTT assay. The cytotoxicity of CFM-4,
-4.6, -4.16, -4.17, Everolimus, and ADR in the RCC cells (A498, UOK262, and UOK268) was
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assessed by MTT assay. First, we seeded 5 X 103 cells in the 96-well plate in triplicate, allowed
the cells to grow in fresh culture media for another 24h, and treated them with respective agents
for the noted dose and time. Control cells were treated with 0.1% DMSO in culture medium. After
treatment, we performed an MTT assay. Briefly, 20 μl of 1mg/ml of MTT was added to each well
and cells were incubated for 2-4h at 370C. MTT was removed, and the resulting formazan products
were dissolved by adding 50μl DMSO/well followed by colorimetric analysis using a multi-label
plate reader at 570 nm (Victor3; PerkinElmer, Wellesley, MA).
3.3.6. Western Blot and protein expression analysis
For protein expression analysis, we conducted western blot experiments. The RCC cells
were treated with DMSO/Vehicle (Control) or indicated dose and time of the noted compound and
were lysed to prepare protein extracts. Cells were harvested and lysed in RIPA buffer (50mM TrisHCI, pH 8.0, 150mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), and 0.1% of protease inhibitor cocktail) for 20 min at 40C. The lysates were
then centrifuged at 14,000 rpm at 40C for 15 min to get rid of debris. We then determined the
protein concentrations of whole cell lysates utilizing the Protein Assay Kit. 50μg from each sample
of supernatant proteins were separated by SDS-10% polyacrylamide gel electrophoresis (SDSPAGE) and transferred to polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA)
by company standard protocol. The membranes were hybridized with primary antibodies followed
by incubation with appropriate secondary antibodies. The antibody-bound proteins were visualized
by treatment with the chemiluminescence detection reagent (Amersham Biosciences) according to
the manufacturer’s instructions, followed by exposure to X-ray film (Kodak X-Omat). The same
membranes were then re-probed with either the anti-β actin or anti-α tubulin antibody, which was
utilized as an internal control for protein loading.
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3.4.Results
3.4.1. Novel Analogs of CFM-4 Suppress Growth of Human NSCLC, TNBC, and RCC
Cells
We first tested the growth-inhibitory effects of CFM-4 and 4.16 on human RCC, NSCLC,
and liver cancer cell lines. CFM-4 and 4.16 inhibited the viability of all cell lines in a dose and
time-dependent manner (Figure. 3.2A and B). Generally, most of cell lines were more sensitive
towards all the CFM, showing at least 50% reduced proliferation in the presence of 20 µM CFM4 and 4.16 (Figure 3.2). Doses of 1 µM and 2 µM of CFM-4 over a 24 h treatment elicited more
than 40% reduced viability of HepG2 and UOK262 cell lines. Also, doses of 5 µM and 10 µM of
CFM-4 showed at least 40% growth cells viability in Huh7, H1299, UOK268, and UOK 262
(Figure 3.2.A). The HepG2, A549, UOK262 cells were relatively less sensitive to CFM4 since a
10 µM dose of CFM-4 caused little more than 20% reduction in their viability (Figure 3.2.A).
However, in case of CFM-4.16, there is an approximately 50% attenuation of the viability of all
cells was indicated when treated with a lower dose of CFM-4.16 over a 24 h period which indicates
its stronger activity against these cell lines (Figure 3.2.B).
In addition, since the RCC, NSCLC, and liver cancer cell lines were relatively more
sensitive to CFM-4.16, these cells were separately treated with various doses of CFM-4 for a
period of 24 h to evaluate the lowest effective dose for these agents. Despite 500 nM dose of both
compounds failed to affect RCC, NSCLC, and liver cancer cells viability, a 1 µM and 5 µM dose
of the CFM-4.16 agent elicited more than 60% loss in the viability of all the cell lines. These data
suggest that the viabilities of the RCC, NSCLC, TNBC, and liver cancer cells were affected
properly by the 1 µM or higher doses of free drug (CFM-4.16) and CFM-4.16 nanoformulation.
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A

B

Figure 3.2. Liver cancer cells (Huh-7 and Hep G2), lung cancer cells (H1299 and A549) and renal cancer
cells (UOK 268 and UOK 262) were treated with the indicated doses of (A) CFM-4 and (B) CFM-4.16 for
24 hours. The number of viable cells was then determined by MTT assay as described. Adapted from 1.
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3.4.2. CFMs inhibit viabilities of RCC cells
Our prior findings had indicated anti-cancer properties of a novel class of CFM compounds
169

, and our recent medicinal chemistry-based structure-activity relationship (SAR) studies

reported identification of CFM analogs, in particular CFM-4.16, that was a superior inhibitor of
parental and drug-resistant human and murine triple-negative breast cancer cells in vitro and in
vivo

169

. Since emergence of resistance to current therapeutics remains a formidable problem in

effective treatment and management of RCCs in clinic 2,96,97, we speculated whether CFM class of
compounds would be effective inhibitors of RCC cells and to the extent, these compounds would
be suitable to inhibit the resistant RCCs. We tested this possibility by conducting studies as
detailed below. First, we evaluated potencies of the parent compound CFM-4 and its analogs CFM4.6, and CFM-4.16 in cell culture studies utilizing RCC cell lines of ccRCC (CAKI-1, A498),
papillary RCC (ACHN, CAKI-2), and HLRCC (UOK 262 and UOK 268) origins

83,170

by MTT

based assays. As shown in Figure 3.3, CFM-4.16 dose of 1.0 and 2.0 μM over a period of 12h
caused a greater loss of viability of all the RCC cells when compared to the RCC cells treated with
similar doses of CFM-4 compound. Since Everolimus is one of the currently used targeted therapy
for RCCs, we tested whether Everolimus treatments also provoked loss of viabilities of the RCC
cells and to the extent anti-RCC effects of Everolimus were different from the CFM-4.16
treatments. The Everolimus doses of 0.2, 0.5, 1.0, and 2.0μM caused a moderate 20-40% loss in
the viabilities of RCC cells, the doses of 5.0, and 10.0μM however provoked a greater than 6070% reduction in the viabilities of the RCC cells (Figure 3.3 C). Given that the molecular masses
of Everolimus, Doxorubicin, and CFM-4.16 are 958.22, 543.5, and 440.35, respectively, a 1μM
dose of Everolimus will have an approximate molar equivalence to a 2.0μM dose of either
Doxorubicin or CFM-4.16. Thus, although treatments with 5.0 or 10.0μM doses of Everolimus,
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CFM-4, and CFM-4.16 provoked a similar 60-80% reduction in viabilities of the RCC cells, a
2.0μM dose of CFM-4.16 induced a 40-60% loss of RCC cell viabilities (Figure 3.3 B) while a
1μM dose of Everolimus caused a moderate 20-40% reduction in RCC cell viabilities (Figure 3.3
C). These data in Figure 3.3 and Figure 7.1. in Appendix suggest that the RCC cells are likely
more sensitive to inhibition by CFM-4.16 when compared with CFM-4 or Everolimus at the
equivalent doses of up to 2μM of each compound. Additional dose response studies with reference
to A498, CAKI-1, and ACHN RCC cells revealed that CFM-4.16 dose for inhibition of the cell
growth by 50% (GI50) was ~1.5-1.8μM, its dose for inducing a 50% cytotoxic effects (LC50) was
5.5-5.7 μM.

Figure 3.3. CFMs inhibit RCC cell growth. We treated noted cell lines either with DMSO (Control), with
various CFMs (A, B, D-F), Everolimus (C), or ADR (D) for indicated dose and time. We determined cell
viability by MTT assay. The data in the histograms represent means of three independent experiments with
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4-6 replicates for each treatment; bars, S.E. A-D, @,#,&,*, E-F, α,β,γ,δ, statistically significant inhibition
(p = <0.05) relative to DMSO-treated respective controls. Adapted from 1.

3.4.3. CFMs inhibit viabilities of the resistant RCC cells
To test whether CFM class of compounds are also effective inhibitors of the resistant
RCCs, as a proof-of-concept strategy, we first generated and characterized several RCC sublines
that were resistant to Everolimus. We cultured A498, UOK 262, and UOK 268 RCC cells in the
chronic presence of escalating doses of Everolimus until the resistance emerged. As shown in
Figure 3.4 A, the GI50 doses for Everolimus were 1.2, 0.02, and 0.02μM for the parental A498,
UOK 262 and UOK 268 RCC cells, respectively. These data in Figure 3.4 A strongly suggest that
all the RCC cells developed a robust level of resistance to Everolimus. We next investigated
whether the CFM compounds inhibited viabilities of the Everolimus resistant RCC cells by
conducting MTT based assays as in Figure 3.3. and 7.1. Appendix. As shown in Figure 3.4 B-D,
a 4.0μM dose of CFM-4 caused ~50% loss of viability of the Everolimus resistant A498 cells while
a moderate ~20% reduction in the viability of the Everolimus resistant UOK 262 and UOK 268
cells was noted. A 4.0μM dose of CFM-4.16 on the other hand provoked ~80% reduction in the
viabilities of all the Everolimus-resistant RCC cells. These data corroborate our current findings
in Figure 3.3 and our recent studies demonstrating increased effectiveness of CFM-4.16 in
attenuating viabilities of the parental RCC cells as well as drug-resistant RCC (Figure 3.4) and
TNBC cells 159.
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Figure 3.4. CFM-4. 16 inhibits Everolimus-resistant RCC cell growth. (A) GI50 values of parental and
drug-resistant RCC cells. In the case of Everolimus-resistant cells, the respective parental and resistant
sublines were treated with 0.02, 0.1, 0.2, 1.0, 2.0, 4.0, and 10.0 μM dose of Everolimus. Percent cell
viabilities were determined relative to respective DMSO-treated controls. The data in the GI50 columns
represent means of three independent experiments. (B-D) Indicated parental and their respective drug
resistant RCC cells were either untreated (Control) or treated with noted doses of Everolimus, CFM-4, or
CFM-4.16 for 12h. We determined cell viability by MTT assay. The histogram columns represent means
of three independent experiments with 4-6 replicates for each treatment; bars, S.E. B-D, α, β, γ, δ,
statistically significant inhibition (p = <0.05) relative to DMSO-treated respective controls. Adapted from
1
.

3.4.4. CFM-4.16 Stimulates apoptosis by activating p38 MAP kinase, c-Jun N-terminal
kinase (JNK) enhancing expression of CCAR-1/CARP-1
CARP-1 is a key transducer of apoptosis signaling by therapeutics such as Doxorubicin,
Etoposide, and Gefitinib

137

, and CARP-1 expression was necessary for transduction of

apoptotic/inhibitory signaling by these therapeutics as well as by our experimental CFM class of
compounds in parental and drug-resistant TNBC cells 159. Since CFM-4.16 was more effective in
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reducing viabilities of parental as well as Everolimus resistant RCC cells (Figure 3.4), we next
investigated molecular mechanisms of apoptosis by CFM compounds and to the extent CARP-1
was required for inhibition of RCC cells by CFMs. Our western blot (WB) analyses revealed that
equimolar (10μM) dose of CFM-4 or CFM-4.16 stimulated CARP-1 expression and activation of
pro-apoptotic, stress-activated protein kinases (SAPKs) in the RCC cells in a time-dependent
manner (Appendix Figure 7.2. A, B). Although activation of both the p38α/β and JNK1/2 SAPKs
occurred as early as 1h of treatment with CFMs, CFM-4.16 caused a rather robust activation of
these SAPKs at 6h treatment period (Appendix Figure 7.2. A, B). Co-incident with the SAPK
activation, treatments with CFMs over a 6h period stimulated activation of PARP and caspase 8,
while causing a significant decline in levels of mitotic cyclin B1 in the RCC cells. Since CFMs
inhibited viabilities of Everolimus-resistant RCC cells, we then determined whether CFMs
provoked apoptosis in the Everolimus-resistant RCC cells as well. As shown in Figure 7.2. C, both
the compounds stimulated CARP-1 expression, activation of SAPKs, PARP cleavage, and loss of
cyclin B1 in the Everolimus-resistant UOK262 RCC cells. Here again, CFM-4.16 caused a
generally higher increase in CARP-1 levels, activation of SAPKs, PARP-1 cleavage in parental or
Everolimus-resistant RCC cells when compared with the cells that were treated with CFM-4.
CFM-4.16 treatments also provoked a greater loss of cyclin B1 in both the parental and
Everolimus-resistant RCC cells when compared with their CFM-4-treated counterparts. These data
suggest that CFMs inhibit RCC cell viabilities in part by promoting apoptosis.
3.4.5. CFM-4.16 Stimulates apoptosis in parental and resistant RCC cells by enhancing
expression of CCAR-1/CARP-1
We next clarified whether the CFM compounds required CARP-1 to inhibit variabilities of
the RCC cells. For this purpose, we first generated and characterized multiple, independent
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hygromycin-resistant stable sublines of UOK262 cells that express reduced CARP-1 as detailed in
methods. The parental UOK262 cells were transfected with a plasmid encoding CARP-1 antisense
or its vector counterpart, and transfected cells were cultured in chronic presence of hygromycin
over a period of 6-8 weeks to obtain resistant sublines essentially following our previously
described methods 159. As shown in Appendix Figure 7.3 A, stable expression of CARP-1 antisense
plasmid caused reduced levels of CARP-1 in two sublines when compared with the levels of
CARP-1 noted in two, vector-expressing sublines or the parental UOK262 cells. We then
determined whether knock-down of CARP-1 expression interfered with loss of viabilities induced
by treatments with CFM compounds. Our data in Appendix Figure 7.3 B demonstrate that
depletion of CARP-1 in the UOK262 cells resulted in a significant abrogation of inhibitory effects
of both the CFM compounds when compared with their vector-expressing counterparts. Taken
together, our findings in Appendix Figures 7.2 and 7.3 suggest that CFMs stimulate apoptosis in
parental and resistant RCC cells and CARP-1 expression is required in transduction of inhibitory
effects of the CFM compounds.
3.4.6. CFM-4.16 suppresses three-dimensional growth of the parental and Everolimusresistant RCC cells
Recent studies have revealed culture of the RCC cells in a three-dimensional (3D) system
as spheroids, and that the overall gene expression patterns of RCC spheroids in 3D more closely
mimicked those observed in RCC tumors in vivo 171. These studies further suggested suitability of
3D RCC spheroids from established cell lines as well as patient-derived, primary RCC tumors for
pharmacological testing and investigating molecular mechanisms of RCC metastasis. Since CFM4.16 inhibited growth of mammospheres derived from parental and drug-resistant human TNBC
cells, we tested whether CFM-4.16 will inhibit growth of the RCC spheroids in 3D culture
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conditions. As shown in Figure 3.5, the parental A498, UOK262, and UOK268 RCC cells as well
as their respective, Everolimus-resistant sublines formed RCC spheres in 3D culture conditions
that are detailed in methods. Consistent with our observations with the human TNBC
mammospheres, CFM-4.16 caused marked disintegration of spheres of parental and Everolimus
resistant human RCC cells (Figure 3.5.).

Figure 3.5. CFM-4.16 inhibits growth of RCC spheres derived from parental and
Everolimus-resistant cells. Parental and Everolimus-resistant RCC cells were grown as spheres
as detailed in Methods. The sphere cultures were either untreated (Control) or treated with CFM4.16 for noted dose and time. The untreated and treated spheres were then photographed as in
methods. Representative photomicrographs of untreated and CFM-4.16 treated spheres are shown.
Adapted from 1.
3.5. Discussion
In this chapter, we initiated further studies to determine whether the CFM-4 and its analogs
inhibit growth of RCC cells; and further explored molecular mechanism(s) of RCC cell death by
these compounds. CFM-4.16 exposure resulted in a somewhat higher loss of RCC cell viability
when compared with their loss of viabilities noted following treatments with CFM-4. It is therefore
feasible that further rational medicinal chemistry modifications of these promising anticancer
agents could yield additional novel small molecule compounds that may have greater potency and
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selectivity in inhibiting RCCs. In an attempt to elucidate apoptosis signaling by chemotherapy,
CARP-1 was identified as a perinuclear protein that was required for apoptosis by EGFR targeted
therapeutics as well as DNA damaging agents such as Adriamycin (ADR) and etoposide

159,160

.

Although CARP-1 is a coactivator of steroid-thyroid receptor superfamily, we focused our efforts
to exploit apoptosis signaling of CARP-1 for development of novel anti-cancer agents.
Approximately one third of RCC patients present metastases at diagnosis, and 30-70% of patients
relapse within five years of surgery 31. During the last decade, several targeted therapies have been
developed and approved for treatment of metastatic RCC. These second-line targeted therapies for
the metastatic RCCs include mechanistic target of rapamycin (mTOR) inhibitors such as
Temsirolimus and Everolimus, and tyrosine kinase inhibitors such as Sunitinib and Sorafenib 166.
Although most of these therapies have substantially improved patient outcomes, none of these
drugs are curative and resistance eventually develops. Here we utilized ccRCC cells and hereditary
non-ccRCC subtypes to generate laboratory models of drug resistance by exposing them to chronic
presence of Everolimus over an extended period. Several Everolimus-resistant sublines of A498
(representative of cc-RCC subtype), and UOK262 and UOK268 (representative of non-cc-RCC
subtype) were obtained and characterized for their resistance to Everolimus. In this proof-ofconcept investigation, we find that CFM compounds are potent inhibitors of parental as well as
Everolimus-resistant RCC cells. In fact, the compound CFM-4.16 seemed to be generally more
effective inhibitor of these cells when compared with the parent compound CFM-4. Nevertheless,
both the compounds function in part by stimulating apoptosis. Since CFMs function in part by
binding with CARP-1 and interfere with activity of the Anaphase Promoting Complex/Cyclosome
(APC/C) E3 ligase, our studies also revealed a CARP-1 requirement in transduction of growth
inhibitory effects of CFM-4.16 in the RCC cells. At the molecular levels, CFMs target mitotic
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cyclin B1 and cause apoptosis in the parental and resistant RCC cells. This loss of cyclin B1 and
stimulation of apoptosis by CFMs in RCC cells would be consistent with our prior findings
demonstrating promotion of G2M cell cycle arrest, loss of mitotic cyclin B1, and apoptosis
stimulation by CFMs in other cancer cell models 158–160,168. In this regard, the novel class of CFM
scaffold that stimulate G2M arrest as well as cause apoptosis hold potential for therapeutic use for
targeting drug-resistant cancers especially in RCC.
3.6. Conclusion
The CFM compounds have been investigated for (i) the molecular mechanisms of RCC
cell growth inhibition, and (ii) to the extent these compounds inhibit growth of drug (Everolimus)resistant RCC cells. Conclusively, the current in vitro data is highly encouraging, and indicate that
CFMs inhibit growth of parental, wild-type as well as Everolimus-resistant RCC cells in part by
promoting apoptosis signaling. Clearly, there is a need for further in vivo testing of these
compounds in animal tumor models of RCC. However, CFM compounds suffer from an inherent
drawback of poor aqueous solubility and its dose escalation for systemic administration remains
highly challenging.
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4. CHAPTER 4: A CARP-1 FUNCTIONAL MIMETIC LOADED IN VITAMIN ETPGS MICELLAR NANO-FORMULATION FOR INHIBITION OF RENAL
CELL CARCINOMA UTILIZING EPR EFFECT

Some results from the following studies have been published: Oncotarget Journal, Cheriyan, V. T.
*, Alsaab, H. O., *, et al., (2017). A CARP-1 functional mimetic loaded vitamin E-TPGS micellar
nano-formulation for inhibition of renal cell carcinoma. Oncotarget, 8(62), 104928. *Equal contribution.
4.1.Objectives
Studies will be performed (i) to test the in vitro efficacy of the CFM 4.16 loaded in vitamin E
TPGS based nano-formulation in parental, wild-type RCC and Everolimus-resistant RCC cells as
well as (ii) perform proof-of-concept studies to explore their antitumor response in a clinically
relevant RCC mouse model. Specifically, we aim to achieve (1) an increased serum bioavailability
of CFM-4.16 nano-formulation following i.v administration; (2) increased nano-formulation
accumulation and retention within the tumor (by the EPR effect) and therefore (3) an increased
localized CFM-4.16 concentration in tumor tissues relative to free drug, thus producing a marked
antitumor response.
4.2. Introduction
Recent studies reported development of various strategies to circumvent the poor aqueous
solubility of many compounds in order to improve the outcomes of anticancer therapy. In this
study, we will thus employ a nanotechnology advanced technique to tackle the poor aqueous
solubility of a potent CFM compound (CFM-4.16) that has restricted its clinical utility as a
therapeutic anticancer agent. Additionally, in order to improve the outcomes of anticancer agents,
strategies to circumvent the poor aqueous solubility have been studied extensively in recent years.
One of these strategies is to utilize D-alpha-tocopheryl polyethylene glycol succinate (Vitamin E
TPGS) which is a water-soluble derivative of a PEGylated vitamin E (Vitamin E conjugated with
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PEG). TPGS has an amphiphilic structure comprised of a hydrophobic alkyl tail and a hydrophilic
polar head. The amphiphilic nature of TPGS confers it an excellent ability to encapsulate
hydrophobic drugs, forming nano-micelles172–175. The nano-micelles with low critical micellar
concentrations thereby improve the solubility, stability and bioavailability of the loaded lipophilic
drug. Other groups previously have demonstrated that TPGS features such as bulky structure and
large surface area makes it as an excellent solubilizer and enhancer for hydrophobic drug
bioavailability. In addition, TPGS delivery system by itself could inhibit P-glycoprotein MDR and
promote a synergistic anticancer effect. We also chose styrene-maleic acid (SMA) polymer with a
relatively low molecular weight of 1.6 kDa for generation of SMA-TPGS block copolymer that
could enhance the formation of nano-micelles. It was selected as a block copolymer with TPGS
based on its favorable properties as reported earlier. The critical reason for choosing SMA for
polymeric nano micelles is due to their favorable properties for in vivo delivery such as high drug
loading, good water solubility, nontoxicity, and biosafety. These nano-micelles have high drug
loading, good water solubility, nontoxicity, and biosafety profiles for use in vivo delivery of drug
payload. In this regard, the native SMA polymer conjugated to neocarzinostatin (SMANCS) was
approved for human use 176–178.
In the current study, we investigated the efficiency of drug delivery of novel CFMs analog
nano-formulation and their effects on circumventing the water solubility obstacle to permit
intravenous administration. Furthermore, we aimed to test the in vitro efficacy of the CFM 4.16
loaded in vitamin E TPGS based nano-formulation in different cancer cell lines as well as
performed proof-of-concept studies to explore the mechanism of action of these newly developed
small molecules inhibitors. Also, we investigated (i) the extent to which these CFM
nanoformulations inhibit growth of drug (Everolimus)-resistant RCC cells, and (ii) whether the
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SMA-TPGS nano-formulation of CFM-4.16 circumvents the solubility concerns of CFM
compounds to permit its intravenous administration in conducting in vivo studies. Our data indicate
that CFMs inhibit growth of parental as well as Everolimus-resistant RCC cells in part by
promoting apoptosis. The TPGS-based nano-formulation of CFM-4.16 inhibits viability of RCC
cells in vitro and their growth as xenografted tumors in immunocompromised mice.
4.3. Materials and Methods
4.3.1. Chemicals and Reagents
CFM-4.16 was synthesized by Dr. Scott Larsen (University of Michigan) and provided to
Dr. Rishi (KCI) and has been recently described. All the CFMs were dissolved in DMSO at a stock
solution of 10-50 mM and stored at –20°C. Everolimus was purchased from SelleckChem, Boston,
MA. Styrene maleic anhydride (SMA, MWt 1600) and D-alpha-tocopheryl polyethylene glycol
succinate (Vitamin E TPGS) were obtained from Sigma Aldrich, St Louis, MO). All other reagents
will be purchased at analytical reagent grade from Sigma Aldrich (St Louis, MO) and used without
further purification.
4.3.2. Cell Lines and Cell culture supplies
RCC cell lines Caki-1, Caki-2, ACHN, and A-498 were kindly provided by and Dr. Rajvir
Dahiya, Department of Urology, San Francisco Veterans Affairs Medical Center and University
of California San Francisco, San Francisco, CA. The RCC UOK262 and UOK268 cells were
kindly provided by Dr. WM Linehan, Urologic Oncology Branch, Center for Cancer Research,
National Cancer Institute, National Institutes of Health, Bethesda, MD. The Caki-1 and Caki-2
were grown in RPMI 1640 medium, and UOK 262, UOK 268, and Huh7 were routinely cultured
in DMEM medium. All the cell culture media were also supplemented with 10% FBS, 100 units/ml
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of penicillin, and 100 μg/ml of streptomycin, and the cells were maintained at 37 °C and 5% CO2.
For cell growth and MTT studies, the cells were cultured in fresh media with 5% FBS prior to their
treatments with various agents.
DMEM, EMEM medium and antibiotics (penicillin and streptomycin) were purchased
from Invitrogen Co. (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from Denville
Scientific Inc. (Metuchen, NJ), and DMSO was purchased from Fisher Scientific (Fair Lawn, NJ).
Enhanced Chemiluminescence Reagent kit was purchased from Amersham Biosciences
(Piscataway, NJ) and the Protein Assay Kit was purchased from Bio-Rad Laboratories (Hercules,
CA). The affinity purified, anti-CARP-1 polyclonal antibodies were described before 160,168. The
mouse monoclonal antibody for b–actin and 3-[4, 5-Dimethylthiazol-2-yl]-2,5diphenyltetrazolium
bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO). Rabbit polyclonal antibodies
for Cyclin B1, Cleaved Caspase-8, PARP, phospho and total p38a/b, phospho and total JNK1/2
SAPKs were obtained from Cell Signaling Technology (Beverly, MA).
4.3.3. SMA-TPGS Synthesis and micellar nano-formulation fabrication and characterization
The block copolymer (SMA-TPGS) was first synthesized by adding known amounts of
TPGS in NaHCO3 buffer at pH 8.9 with fixed amounts of anhydrous SMA to afford the anhydride
ring opening reaction of SMA with the alcohol group of TPGS. All unconjugated reagents were
removed by ultrafiltration (Millipore TFF, Milford, MA) of the SMA-TPGS conjugate prior to
its lyophilization. We characterized nano-micelles by proton nuclear magnetic resonance
spectroscopy (1H NMR) and Fourier transform infrared spectroscopy (FTIR). The structure of
the synthesized SMA-TPGS copolymer was detected by 1H NMR in D2O. The -CH protons and
methyl protons of SMA segment had signals at 5.2 and 1.69 ppm, respectively. The -CH2 protons
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of PEO part of TPGS had the peak at 3.65 ppm. We noted the lower peaks in the aliphatic region
that belong to various moieties of vitamin E tails 179,180. The proper synthesis of the SMA-TPGS
copolymer was also confirmed by the FTIR analysis and was not found to be a physical mixture
of TPGS with SMA as all measurements indicated the absence of any free crystalline particles
in nano-micelles preparation. Both SMA and TPGS inhibited crystallization of CFM-4.16 during
nano-micelles formulation. We then fabricated the CFM loaded micelles according to our earlier
published protocols

155,161,162,181–187

, followed by characterization of micelles for size, charge,

critical micelles concentration (CMC), and drug loading as below. For Morphology,
Transmission Electron Microscopy (TEM) of the nanoparticles was assessed using JEOL JEM1000 instrument (JEOL Ltd, Tokyo, Japan). Then, the products obtained were stored in the
freezer until further use.
4.3.4. Particle size, and zeta potentials
The particle size and surface charge (zeta potential, ), measurements were performed
using a Beckman Coulter Delsa Nano-C-DLS Particle analyzer (Miami, FL) equipped with a 658
nm He-Ne laser. For particle size, we suspended the nano-micelles in de-ionized (DI) water and
detected the scattered light at 165° angle. We then obtained the peak average histograms from the
intensity, volume and number from 70 scans to calculate the average diameter of the particles. The
zeta potentials were evaluated by measuring the electrophoretic mobility of the charged particles
under an applied electric field.
4.3.5. The Loading efficiency of SMA-TPGS-CFM nano-micelles
We evaluated the CFM-4.16 loading content percentage in SMA-TPGS nano-micelles by
High-Performance Liquid Chromatography (HPLC). First, a method for analyzing drug content
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was developed and validated according to ICH guidelines 188. We measured the standard curve of
CFM-4.16 in DMSO and its successive dilutions with mobile phase at 309 nm (λ

max).

The

calibration curve was linear in the range of 50–50,000 ng/ml with a correlation coefficient (R2) =
0.9999. The loading efficiency of micelles was calculated by dissolving a known amount of nanomicelles directly in DMSO and further dilution of drugs with the mobile phase followed by
determination of the absorbance at 309 nm with respect to the standard curve as described
previously 169.
4.3.6. Drug Encapsulation Efficiency (EE)
Free drug (non-incorporated in the SMA-TPGS) was separated by ultrafiltration
centrifugation technique. Briefly, 1 mL of CFM-4.16 and SMA-TPGS-CFM 4.16 colloidal
solution were placed in the upper chamber of a centrifuge tube matched with an ultrafilter and
centrifuged for 15 min at 4000 rpm. The total drug content in CFM-4.16 nano-formulation was
determined as follows. Aliquots of 1mL formulation dispersion were diluted appropriately by
ethanol to dissolve the TPGS-SMA ingredient, and the resulting suspension was then filtrated
through 0.45µm membrane filters. The filtered solution was analyzed by Waters® Alliance e2695
HPLC using Symmetry® C18 column (250mm × 4.6mm, 5µm). The mobile phase was a mixture
of Acetonitrile, Methanol, 10mM KH2PO4 buffer (65:20:15 v/v) with pH adjusted to 2, and the
flow rate was maintained at 1.0mL/min. All the samples were analyzed at 309nm using empower
PDA software. We then calculated the encapsulation efficiency (EE) and drug loading content
(DLC) by the following equations:

𝐃𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 (𝐃𝐋𝐂) =

𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
𝐞𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬
𝐓𝐨𝐭𝐚𝐥 𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
𝐥𝐨𝐚𝐝𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬

𝐄𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐄𝐟𝐟𝐞𝐜𝐢𝐞𝐧𝐜𝐲 (𝐄𝐄) =

𝐱𝟏𝟎𝟎

𝐌𝐚𝐬𝐬 𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
𝐞𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬
𝐓𝐨𝐭𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
𝐢𝐧𝐢𝐭𝐢𝐚𝐥𝐥𝐲 𝐥𝐨𝐚𝐝𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬

𝐱𝟏𝟎𝟎

Equation (1)

Equation (2)
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4.3.7. Cell viability assays (MTT)
The cytotoxicity of CFM-4.16, SMA-TPGS copolymer, SMA-CFM-4.16, SMA-TPGSCFM-4.16 in the RCC cells (A498, UOK262, and UOK268) was assessed by MTT assay. First,
we seeded 5 X 103 cells in the 96-well plate in triplicate, allowed the cells to grow in fresh culture
media for another 24h, and treated them with respective agents for the noted dose and time. Control
cells were treated with 0.1% DMSO in culture medium. After treatment, we performed an MTT
assay. Briefly, 20 μl of 1mg/ml of MTT was added to each well and cells were incubated for 2-4h
at 370C. MTT was removed, and the resulting formazan products were dissolved by adding 50μl
DMSO/well followed by colorimetric analysis using a multi-label plate reader at 570 nm (Victor3;
PerkinElmer, Wellesley, MA).
4.3.8. Protein expression (WB) Assays
For protein expression analysis, the cells will be either untreated or treated with CFM-4.16
or SMA-TPGS-CFM-4.16 nano-formulation for various times. Cells will be lysed in cell lysis
(10X) buffer containing 0.1% of protease and phosphatase inhibitor cocktail (Sigma) for 20 min
at 4ºC. The cell lysates will be centrifuged at 14,000 rpm at 4ºC for 15-20 min to remove debris.
Protein concentrations of the clarified cell lysates will be determined using the Protein Assay Kits.
The cell lysates (50-100µg from each sample) will be separated by SDS-PAGE and transferred to
PVDF membrane (Bio-rad, Hercules, CA) by standard procedures. The membranes will be then
hybridized with primary antibodies followed by incubation with appropriate secondary antibodies.
The antibody-bound proteins were pictured by treatment with the chemiluminescence detection
reagent based on manufacturer’s instructions, followed by exposure to X-ray film (Denville
Scientific Inc.). The same membranes will be re-probed with the anti--actin antibody, which will
be used as an internal control for protein loading.
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4.3.9. Three-dimensional Renal sphere assays
The RCC cells were obtained from xenograft tumors derived from parental cells (see
below) or from the parental and Everolimus-resistant RCC cells from a two-dimensional culture
plate with ~70-80% confluence. We performed the three-dimensional renal sphere cultures by
essentially following the methods described by us before 169. Briefly, the cells were washed twice
in 1 x PBS and trypsinized following established protocols. We then pelleted the cells at 200 x g
at room temperature and re-suspended them in 5ml of sphere media (DMEM/F12 supplemented
with 2mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 1 x B27 supplement,
20ng/ml recombinant human epidermal growth factor (EGF; Sigma), and 10ng/ml recombinant
human basic fibroblast growth factor (bFGF; R&D Systems). We seeded ~5000 viable cells per
ml in an ultra-low adherent 60mm plate and incubated them at 37°C and 5% CO2 for two weeks
without disturbing the plates. After the spheres formed, we added fresh media with or without
10µM CFM-4.16 and continued incubating cells for additional 24h at 37°C and 5% CO2. At the
end of the incubation period, we photographed the spheres in the untreated and treated plates as
described [45].
4.3.10. Maximum tolerated dose (MTD) analysis and experimental design
Healthy non-tumor mice will be used to establish the MTD of the CFM-4.16. The MTD
of CFM-4.16 is 30 mg/kg

159

, thus the tolerance study will be find. The dose-limiting toxicity

(DLT) is weight loss ≥10%. The study will begin at dose 30 mg/kg for CFM-4.16 and 60 mg/kg.
If there are any DLTs, the level of CFM-4.16 will be reduced to 25 mg/kg and another cohort
evaluated. If there are any DLT in this cohort, then CFM4.16 will be reduced by 20%.
4.3.11. Establishment of RCC cell-derived xenografts in immunocompromised mice
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The experiments involving generation of RCC cell-derived sub-cutaneous xenografts were
performed according to our previously published methods and protocols approved by the
Institutional Laboratory Animal Care & Use Committee (IACUC) at the Wayne State University
160,169

. Female, 5-weeks old NCR SCID mice with Lc Background were purchased from Charles

River Laboratories (Horsham, PA). For subcutaneous (sc) tumor xenograft studies, we first
determined maximal tolerated doses for CFM-4.16 (prepared in 10% DMSO/Cremophor +
distilled, sterile water, and pH adjusted to 4.5), SMA-TPGS copolymer, SMA-TPGS-CFM-4.16,
and SMA-CFM-4.16 preparations. The MTD for free CFM-4.16 (prepared in DMSO/Cremophor)
have been described before, and a 30mg/kg/day iv injection was judged safe a total dose of
482mg/kg provoked a mild ataxia with some tail and leg twitching that resolved within 1-2
minutes. This dose/schedule of free CFM-4.16 produced a mild weight loss of 1.6% body weight
by day 7(recovery by day 18). No other histological abnormalities were noted

160,169

. A

30mg/kg/day dose of SMA-TPGS, was injected (iv) while a 30mg/kg/day of SMA-TPGS-CFM4.16 was administered by oral gavage in two female, NCR SCID mice for 10 days. The animals
did not show any signs of toxicity, discomfort, or any histological abnormalities. These
observations indicate suitable toxicity profile of SMA-TPGS copolymer and its CFM-4.16
formulation. However, the iv injections of a 30mg/kg were best tolerated when administered on
alternate days. Accordingly, for the efficacy studies we chose to administer daily the block
copolymer by iv route while the micellar formulation with CFM-4.16 was administered by oral
gavage. The iv administration of the CFM-4.16 micellar formulation was conducted on every
alternate day.
For efficacy studies, after a suitable period of acclimation, we subcutaneously implanted a
suspension of 1 x 106 A498 RCC cells in 200µl of serum-free Hank’s balanced salt solution in
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flanks of each animal using a 27-gauge needle. Tumors were allowed to grow unperturbed for 1014 days. When tumors became palpable (200 mm3), the mice were randomly assigned to treatment
or control groups of eight animals each. Mice were treated with Control, PBS only, SMA-TPGS
copolymer (30mg/kg; iv), SMA-TPGS-CFM-4.16 formulation (30mg/kg/day) by oral gavage for
10 days. In the case of the group of mice treated with iv administration of SMA-TPGS-CFM-4.16
formulation (30mg/kg), only two injections were administered where the first dose was followed
by the second dose on the alternate day. The tumor weight and volume were measured daily, and
mice were observed for changes in weight and side effects. The endpoints for assessing antitumor
activity consisted of tumor weight, tumor growth inhibition (%T/C), and tumor cell kill Log10.
Tumor weight (mg) = (A X B2)/2 where A and B are the tumor length and width (in mm),
respectively. Tumor growth inhibition (T/C) was the median tumor weight in the treated group (T)
when the median tumor weight in the control group reached 750mg. Results were expressed as
percentage. According to NCI-accepted criteria, a treatment is considered effective if T/C is <
42%. Tumor growth delay (T-C) is the difference between the median time (in days) required for
the treatment group tumors (T) to reach 1000 mg and the median time (days) for the control group
tumors to reach the same weight. The animals were sacrificed on day 10 and tumor tissues were
collected immediately after tumor volume measurement. Tumor volumes were calculated by the
modified ellipsoidal formula. Tumor volume = 1/2(length × width2). Representative tumor
samples were stored at –80°C for subsequent analysis.
4.3.12. Statistical analysis
The Data will be presented as mean ± SD for the absolute values for all experiments. The
cell growth inhibition after treatments will be statistically evaluated using Graph Pad Prism 6.0
software (Graph Pad Software Inc., San Diego, CA Comparisons will be made between control
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and treatment groups. P<0.05 will be used to indicate statistical significance. For in vivo
experiments, the statistical significance of differential findings between all formulations and
control mice will be determined by Student's t-test. The p-values smaller than 0.05 will be
considered statistically significant. The data were expressed as mean ± SEM and analyzed using
a two-tailed Student t-test or one-way ANOVA followed by a post hoc test. A p value of <0.05
was considered statistically significant.
4.4. Results
4.4.1. Nanomicellar formulation Synthesis and characterization
The block copolymer (SMA-TPGS) was first synthesized and well characterized. The soformed SMA-TPGS conjugate was purified by ultrafiltration to remove all unconjugated
molecules before lyophilizing. Figure 4.1 illustrates the schematic representation of the
Nanocarrier synthesis by using EDC/NHS coupling chemistry.
4.4.1.1. H-NMR and FTIR
Nanomicelles were characterized by proton nuclear magnetic resonance spectroscopy (1H
NMR) and Fourier transform infrared spectroscopy (FTIR). The structure of the synthesized SMATPG copolymer was detected by 1H NMR in D2O. Figure 4.2(A) shows a typical 1H NMR
spectroscopy of the SMA-TPGS copolymer and monomers. The signals at 5.2 and 1.69 ppm were
assigned to the -CH protons and methyl protons -CH3 of SMA segment, respectively. The peak at
3.65 ppm was assigned to the -CH2 protons of PEO part of TPGS. The lower peaks in the aliphatic
region belong to various moieties of vitamin E tails 173,179,189. In FTIR analysis, we confirmed that
the SMA-TPGS copolymer was synthesized by the EDC/NHS coupling chemistry as it is shown
in Figure 4.2(B). The product was not a physical mixture of TPGS with SMA and all measurements
indicated the absence of any free crystalline particles in nanomicelles preparation and both SMA
and TPGS could inhibit crystallization of CFM4.16 during nanomicelles formulation.
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A.

TPGS

SMA
pH 8.9,
NaHCO3

SMA-TPGS copolymer

CFM-4.16

Self-Assembly of SMA-TPGS
after encapsulation of CFM-4. 16

SMA-TPGS copolymer
micelle formation
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B.

CFM 4.16
mechanism
of action

Figure 4.1. (A) The pictorial representation of SMA-TPGS copolymer synthesis with
encapsulation of CFM-4.16 and (B) accumulation of nano-micelles (SMA-TPGS-CFM-4.16) and
internalization at tumor site by endocytosis due to EPR effect. Then, a schematic representation
for mechanism of action of CFM-4.16. It is works on inhibition of CARP-1 binding with APC/C
subunit APC2. Also, it inhibits the growth of tumor cells in part by inducing CARP-1 expression,
promoting PARP cleavage, activating pro-apoptotic stress-activated protein kinases (SAPK) p38
and JNK, and apoptosis.
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(A)

(B)

Figure 4.2. (A) 1H NMR profile for polymers used (SMA and TPGS) and the conjugated polymer
(SMA-TPGS). The structure of the synthesized SMA-TPGS copolymer was detected by 1 H NMR
in D2O. The -CH protons and ring protons of SMA segment had signals at 1.69 ppm and 7.3 ppm,
respectively. The-CH2 protons of PEO part of TPGS had the peak at 3.65 ppm. We noted the lower
peaks in the aliphatic region that belong to various moieties of vitamin E tails. These peaks have
been identified as well in the conjugated polymer as indicated by arrows. (B) FTIR data for
polymers used (SMA and TPGS) and the conjugated polymer (SMA-TPGS). The arrows indicated
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forming an amide bond between the conjugated polymer (SMA-TPGS). Peaks were identified for
C-N bond, C=O stretching, and N-H stretching at around 1100, 1640-1690, and 3100-3500 cm−1,
respectively. Adapted from 1.
4.4.1.2.Particle size distribution and zeta potential
Using dynamic light scattering (DLS), the average size and size distribution of the micelles
was shown in Figure 4.3 and Table 1 (mean ± SD, n=3). The mean diameter, the polydispersity
index, and the Zeta potential of SMA-TPGS-CFM-4.16 were 144.6nm±20nm, 0.275, and -7.86Mv,
respectively. The drug-loaded nanoparticles can be prepared with or without TPGS added as a
copolymer in the fabrication process. This is because the TPGS component in the copolymer has
a self-emulsifying function. This is an advantage of the SMA-TPGS copolymer in nanoparticle
formulation, which circumvents the side effects of the traditional formulation vehicle Cremophor
EL®, which has been used for various poorly-water soluble drugs.
The particle size for all samples was found around 146 nm with narrow size distribution of
less than 0.275 polydispersity. The obtained results, of particle size of CFM4-16 loaded
nanomicelles was ~145 nm and surface charge were -7.86 mV Figure 4.3 (A). It can be observed
from Table 4.1 that addition of TPGS in the process as emulsifier slightly increased the particle
size. This is because the coating effects of TPGS on the particle surface and extra TPGS on the
particle surface may cause aggregation of the formed nanoparticles. Zeta potential determines the
particle stability in dispersion. High absolute value of the zeta potential defines high surface charge
of the nanoparticles, which leads to strong repellent interactions among the nanoparticles in
dispersion and thus high stability. The zeta potential of the TPGS emulsified, CFM-4.16-loaded
SMA-TPGS nanoparticles was found to be about -7.86 mV. Similar results were found for the
SMA-CFM-4.16 loaded nanoparticles.
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(A)

(B)

Figure 4.3. (A) Particle size and Zeta potential characterization of SMA-CFM and FA-SMA-CFM
using Dynamic light scattering (DLS) technique; (B) Transmission Electron Microscopy for
optimized SMA-TPGS Nano micelles.
4.4.1.3. Critical Micellar Concentration (CMC) and TEM (Morphology)
Additionally, Surface morphology of the drug-loaded SMA-TPGS nanoparticles was
examined by Transmission Electron Microscopy (TEM). It showed in Figure 4.3 (B) the particle
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size (160nm) little bigger than the one tested by DLS. It also showed the micelles nanoparticles
were spherical or quasi-circular and homogenous with no aggregates were existed. The particles
seemed to have smooth surface within the TEM resolution level. The smooth surface may
contribute to a slower drug release from the nanomicelles than that from those of rough surface.
No difference was noticed between CFM-4.16 loaded and unloaded nanomicelles in term of
morphology. The loading of CFM-4.16 has no significant effect in nanomicellar mean diameter,
polydispersity index, and Zeta potential in comparison to unloaded nanomicelles. These results
indicate that the size and surface properties are optimal and safe for intravenous injection as well
as ideal for tumor delivery by passive targeting (by the EPR-effect153,155,190,191). The micelles were
also characterized for critical micelles concentration (CMC) and it was identified as 0.01 mg/ml
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Figure 4.4. (A) Critical micellar concentration (CMC) for SMA-TPGS nanomicelles.(B) HPLC
method validation and chromatogram.

4.4.1.4. Drug Loading and Encapsulation efficiency
It has been known that the polymer used in the fabrication process and the drug loading
level are important factors to influence the particle size and size distribution and the drug
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encapsulation efficiency in the polymeric nanoparticles

192

; as results, it will determine the drug

release kinetics, cellular uptake and then the therapeutic efficacy of the drug-loaded nanoparticles
189,193,194

. Table 4.1 also shows the drug loading and TPGS effects on size and size distribution and

the drug loading efficiency. It can be identified that the SMA-TPGS nanoparticles prepared with
no emulsifier (TPGS) added can result in satisfactory drug EE, which was found to be 77% for
17% drug loading and with TPGS to be 85.5% for 29% drug loading found by HPLC as shown in
Figure 4.4 (B). This is normal since the higher the drug loading is because there will be more space
for drug encapsulation with taking the advantage of TPGS amphiphilic structure. For the less drug
loading of 17% in case of SMA-CFM-4.16; however, the EE of the CFM-4.16-loaded SMA-TPGS
nanoparticles can be improved by adding TPGS in the process as emulsifier. Nevertheless, the
amount of TPGS to be added should be carefully figured out. The amphipathic surfactants align
themselves at the oil–water interface to promote the stability of the particles by lowering the
surface energy and thus resist coalescence and flocculation of the particles.
Table 4.1. Characterization of SMA-TPGS nano-micelles
Sample

CMC
(mg/ml)

Hydrodynamic
size (nm)

PDI

Zeta
potential
(mV)
-7.86 ±4

EE (%)

SMA-TPGS0.010
144.6±20nm
0.275±0.05
85.5±12
CFM-4.16
SMA-CFM-4.16
0.023
123±31nm
0.163±0.07
-18±5
77±9
Abbreviations: SMA, styrene maleic acid; TPGS, d-α-tocopheryl polyethylene glycol succinate;
CMC, critical micelle concentration; PDI, polydispersity index; EE, encapsulation efficiency.

4.4.1.5. Stability indication characterization
Storage conditions of 4 °C, 25 °C, and 35°C with light protection for 2 months as shown
in Table 4.2 indicated that the CFM-4.16 remains encapsulated in the nano-micelles, indicating
that SMA-TPGS-CFM-4.16 nanoformulations were very stable with a recovery percentage of
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99.73±1.10 at 4 °C, 94.9±7.2 % at 25 °C, and 92.88 ±1.78 at 35°C. These results indicated that
both conditions (4 °C and 25 °C) would be more appropriate for storing the nanoformulations.
Table 4.2. Percent drug content of nanomicellar formulations after 60 days (n=3). Values
expressed as mean ± standard deviation (SD)
Formulation
SMA-TPGS-CFM4.16
(% drug content)
SMA-CFM4.16
(% drug content)

Temperature
4ºC
99.73±1.10

25ºC
94.9±7.2 %

35ºC
92.88 ±1.78

101.41± 0.53

96.42±0.42

90.81±1.32

4.4.2. Nanomicellar formulation of CFM-4.16 improve its release kinetics characteristics
The CFM compounds have poor aqueous solubility and consequent poor bioavailability
for their use and development as potential anti-cancer agents. To address this issue, we previously
generated and tested nano-lipid formulations (NLFs) of CFM-4 and CFM-4.16 compounds. These
NLFs resulted in significant improvements in overall bioavailabilities of CFM-4 and CFM-4.16
when compared with the respective free compound

160,169

. Here we generated nano-micellar

formulations of CFM-4.16 and tested their abilities to inhibit growth of parental and resistant RCC
cells in vitro and in vivo. As a first step, we synthesized, purified, and characterized a block
copolymer (SMA-TPGS) as detailed in methods. The proton nuclear magnetic resonance
spectroscopy (1H NMR) and Fourier transform infrared spectroscopy (FTIR) analysis revealed that
the SMA-TPGS copolymer was a conjugate and not a physical mixture of TPGS with SMA Next,
we generated and characterized SMA-CFM-4.16 and SMA-TPGS-CFM-4.16 formulations. The
mean diameter, the polydispersity index, and the Zeta potential of SMA-TPGS-CFM-4.16
formulation were 144.6nm ±20nm, 0.275 ±0.05, and -7.86 ±4 mV, respectively. The mean
diameter, the polydispersity index, and the Zeta potential of SMA-CFM-4.16 formulation however
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were 123nm ±31nm, 0.163 ±0.07, and -18 ±5 mV, respectively. The slight increase in the particle
size of the TPGS containing formulations is understandable, due to the hydrophilic PEG chains
protruding out thereby increasing the hydrodynamic diameter. The critical micelles concentration
(CMC) of the formulations was 0.010 and 0.023 mg/ml for SMA-TPGS-CFM-4.16 and SMACFM-4.16, respectively indicating high stability even on dilution of the sample. The Transmission
Electron Microscopic (TEM) analyses did not indicate any morphological differences between
CFM-4.16 loaded and unloaded nano-micelles (appendix). The loading of CFM-4.16 also had
insignificant effect on the nano-micellar mean diameter, polydispersity index, or Zeta potential in
comparison to the unloaded nano-micelles.
The type of polymer and the drug loading levels are critical factors that often influence
drug release kinetics, cellular uptake and the therapeutic efficacy of the drug-loaded nanoparticles
192,195,196

. We then determined the encapsulation efficiency (EE) and drug loading content (DLC)

for our formulations as detailed in methods. The EE and DLC for the SMA-CFM-4.16 was 77%
and 17% respectively. The EE and DLC parameters for SMA-TPGS-CFM-4.16 preparation were
85.55 and 29%, respectively, suggesting improved loading due to the inclusion of emulsifier,
TPGS. We next determined the stability of the formulations by their extended (2 months) storage
at 4°C, 25°C, or 35°C with light protection. CFM-4.16 remained encapsulated in the SMA-TPGS
nano-micelles with a recovery percentage of 99.73 ±1.10 at 4°C, 94.9 ±7.2 at 25°C, and 92.88
±1.78 at 35°C. The recovery percentage of CFM-4.16 in SMA encapsulated formulation was
101.41 ±0.53 at 4°C, 96.42 ±0.42 at 25°C, and 90.81 ±1.32 at 35°C. Altogether, our results indicate
that the CFM-4.16 micellar formulations have suitable drug loading and particle characteristics
and can be stored at 4°C or at room temperature (25°C). Based on this information, we proceeded
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to determine whether the CFM-4.16 nano-micellar formulations inhibit growth and viability of
parental and drug-resistant RCC cells in vitro and in vivo as detailed below.
4.4.3. Nanomicellar formulation of CFM-4.16 inhibits growth of parental and Everolimusresistant RCC cells in vitro and in vivo in part by stimulating apoptosis
Next, we treated the parental RCC cells and their respective, Everolimus-resistant sublines
with various doses of block copolymer (SMA-TPGS), free CFM-4.16, SMA-CFM-4.16, and
SMA-TPGS-CFM-4.16 for 24h. The RCC cell viabilities were determined as described in
methods. As shown in Figure 4.5 A and B, the treatments of cells with various doses of block
copolymer alone elicited a very modest to no loss of their viabilities when compared with their
untreated counterparts. The free CFM-4.16 or its nano-micellar formulations, on the other hand,
inflicted a significant loss of viabilities of the parental as well as Everolimus-resistant RCC cells
when compared with their respective, untreated counterparts. Of note is the fact that the free
compound or its formulations at the three respective doses of each provoked a generally similar
degree of reduction in RCC cell viabilities that ranged between 40-80%. A498 parental and
resistant RCC cells albeit were more sensitive to the 10μM dose of either of the micellar
formulations when compared with their CFM-4.16 treated counterparts, overall a similar range of
reduction in the viabilities of cells that were treated with free compound or its micellar
formulations would suggest for an excellent in vitro activity of CFM-4.16 formulations. Consistent
with our data in Chapter 3, the western blot analysis further revealed that treatments of parental or
Everolimus-resistant RCC cells with 10μM dose of respective micellar formulations of CFM-4.16
also caused activation of pro-apoptotic SAPKs, P38α/β and JNK1/2, CARP-1 expression, and
PARP cleavage when compared with their respective block copolymer (SMA-TPGS)-treated cells
(Figure 4.5. C, D).
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Figure 4.5. Nano-micellar formulations of CFM-4. 16 inhibits growth and stimulates apoptosis in
parental and Everolimus-resistant RCC cells. (A, B) Indicated RCC cells were either untreated
(Control), treated with SMA-TPGS, CFM-4.16, SMA-CFM-4.16, or SMA-TPGS-CFM-4.16 for
noted dose and time. (A, B) Cell viability was determined by MTT assay. The histogram columns
represent means of three independent experiments with 4-6 replicates for each treatment; bars, S.E.
(C, D) Cell lysates were analyzed by Western blotting (WB) as noted in Methods for levels of
CARP-1, cleaved PARP and activation (phosphorylation) of pro-apoptotic p38, and JNK1/2
SAPKs essentially. Adapted from 1.

C
Cell Line

CFM-4.16, 72h, IC50 (uM)

A498 Wild type

≈0.90

UOK262 Wild type

≈0.85

HEK 293 Wild type

≈9.2

HK2 Wild type

≈3.8
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Figure 4.6. RCC cells are more sensitive to inhibition by CFM-4.16 when compared with noncancer renal epithelial cells. (A, B) Indicated cells were treated with 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, and
10.0 uM dose of CFM-4.16. Percent cell viabilities were determined relative to respective DMSOtreated controls. The histogram (Lines in A or Columns in B) represent means of two independent
experiments with 4-6 replicates of each dose for the respective cell type (C) IC50 values of RCC
and Renal epithelial cells treated with CFM-4.16 as in panels A and B.

4.4.4. Nanomicellar formulation of CFM-4.16 inhibits growth of parental and Everolimusresistant RCC cells in vivo
We next examined the in vivo antitumor efficacy of nano-micellar formulation of CFM4.16 (SMA-TPGS-CFM-4.16) in a highly aggressive RCC A498 orthotropic xenograft tumor
bearing SCID mice as described in methods and our published protocols

157,159

. In our previous

studies, we prepared CFM-4.16 by dissolving it in 10% DMSO/Cremophor plus sterile, distilled
water with a pH of 4.5. We administered a dose of 30mg/kg/day of this preparation by intravenous
(tail vein) injections for a total dose of 482mg/kg in SCID mice bearing human TNBC cell-derived
xenografts. With the exception of a mild, <2% loss in body weight, the preparation did not cause
any histological abnormalities in the treated animals and lacked a therapeutic T/C values

159

. On

this basis, we chose a 30mg/kg/day dose of CFM-4.16 (free compound as DMSO/Cremophor
preparation or nano-micellar formulation) for use in current in vivo experiments. As shown in
Figure 4.7A, intravenous (iv) administration of vehicle (Control) SMA-TPGS (total dose of
120mg/animal), DMSO/Cremophor preparation of CFM-4.16 (total dose of 240mg/animal), or
administration of SMA-TPGS-CFM-4.16 (total dose of 210mg/animal) by oral gavage failed to
inhibit tumor growth. However, only two i.v. injections of 30mg/kg/day of SMA-TPGS-CFM4.16 (total dose of 60mg/animal) caused a significant reduction in tumor size when compared with
the tumor sizes noted in the other treatment groups (Figure 4.7A). The HPLC analysis of the tumors
from animals treated with i.v. injections of SMA-TPGS-CFM-4.16 revealed presence of CFM-
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4.16 in tumors. In addition, after the completion of the animal experiment, tumors from treatment
and control groups were dissected, and cryosectioned for imaging of apoptotic signs using TUNEL
(Terminal deoxynucleotidyl transferase dUTP nick end labeling) and CARP-1. The immunohistological analysis of tumors from animals treated with i.v. injections of SMA-TPGS-CFM-4.16
showed elevated levels of CARP-1 and TUNEL-positive cells when compared with the tumors
derived from the animals of control group (Figure 4.7B). Thus, the data suggest that nano-micellar
formulation of CFM-4.16 enhance anti-tumor efficacy of CFM-4.16 when administered i.v. but
not orally, at a significantly lower total dose when compared with the free compound.

Figure 4.7. Nano-micellar formulation of CFM-4. 16 inhibits growth of RCC cell-derived
xenografts. (A) Histogram showing tumor size in the vehicle-treated (indicated as Control), CFM4.16, or SMA-TPGS-CFM-4.16 (p.o. or i.v.) treated, RCC (A498) xenograft-bearing animals. The
xenograft establishment, treatment and analysis procedures were carried out essentially as detailed
in Methods. The columns represent average values from a total of eight animals in respective
group, bars, SE, significant where *p = 0.05 vs Control. (B) SMA-TPGS-CFM-4.16 treatments
(iv) induce CARP-1 expression and apoptosis in RCC tumor xenografts. Representative tumor
tissues from two animals each from the vehicle-treated (noted as Control) or SMA TPGS-CFM4.16 treated groups were fixed in formalin, paraffin embedded, processed, and subjected to
immuno-staining as detailed in Methods. Photomicrographs (400 x magnification) are shown for
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apoptosis (by TUNEL assay), and levels CARP-1 protein as noted in methods. Elevated apoptosis
is indicated by increased brown staining or dark-brown spots in SMA-TPGS-CFM-4.16 panels
stained with anti-CARP-1 antibodies or TUNEL, respectively. Adapted from 1.

(A)

(B)

(C)

Figure 4.8. (A) Body weight changes of mice during treatment course. The lines represent average body
weight from a total of eight animals in respective group that were measured on the indicated days; bars, SE.
(B) Tumor size of mice during treatment. The line represents average values from a total of eight animals
in respective group, bars, SE. (C) Amount of CFM4.16 remaining in the blood after the last injection of
drug. The histogram columns represent means of CFM-4.16 concentrations from three animals from the
indicated treatment group; bars, S.E.
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4.5. Discussion
CFM-4 and its analog CFM-4.16 have poor aqueous solubility of <1mg/ml. This attribute
contributes to poor dissolution with consequent poor absorption and bioavailability. Recent
advances in nano-formulation-based technology have allowed optimization of poorly soluble
compounds for preclinical as well as clinical testing and use. In our prior proof-of-concept studies,
nano-lipid formulations of CFM-4 and CFM-4.16 compounds were prepared by combining highmelting solid lipid carriers and vitamin E TPGS co-surfactant. These formulations were
demonstrated to not only enhance solubility and oral bioavailability of the CFMs, but also were
effective in suppressing NSCLC and TNBC cell-derived tumor growth in pre-clinical animal
models when administered orally 159,160. Here we prepared a polymeric micelle based nano-drug
delivery system of CFM-4.16 to improve its dissolution and bioavailability. A nanomicellar
formulation of SMA-TPGS and CFM-4.16 resulted in improved dissolution and consequent
enhanced absorption, which was also evident by the improved pharmacokinetic profile as
previously reported 159,160. Vitamin E-TPGS is FDA approved co-surfactant that acted as stabilizer
and permeation enhancer while SMA contributed to good micellar property

172,197,198

. Thus,

chemical conjugation of SMA and TPGS, namely SMA-TPGS creates more hydrophobic space,
which provides higher CFM-4.16 encapsulation efficacy. Due to the crystalline nature of matrix
lipids in solid particles, the space for the drug loading is often limited. Size and surface coating
also play an important role in determining the mechanism and efficiency of nanoparticle. The
particle size of ~145 nm and surface charge is -7.86 mV of the CFM-4.16 loaded nanomicelles are
optimal and safe for systemic (intravenous or oral) drug administration as well as competent for
tumor delivery by passive targeting EPR-effect 178,190,199.
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Our preliminary studies here indicate that both free and SMA-TPGS formulation of CFM4.16 inhibit growth of RCC cells in vitro, in part by stimulating apoptosis. Consistent with our
prior findings, CFM-4 or CFM-4.16 caused loss of cyclin B1, and upregulation of CARP-1,
activation of p38 and JNK1/2 SAPKs, and cleavage of PARP in the RCC cells. Intravenous
administration of the nano-micellar formulation of CFM-4.16 inhibited growth of RCC cellderived tumor xenografts in vivo in part by stimulating CARP-1 levels and apoptosis. Taken
together, our current data provide us with a further rationale to develop CFM compounds and their
formulations for targeting parental and resistant RCCs.
4.6. Conclusions
CARP-1 functional mimetics (CFMs) are novel small molecule inhibitors of RCC. In
addition, CFMs induce apoptosis by activating SAPKs and elevating CARP-1. In this study, we
employed a nanotechnology to tackle the poor aqueous solubility of a potent CFM compound
(CFM-4.16) which restricts its in vivo therapeutic efficacy. This SMA-TPGS-CFM-4.16
formulation maintained its nanoparticulate nature, homogenous polydispersity and high drug
encapsulation efficacy. Since free CFM-4.16 or SMA-TPGS-CFM-4.16 elicited similar effects on
cell viability, and levels of apoptosis would indicate that the anti-cancer effects of CFM-4.16 are
retained in nanoformulation. Moreover, the physicochemical analyses indicate an optimum release
of CFM-4.16 from nanoformulation. Together the physicochemical characteristics and biological
activity of SMA-TPGS-CFM-4.16 seem promising for their use in future pre-clinical in vivo
studies for the RCC tumor models.

79

5.
CHAPTER 5. TUMOR HYPOXIA DIRECTED MULTIMODAL
NANOTHERAPY FOR OVERCOMING DRUG RESISTANCE IN RENAL CELL
CARCINOMA AND REPROGRAMMING MACROPHAGES
Results from the following studies have been submitted to Biomaterials Journal: CA-IX as a
selective approach for targeting RCC and overcoming resistance with combining drugs
approach
5.1. Objectives
Studies conducted includes: (i) Development of an ATZ-conjugated polymeric lipid
nanoformulations library for the selective delivery of a drug cocktail to the hypoxic region of
therapy resistant RCC. (ii) Also, to alleviate the RCC drug resistance, we have used Sorafenib
(Sor) in combination with tumor hypoxia directed nanoparticle (NP) loaded with a new class of
apoptosis inducer, CFM 4.16 (C4.16), namely CA IX-C4.16. (iii) Authenticated RCC cell lines
such as WT (A498, UOK262) and Evr-res (A498, UOK262) will be utilized as RCC cells, as well
as Raw 264.7 (macrophage) for macrophage phenotyping studies. The following will be
investigated (1) a synergistic anticancer effect of CFM-4.16 with TKIs, (2) the role of M2macrophages in tumor immune evasion, and (3) the mechanism of inhibiting tumorigenic crosstalk between RCC epithelial cells and M2-macrophages using NPs. The tumor environment
mimetic advance spheroid and Transwell cell culture models will be used to establish efficacy.
5.2. Introduction
Renal Cell Carcinoma (RCC) contributes to >90% of the most common form of kidney
cancer and remains one of the ten leading causes of cancer deaths. It has been estimated
that each year around 60,000 new patients are diagnosed with, and about 13,500 succumb
to RCC 8. Thus, RCC represents one of the most lethal malignant urological tumor 200. The
common form of RCC (more than 95%) is clear cell renal cell carcinoma (ccRCC) 83. The
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mutation and inactivation of tumor suppressor Von Hippel-Lindau (VHL) gene is
frequently observed in this malignancy that leads to a higher intracellular level of hypoxiainducible factors 1α and 2α (HIF1α and HIF2α). The increased level of HIF-1α in RCC
effectively regulates the tumorigenesis by upmodulating the function of AKT and VEGFR
kinases that play an essential role in cellular metabolism, apoptosis inhibition, and hypoxia
induction

201

. All these factors promote RCC to develop resistance to radiotherapy and

conventional chemotherapy

202,203

. Several receptor tyrosine kinase inhibitors (TKIs),

mammalian target of rapamycin inhibitors (mTOR) and serine-threonine kinase (STK)
inhibitors are clinically approved for the treatment of RCC

166

, although the benefit of

overall progression-free survival remains poor (5-year survival rate of <10%). Thus, there
is an urgent unmet need for targeted combination therapies with novel cell killing
mechanisms

102,204

. Although, TKIs and mTOR inhibitors have increased therapeutic

possibilities for treating RCC, a substantial proportion of patients do not respond
adequately, and therapy resistance almost inevitably occurs. Recently, new strategies have
also emerged that include immunotherapy such as PD-1 inhibitor (Nivolumab)

117

and the

combination of chemo-immune therapy 103. These developments suggest that combination
treatments aimed at different, non-related pathways could be advantageous

112,113,146

. In

addition, due to the increase in vascular nature and high level of vascular permeability
factor, ccRCC patients have benefited from anti-VEGFR cancer therapy. Over a period of
time, the majority of the RCC patients ultimately develop a refractory response to antiVEGFR treatment that is due to poor vascularization at the tumor core associated with
tumor hypoxia 205. In this regard, delivery of the therapeutic payload to the tumor hypoxic
(core) is a rational approach for improving the current therapy. Additionally, development
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of novel synergistic therapeutic strategies, such as the resurrection of apoptosis, inhibition
of AKT, and suppression of tumorigenic macrophages are desirable to tackle the current
clinical challenges of drug-resistant and highly aggressive RCC

157

. We have developed

Evr-res RCC cell model to evaluate the reversal of drug resistance using nano-combination
therapy. We pursued different combination regimens, including drugs Evr (mTOR
inhibitor) and Sorafenib or Cabozantinib (both VEGFR and MET inhibitors).
The hypoxic tumor environment, highly prevalent in poorly vascularized and necrotic tumor
core is well known to stimulate expression of VEGF and CA IX. CA IX is a membranebound protein that is overexpressed on the surface of many cancer cells in a hypoxic
environment

122

. CA IX tightly controls the acid-base balance in the kidney

122

, whereas

during malignancy CA IX is involved in tumor cell survival and metastasis, and its
increased expression correlates with poor clinical outcome. More than 7-clinical trials are
underway to target CA IX in RCC and other solid tumors [NCT00059735, NCT00884520]
that fortifies CA IX as an excellent biomarker for selective hypoxia mediated payload
delivery. Numerous studies have investigated CA IX distribution in normal tissues and
malignancies

124–129

. Over-expression of CA IX has been documented in 93-97% of

ccRCCs with rather low to limited expression in normal tissues/organs making it a selective
biomarker for RCC

123

. Indeed, CA IX is almost homogeneously over-expressed in the

ccRCC subtype 84,111,124–129. Given the favorable tissue distribution, the potential of CA IX
targeting of RCC for diagnosis or therapy has also been studied

130,131

. Due to the unique

molecular attribute of RCC, CA IX is regarded as an excellent target for diagnosis and
possibly for targeted therapy 111,126–128,132. Clinical trials have unambiguously demonstrated
that CA IX can be targeted to RCC tissues with minimal damage to normal tissues, further
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highlighting suitable toxicity profiles of CA IX targeting
currently approved therapies against CA IX

164

133,134

. However, there are no

. Monoclonal antibodies have been used to

target CA IX, but their large molecular weight limits penetration through the poorly
vascularized tumor and their slow blood clearance minimize their utilization as tumor
imaging agents or radiotherapeutics because of high background and toxicity

134

. Finally,

some recent studies have investigated whether small molecule CA IX-inhibitors can be
used in serum assays or as an imaging target to monitor therapy responses

127–129

.

Importantly, there is a critical need to develop safe and effective delivery vehicles that can
carry the payload to the desired target tissue and cells

157,185,206–209

.

Toward this end, we developed a simple and efficient multistage nanoplatform for
systemically targeted polypharmacy payload delivery to induce the combination of
chemotherapeutic and immunotherapeutic effect in RCC. The oligomer we developed
comprised of Vitamin-E- α-D-Tocopherol (TPGS) and styrene maleic anhydride (SMA)
ligated with Acetazolamide (ATZ), namely CA IX-SMA-TPGS. The CA IX-SMA-TPGS
oligomer was further encapsulated with C4.16 to obtain highly potent therapeutic payload
containing nanoparticle CA IX-C4.16, respectively. The CA IX-C4.16 NPs have
homogenous nanoparticle nature with narrow polydispersity index that is suitable for in
vivo delivery. For ease of chemical synthesis of oligomers, we utilized copper free ‘click’
chemistry. We have discovered and demonstrated CCAR1/CARP-1 protein as an inducer
of apoptosis in RCC and other types of cancer. Upregulation of CARP-1 activates
“apoptosis hallmarks”, such as caspase mediated PARP cleavage, downregulation of
PI3K/AKT signaling and loss of cyclin B1 in RCC 157. Our collaborator recently identified
the potent activators of CARP-1, a library of small molecule CARP-1 functional mimetic

83

(CFM) compounds. CFM-4.16 (namely C4.16), is highly efficient in RCC cell killing as
noted from NCI-60 screen

157

. Our data revealed that C4.16 is a superior inhibitor of both

WT and Evr-resistant RCC cells with 4-5-fold improvement in IC50 value as compared to
FDA approved Evr or Sor. In 2007, Sorafenib (Sor), a potent multi-kinase inhibitor of
tumor-cell proliferation and angiogenesis, was clinically approved for oral treatment of
advanced RCC with the median progression-free survival of 5.5 months

210

. Along with

this encouraging clinical outcome, there are a few reports on durable responses of Sor or
the other VEGFR pathway blockers. However, the majority of patients develop resistance
to Sor within a median of 5–9 months 211. Thus, more efficient and divergent combination
therapy for inhibiting multiple tumorigenic pathways in RCC is required. Toward this, we
found the combination of Sor and CA IX-C4.16 showed remarkable synergy in killing WT
and Evr-res RCC cells. This combination treatment caused a complete wipeout of activated
AKT (P-AKT) level, upregulated apoptosis hallmarks, such as caspase 3/7 and annexin V.
The CA IX-C4.16+Sor is promising in upmodulating tumoricidal function of M-1
macrophage, while downmodulating tumorigenic M-2 macrophage-associated biomarkers,
such as CD206, arginase-1. Further, NIR imaging of CA IX-SMA-TPGS-S0456 confirmed
the selective tumor accumulation of the vehicle with ~6-fold higher tumor/liver as
compared to control. The high intensity of NIR-dye in tumor core indicates selectivity of
CA IX-SMA-TPGS-S0456 in tumor hypoxia targeting. Finally, the significant tumor
growth inhibition by CA IX-C4.16+Sor in Evr-res A498 model underscores the rationale
of using Sor in combination nanotherapy as a promising platform in reversing drug
resistance with untraceable liver and kidney toxicity (Scheme 1).
5.3. Materials and methods
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5.3.1. Cell culture, reagents, and chemicals
Structure and synthesis of the C4.16 compound have been previously described
157,159

. A stock solution of 50mM of C4.16 was solubilized in dimethyl sulfoxide (DMSO)

and stored at –20°C for further use. Sor was obtained from LC Laboratories, Woburn, MA,
and a 10mM stock solution was prepared in DMSO and stored at –20°C. Everolimus (Evr)
was obtained from selleckchem, Boston, MA, and a 10mM stock solution were prepared in
DMSO and stored at –20°C. Acetazolamide (ATZ), ‘click’ chemistry reagents, Styrene
maleic anhydride (SMA, MW 1600), D-alpha-tocopheryl polyethylene glycol succinate
(Vitamin E-TPGS), and 3-[4, 5-Dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium bromide
(MTT) were purchased from Sigma-Aldrich (St Louis, MO). NIR dye, S0456 was obtained
from FEW Chemicals GmbH, Germany. We obtained all other analytical grade reagents
from Fisher Scientific (Hampton, NH) and Sigma-Aldrich (St Louis, MO) and used them
without further purification. DMEM, RPMI medium and antibiotics (penicillin and
streptomycin) utilized in this work were purchased from Invitrogen Co. (Carlsbad, CA).
Fetal bovine serum (FBS) and DMSO were purchased from Fisher Scientific (Fair Lawn,
NJ). The Protein Assay Kit was obtained from Bio-Rad Laboratories (Hercules, CA). The
rabbit monoclonal antibodies for –actin was acquired from Sigma-Aldrich (St. Louis,
MO). We purchased rabbit monoclonal antibodies to phospho- and total AKT, and
Carbonic Anhydrase-IX (CA IX) from Cell Signaling Technology (Beverly, MA).
5.3.2. Cell lines development and culturing condition
The human RCC A498 cells were from ATCC and kindly provided by Dr. Rajvir
Dahiya (UCSF). All the cells were regularly maintained following procedures published

85

before

212,213

. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)

with GlutaMAX that was supplemented with 10% FBS, 100 units/ml of penicillin, and
100 μg/ml of streptomycin, and the cells were cultured at 37°C and 5% CO2. For cell
viability and MTT studies, the cells were cultured in fresh media supplemented with 10%
FBS before their treatments with various agents 214,215. Resistant RCC cell-lines, including
Evr-res A498, have been already established and validated in our previous work

157

. For

inducing hypoxia, cells were treated with 200 M Cobalt Chloride (CoCl2) in standard
growth media for 72 h before experiment

216,217

. RCC 3D-spheroid cell lines were grown

in low density with 2% FBS containing culture media and before treatment they were
induced with the hypoxic condition.
5.3.3. General procedure for synthesis of compound SMA-TPGS and ATZ-SMA-TPGS by
Copper-free 'click' chemistry
As illustrated in Figure 1 (Scheme 1), we first synthesized acetazolamide-amine (ATZNH2) from acetazolamide (ATZ) by acid hydrolysis as previously described

218

. Subsequently,

ATZ-NH2 was being reacted with DBCO-NHS-ester to finally arrive at ATZ-DBCO (compound
a) which is CA IX (hypoxia) targeting ligand. Secondly, in scheme 2, we synthesized SMA-TPGS
oligomer (SMA-TPGS) by adding known amounts of TPGS in NaHCo3 buffer at pH 8.9 with
fixed amounts of anhydrous SMA to permit its anhydride ring opening reaction with the alcohol
group of TPGS. Then, we conjugated the oligomer with azido functional compound (NH2-PEG8N3) by acid-amine coupling (EDC/NHS) reaction to finally get (compound b). Finally, the Cupper
free click chemistry reaction will occur by reacting (compound a) with (compound b) to form
triazole ring. All unconjugated reagents were removed prior lyophilization.
5.3.4. Preparation and Characterization of C-4.16-loaded NPs
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After ‘click’ reaction, we obtained CA IX-SMA-TPGS (CA IX-targeted oligomer), and in
parallel, we generated SMA-TPGS (non-targeted oligomer). Both, (SMA-TPGS and CA IX-SMATPGS-C4.16) NPs were developed using our previously reported methods with slight modification
157

. In brief, 100 mg of conjugated polymer was dissolved in 100 ml of deionized (DI) water under

stirring. Then C4.16 (30 mg) was dissolved in 1 ml of DMSO and mixed with the polymer solution.
Subsequently, 40 mg of EDC was added dropwise into solution and pH was kept at 5.0 to stir for
30 min. Then, the pH was raised to 11 and kept for other 30 min. Finally, pH was adjusted to 7.8
– 8.0 and the free drug C4.16 were removed by dialysis for 4-5 h in a bag with a cut-off of MW 2
kDa. Then, the products obtained were lyophilized to obtain the final powder and stored in the
freezer until further use. Subsequently, the particle size and surface charge (zeta potential)
measurements were performed using a Beckman Coulter Delsa Nano-C-DLS Particle analyzer
(Miami, FL) equipped with a 658 nm He-Ne laser. For particle size, we suspended the NPs in DI
water and detected the scattered light at 165° angle. We then obtained the peak average histograms
of intensity, volume and number from 70 scans to calculate the average diameter of the particles.
The zeta potentials were evaluated by measuring the electrophoretic mobility of the charged
particles under an applied electric field. For Morphology, Transmission Electron Microscopy
(TEM) of the NP was evaluated using JEOL-JEM-1000 instrument (JEOL Ltd, Tokyo, Japan). We
also characterized oligomer by proton nuclear magnetic resonance spectroscopy (1H NMR) and
Fourier transform infrared spectroscopy (FTIR). The structure of the synthesized SMA-TPGS and
CA IX-SMA-TPGS copolymer was detected by 1H NMR in D2O as previously described

157209

.

The proper synthesis of the SMA-TPGS and CA IX-SMA-TPGS oligomer was also confirmed by
the MALDI/MS and was found not to be a physical mixture of TPGS with SMA as all
measurements indicated the absence of any free crystalline particles before NPs preparation.
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5.3.5. The Drug Loading (DLC) and Encapsulation efficiency (EE) of C4.16 loadednanoparticles
We evaluated the C4.16 loading content percentage and the encapsulation efficiency (EE
%) in NPs by High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA). Samples
of the C4.16 NPs preparations were taken, and the unentrapped C4.16 was quantified using our
previously published HPLC method

157

. The loading efficiency of micelles was calculated by

dissolving a known quantity of NPs directly in DMSO and further dilution of drugs with the mobile
phase followed by determination of the absorbance at 309 nm (λ max) with respect to the standard
curve. Free drug (unentrapped C4.16 in the SMA-TPGS or CA IX-SMA-TPGS) was separated by
ultrafiltration centrifugation technique. Briefly, 1 mL of CA IX-SMA-TPGS-C4.16 (targeted CA
IX-C4.16 NPs) and SMA-TPGS-C4.16 (non-targeted) colloidal solutions were placed in the upper
chamber of a centrifuge tube matched with an ultrafilter and centrifuged for 15 min at 4000 rpm.
The total drug content in C4.16 NPs was determined as follows. Aliquots of 1mL formulation
dispersion were diluted accordingly by ethanol to dissolve the ingredient, and the resulting
suspension was then filtrated through 0.45µm membrane filters. The filtered solution was analyzed
by Waters® Alliance e2695 HPLC using Symmetry® C18 column (250mm × 4.6mm, 5µm). The
mobile phase was a mixture of Acetonitrile, Methanol, 10mM KH2PO4 buffer (65:20:15 v/v) with
pH adjusted to 2, and the flow rate was maintained at 1.0mL/min. All the samples were analyzed
using empower PDA software. We then calculated the encapsulation efficiency (EE) and drug
loading content (DLC) by the following equations:

Drug loading content (DLC) =

The weight of C−4.16
encapsulated in micelles
Total weight of C−4.16
loaded in micelles

x100

Equation (1)
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Encapsulation Effeciency (EE) =

Mass of C−4.16
encapsulated in micelles
Total mass of C−4.16
initially loaded in micelles

x100

Equation (2)

5.3.6. Expression of CA IX by A498 RCC cells and A498 RCC tumor models
The expression of CA IX on the surface of A498 and Evr-A498 cells was investigated
under a normoxic or hypoxic condition by exposing cells to normoxia (no treatment) or hypoxia
(cobalt chloride, CoCl2 treatment) for 72 h, followed by CA IX detection using
immunofluorescence analysis or western blot. Proteins from tumor tissues were extracted using
RIPA buffer with the Halt Protease and Phosphatase Inhibitor Cocktail. A498 cells or tumors were
fixed with 4% cold paraformaldehyde for 15 min after incubation for 24 h under normoxic or
hypoxic condition. Cells were washed three times with DPBS and blocked with 10% bovine serum
albumin for 1 h at room temperature, then incubated with primary rabbit monoclonal anti-CA IX
antibody (20 μg/mL) overnight at 4 °C. Cells were subsequently washed three times followed by
incubation with FITC-conjugated rabbit anti-mouse secondary antibody for 1 h at room
temperature. A498 cells under the normoxic or hypoxic condition, only treated with FITCconjugated goat anti-mouse secondary antibody served as controls to avoid interference of cell
auto-fluorescence. Cells were observed using a Confocal Laser Scanning Microscope (CLSM).
For tumor tissues, mice were implanted with A498 cells using the technique previously reported
157

. Briefly, A498 cell suspensions were prepared in PBS and mice were injected with 1 × 106 cells

subcutaneously by syringes with 29-gauge needles. On day 14 after tumor cell implantation, mice
were sacrificed, and RCC tumor tissue was collected for histology performed by Biobank core
facility.
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5.3.7. Hypoxic core penetration of CA IX-SMA-TPGS oligomer in hypoxic A498 3D tumor
spheroid
Cancer cell specific uptake of CA IX-SMA-TPGS oligomer was performed in tumor
spheroids by immunofluorescence. Cells were cultured with ~70-80% confluence. We cultured
Evr-res A498 cells to form 3D spheroid structure based on previously published methods

157,159

.

Briefly, the cells were washed twice in 1 x PBS, trypsinized and pelleted the cells with 200 x g
centrifugation at room temperature. It was re-suspended in 5ml of sphere media (DMEM/F12
supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 1 x B27
supplement, 20ng/ml recombinant human epidermal growth factor (EGF; Sigma), and 10ng/ml
recombinant human basic fibroblast growth factor (bFGF; R&D Systems). Cells were seeded
approximately 5000 cells per ml on an ultra-low adherent 60mm plate and incubated at normal cell
culturing conditions for two weeks without disturbing the plates. Seventy-two h prior to treatment,
media was replaced with the hypoxic condition. Once the sphere was formed, spheres were treated
with 1µM Rhodamine B conjugated CA IX-SMA-TPGS oligomer (CA IX-Rhoda-B) for 4 h or
kept untreated at 37°C and 5% CO2. At the end of the incubation period, the spheroids were washed
with cold DPBS and scanned beginning from the top of the equatorial plane to obtain the Z-stack
images by CLSM for the spheres of untreated and treated plates as described as reported before
196

.

5.3.8. In vitro cytotoxicity assay
MTT assay was used to evaluate the anti-cancer effects of targeted CA IX-C4.16 NP and
free anticancer drugs (C4.16, Evr, and Sor) in CA IX-positive (A498 RCC cells). First, the cells
were seeded in a 96-well plate at a density of 5x103 cells per well and allowed to grow in fresh
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culture media overnight. Cells were subjected to parallel treatments under hypoxic and normoxic
conditions as described above. After 20 h, the medium was removed, and the cells were washed
twice with PBS. Cells were then treated with various concentrations of respective agents for the
noted dose and time. Control cells were treated with 0.1% DMSO in the culture medium219–221.
After treatment, cell viabilities were measured by the MTT assay. Briefly, 20 μl of 1mg/ml of
MTT was added to each well and cells were incubated for 2-4 h at 370C. MTT was removed, and
the resulting formazan products were dissolved by adding 50μl DMSO/well followed by
colorimetric analysis at 595nm using a multi-label plate reader (Victor3; PerkinElmer, Wellesley,
MA).
5.3.9. Apoptosis analysis by flow cytometry and Caspase 3/7 Glo assay
We determined apoptosis induction in A498 RCC cells that were treated with free C.4.16
or CA IX-C4.16 NP by flow cytometry with Annexin V/7-AAD dual staining. The percentage of
Annexin V-/7-AAD - (R5), Annexin V+/7-AAD - (R6) and Annexin V-/7-AAD + (R4) and Annexin
V-/7-AAD

+

(R3) cells were obtained to determine the number of live, as well as early and late

apoptotic, and necrotic cells. To evaluate caspase-3/7 activities, cells were cultured and treated
with DMEM medium (Free oligomer or control), C4.16, Sor, or C4.16+Sor for 24 h and were
tested by Caspase-Glo 3/7 Assay (Promega) according to the manufacturer’s recommendations.
5.3.10. Western Blot analysis
The RCC cells were treated with DMSO/Vehicle (Control) or indicated dose and time of
the noted compound. Cells were harvested and lysed in RIPA buffer (50mM Tris-HCI, pH 8.0,
150mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate
(SDS), and 0.1% of protease inhibitor cocktail) for 20 min at 40C. The lysates were then
centrifuged at 14,000 rpm at 40C for 15 min to get rid of debris. We then determined the protein
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concentrations of whole cell lysates using the Bradford Protein Assay Kit. Supernatant proteins,
50μg from each sample, were separated by SDS-10% polyacrylamide gel electrophoresis (SDSPAGE) and transferred to polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA)
by standard procedures. The membranes were hybridized with primary antibodies followed by
incubation with appropriate secondary antibodies. The antibody-bound proteins were visualized
by treatment with the chemiluminescence detection reagent (Amersham Biosciences) according to
the manufacturer’s instructions, followed by exposure to X-ray film (Kodak X-Omat). The same
membranes were then re-probed with the anti-β actin antibody, which was used as an internal
control for protein loading.
5.3.11. Reprogramming macrophages with (CA IX-C4.16+Sor)
Transwell inserts 0.4 μM Corning, Falcon®, catalog number: 353493 and Corning® 6 well cell
culture plates were used. Figure 6 A shows a diagram representing a brief outline of the steps of
the protocol and a timeline indicating the order of events that were all carried out under sterile
conditions following protocol published by Smith et al. Briefly, Raw264.7 cells were placed into
the Transwell inserts. Raw-264.7 cells were first polarized to M1-macrophage using IFN- and
LPS, and to M2-macrophage using IL-4 recombinant protein. Then, A498 RCC cell lines were
cocultured with activated macrophages followed by treatment of Sor, C4.16, and CA IXC4.16+Sor for 24 h. Caspase 3/7 assay was performed in Evr-res A498 cells treated with Sor,
C4.16, and CA IX-C4.16+Sor while co-culturing with Raw-264.7 macrophage to demonstrate
whether combination treatment can reeducate macrophage to induce apoptosis mediated A498 cell
death.
5.3.12. A-498 Three-dimensional RCC tumor spheroids uptake
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CA IX expression of tumor spheroids was checked by immunofluorescence. The RCC cells
were obtained from xenograft tumors derived from WT cells and Everolimus-resistant RCC cells
from a two-dimensional culture plate with ~70-80% confluence. We performed the threedimensional renal sphere cultures by mostly following the methods described before [14,36].
Briefly, the cells were washed twice in 1 x PBS and trypsinized following established protocols.
We then pelleted the cells at 200 x g at room temperature and re-suspended them in 5ml of sphere
media (DMEM/F12 supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 U/ml
streptomycin, 1 x B27 supplement, 20ng/ml recombinant human epidermal growth factor (EGF;
Sigma), and 10ng/ml recombinant human basic fibroblast growth factor (bFGF; R&D Systems).
We seeded approximately 5000 cells per ml in an ultra-low adherent 60mm plate and incubated
them at normal cell culturing conditions for two weeks without disturbing the plates. After the
spheres formed, we added fresh media with or without 1µM Rhodamine B conjugated CA IX
targeted-OMs and continued incubating cells for additional 4h at 37°C and 5% CO2. At the end of
the incubation period, the spheroids were washed with cold DPBS and scanned began from the top
to the equatorial plane to obtain the Z-stack images by CLSM for the spheres in the untreated and
treated plates as described as reported before by another group [42].
5.3.13. Antitumor therapy study in highly aggressive Evr-res A498 tumor in nu/nu xenograft
model
The generation of RCC cell-derived subcutaneous tumor was done according to our
previously published protocols approved by the Institutional Laboratory Animal Care & Use
Committee (IACUC) at the Wayne State University 157,159. Female, 5-6 weeks old nu/nu mice were
obtained from Jackson Laboratory, Bar Harbor, ME. For therapy studies, after an appropriate
period of acclimation, a suspension of 1 x 106 Evr-res A498 cells in 150µl PBS was subcutaneously
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implanted in flanks of each animal using a 27-gauge needle. Tumors were allowed to grow for 10
days. When tumors became palpable (200 mm3), the mice were randomly assigned for treatment
or control groups of five animals each. Mice were treated with Vehicle (Control), CA IX-C4.16
NP (24mg/kg/day), Sor (10mg/kg/day) via intravenous (i.v) administration. Sor was formulated
with 10% Kolliphor EL in PBS with DMSO concentration is <5%. In case of CA IX-C4.16 and
Sor combination, only two doses were administered where the first dose was on day 1 was followed
by the second dose on the third day. The tumor volume was measured, and mice were monitored
for body weight changes. Antitumor activity was measured by using NIH formula, tumor volume
(mm3) = 1/2(length × width2). The tumor volume of the last day of therapy study was represented
to demonstrate the endpoint outcome of combination therapy as described before 157. The animals
were sacrificed, and tumor tissues were collected. Representative tumor samples were stored at –
80°C for subsequent analysis. The histology of normal organs (Kidney and Liver) was performed
by Biobank core facility.
5.3.14. NIR imaging and bio-distribution of CA IX-SMA-TPGS-S0456 oligomer
A CA IX-targeted oligomer was conjugated with Near-infrared (NIR) dye CA IX-SMATPGS-S0456, namely CA IX-S0456 (CA IX-oligomer) and administered via i.v route to 5-6 weeks
old nu/nu mice, and the bio-distribution of NIR dye was monitored after 24 h of the single dose
with 10 nmole NIR dye per mouse. Fluorescence images were collected in Bruker Carestream
Xtreme in vivo imaging system at excitation (750 nm) and emission (830 nm) wavelength. The
bio-distribution and tumor-targeting properties of CA IX-S0456 was evaluated after euthanizing
the mice after 24 h post i.v injection. The instrument has dual fluorescence and X-ray imaging
modalities with light source: 400 W Xenon illuminator. Both fluorescence and X-ray images of
the mouse were merged to demonstrate the localization of NIR dye. We obtained PDx tumor mice
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from Jackson laboratory, and tumor slice was passaged to mice using trocar and imaging was
performed as similar with nu/nu mice.
5.3.15. Statistical analysis
The statistical analysis was done using Prism 7.0 software (Graph Pad Software Inc., San
Diego, CA). The data were expressed as mean ± SEM and analyzed using a two-tailed Student ttest or one-way ANOVA followed by a post hoc test unless specified otherwise. A p value of <0.05
was considered statistically significant.
5.4. Results and discussion
5.4.1. General procedure for synthesis of compound SMA-TPGS and ATZ-SMA-TPGS by
Copper-free 'click' chemistry
The current work aims to synthesize and formulate nanosystems targeting hypoxia in
tumors. CA IX enzyme on the surface of kidney cancer cells was targeted by ATZ-containing
oligomers using a modular copper-free 'click' chemistry-based approach. As illustrated in Scheme
1 of Figure 5.1, we first synthesized acetazolamide-amine (ATZ-NH2) from acetazolamide (ATZ)
by acid hydrolysis as previously described 218. Subsequently, ATZ-NH2 was reacted with DBCONHS-ester to arrive at ATZ-DBCO (compound a) which functions as a CA IX targeting ligand.
Second, in Scheme 2 of Figure 5.1, we synthesized SMA-TPGS oligomer (SMA-TPGS-Cys) by
adding known amounts of TPGS and Cysteine in dichloromethane at pH 8 with fixed amounts of
anhydrous SMA to permit its anhydride ring opening reaction with the alcohol group of TPGS and
amine group of cystine. Then, we conjugated the SMA-TPGS-Cys with azido (N3) group of (NH2PEG8-N3) compound by acid-amine coupling (EDC/NHS) reaction to finally get (compound b).
Finally, the Copper-free ‘click’ reaction was carried out by reacting compound ‘a’ with compound
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‘b’ to form triazole ring, compound ‘c’. All unconjugated reactants were removed by dialysis prior
to lyophilization. The compound ‘c’ was reacted with Rhodamine B NCS to obtain “CA IXRhoda” for in vitro 3D spheroid uptake study 222 and reacted with S0456 to get “CA IX-S0456”
for in vivo tumor imaging

163

. S0456 is a near-infrared (NIR) fluorescent dye used in phase III

clinical trials for image guided tumor surgery

223

. The final compounds were characterized by

MALDI-MS, 1H-NMR (Supplementary, S1 A-C) to assure chemical identity. 1H-NMR results
confirmed the triazole ring formation in CA IX-SMA-TPGS (Supplementary, S1 A, C) as the
characteristic peaks were found for the -NH group of-triazole ring around 7.9 ppm, O-CH2 of
triazole ring around 5.2, and CH2-N3 peak around 4.2 respectively. The molecules were analyzed
by MALDI-MS spectroscopy to confirm the chemical conjugation. This work expands upon our
previous success in the design, synthesis, and development of SMA-TPGS-C4.16 and SMA-C4.16
nanomicellar formulation 157.
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Figure 5.1. Scheme 1 and 2 indicate the general procedure for acetazolamide-oligomer fragment
synthesis. Scheme 3 indicates the preparation of OMs with C-4.16 and mechanism of CA IX
receptor mediated internalization of OMs in RCC. Summary of tumor hypoxia directed
nanotherapy in combination with Sorafenib for achieving multiple benefits against cancer, such as
reversing drug resistance, inducing apoptosis and reprogramming macrophages.
5.4.2. Preparation and characterization of CA IX targeting NP
The oligomers (SMA-TPGS and CA IX-SMA-TPGS) conjugate was purified by
ultrafiltration (Millipore TFF, Milford, MA) and then lyophilized. The NPs were prepared with
different methods, such as solvent evaporation, and oil-in-water emulsion method to formulate
spherical micelles with SMA-TPGS and CA IX-SMA-TPGS. Both, CA IX targeted NP and nontargeted NP were loaded with water-insoluble C4.16 to produce CA IX-C4.16 NPs and SMATPGS-C4.16. The NPs were characterized for size, charge and drug loading and these parameters
are presented in Table 1. The particle size of non-targeted C4.16 loaded NPs were ~105.2 nm with
a Polydispersity index (PDI=0.165) (Figure 5.2A). Morphology of the NP was also assessed using
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Transmission Electron Microscopy (TEM) instrument (Figure 5.2 B) and the particle size
resembled with DLS data and a favorable negative surface charge of NPs was noted (Figure 5.2C).
After incorporation of targeting ligand (ATZ) to NPs, the particle size slightly increased compared
to that of the non-targeted NPs suggesting the presence of ATZ on the surface of NPs. These results
indicate that both the size and surface properties are optimal and safe for intravenous injection as
well as ideal for tumor delivery. The Figure 5.2 C show histograms of comparative analyses of the
particle size and zeta potential of the NPs. Figure 5.2 D indicates the results of MALDI-MS
analysis of CA IX-SMA-TPGS and SMA-TPGS. The increment of molecular weight in CA IXSMA-TPGS (m/z 3126) compared to SMA-TPGS (m/z 2399) and their corresponding fragmented
peaks indicates the successful conjugation of ATZ to the SMA-TPGS polymers. Also, The C4.16
loading content and encapsulation efficiency in both NPs were evaluated by High-Performance
Liquid Chromatography (HPLC). First, a method for analyzing drug content was developed and
validated according to ICH guidelines 188. The loading efficiency of micelles was then calculated
by dissolving known quantity of NPs directly in DMSO followed by determination of the
absorbance at 309 nm with respect to the standard curve performed by HPLC method. The
encapsulation efficiency was 85 % and 75.5 % for SMA-TPGS NPs and CA IX-C-4.16 NPs,
respectively.
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Figure 5.2. Oligomicelles formulation and characterization. (A) Hydrodynamic size of targeted
CA IX-C4.16 OMs and non-targeted SMA-TPGS-C-4.16 OMs and (B) Zeta potential by Dynamic
Light Scattering (DLS) are shown. (C) The morphology of representative OMs is characterized by
TEM as shown. Scale bar = 100 nm. (D and E) MALDI-MS analysis of ATZ-SMA-TPGS and
SMA-TPGS are shown. The increment of m/z value in ATZ-SMA-TPGS (m/z 2239.1) compared
to SMA-TPGS(m/z1565.6) oligomers indicates the successful conjugation of ATZ to the SMATPGS polymers.
Table 5.1. Characterization of Oligomicelles.
Sample

CMC
(mg/ml)

Hydrodynamic
size (nm)

PDI

Zeta
potential
(mV)
-10.21 ±4

EE (%)

ATZ-SMA0.021
159.5±20nm
0.094±0.05
75.5±12
TPGS-C-4.16
(Targeted)
SMA-TPGS-C0.010
105.2±31nm
0.165±0.07
-7.86 ±4
85±9.8
4.16 (nontargeted)
Abbreviations: C-4.16, CARP-1 Functional Mimetics; SMA, styrene maleic acid; TPGS, d-αtocopheryl polyethylene glycol succinate; ATZ, Acetazolamide; CMC, critical micelle
concentration; PDI, polydispersity index; EE, encapsulation efficiency.

5.4.4. Rationale for choosing CA IX protein for RCC therapy

99

In this study, we have shown that CA IX was overexpressed in A498 and Evr-res A498 RCC cells
and tumor. In Figure 5.3A, immunohistochemistry of CA IX-positive A498 RCC tumor xenografts
collected from tumor tissue section is shown. The intense bright green fluorescence indicates the
presence of CA IX. In Figure 5.3B, Western blot data show levels of CA IX protein in A498 and
Evr-res A498 RCC cells that were cultured under normoxic (no cobalt chloride treatment) or
hypoxic conditions (treated with cobalt chloride for 72 hrs.). Together with immunohistological
localization of CA IX in RCC tumor, the up-regulation of CA IX expression in hypoxic WT and
Evr-res A498 RCC cells in comparison to their respective, normoxic counterparts provides a
rational strategy for delivering the payload into the hypoxic core of RCC tumor. Moreover, CA IX
has been shown to be specifically overexpressed in 93 to 97% of both ccRCC and some papillary
RCCs, with limited expression in normal tissues

224

. CA IX is also an important biomarker for

RCC, and it plays a pivotal role in tumor progression, acidification, metastasis, and the intratumoral hypoxic condition. CA IX expression on the cell surface is associated with induction of
tumor hypoxia through regulation of HIF1 The clinicopathological analysis have supported the
fact that overexpression of CA IX in RCC is linked to poor disease prognosis and resistance to
chemo and immunotherapy. Many clinical trials are evaluating CA IX linked inhibitors or
antibodies for monotherapy or diagnostic imaging. Recently, a small molecule, acetazolamide
(ATZ), with high affinity (Kd~ 8.3 nM) to CA IX 225 has been reported to deliver the payload into
the inner core (more than the periphery) of a tumor 163,218. These results signify that CA IX is an
excellent target for site-specific delivery of therapeutic payloads to renal tumors 226,227. Along these
lines, we developed ATZ-conjugated NPs for selective delivery of drug cocktail to the hypoxic
region including the tumor core of therapy resistant RCC. It is well established that the hypoxic
tumor core harbors aggressive and drug-resistant stem-like cells can persist after initial drug
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therapy, which can invade normal tissues and metastasize to distant sites forming secondary
tumors. Targeting the hypoxic core using CA IX is thus a highly innovative approach needing
immediate attention.

Figure 5.3. Overexpression of CA IX protein in A498 RCC cells and xenograft model. (A)
Immunohistochemistry of CA IX positive A498 renal cell carcinoma tumor xenografts collected
from tumor tissue section is shown. The intense bright green fluorescence indicates the rationale
of choosing CA IX as an excellent RCC targeted therapy. (B) Western blot detection of CA IX
protein in A498 and EV-A498 RCC cells lysates after normoxia (no cobalt chloride treatment) and
hypoxia (treated with cobalt chloride for 72 hrs. to induce hypoxia) are shown. The fold upregulation of CA IX expression in hypoxic WT and EV-res A498 RCC cells than normoxia
provides a solid foundation for delivering the payload into oxygen deprived regions and hypoxic
core of RCC tumor.
5.4.5. Selective uptake and tumor spheroid core penetration of CA IX oligomers to RCC.
The 3 D spheroid cell culture model is an in vivo mimetic study for testing NPs deep tumor core
penetration ability. Thus, culturing A498 RCC cell lines with a spheroid model in hypoxic
condition could be predictive of the tumor permeability of CA IX targeted NPs. In Figure 5.4 C,
we found that the rhodamine-conjugated ATZ oligomer (CA IX-Rhoda) has deep tumor matrix
penetration and superior uptake in hypoxic Evr-res A498 spheroid model. The cell uptake study

101

of CA IX targeted NPs was performed using Evr- res A498 spheroid model followed by imaging
of spheroid using confocal microscopy. Interestingly, Z-stacking from 10, 40, 60, and 100 µm in
confocal microscopy of CA IX targeted oligomer-treated cells indicate that rhodamine-signal is
significantly higher in the core of the spheroid than the periphery (Figure 5.4. C-D). This is a strong
indication that CA IX targeted oligomer can penetrate deep into the tumor spheroid and likely
reached the hypoxic regions very efficiently. The highest fluorescence intensity at the center (as
indicated by arrow) of 3D- plot (Figure 5.4 C) suggests that CA IX targeted oligomer efficiently
reached the core of tumor spheroid. Also, in Figure 5.4 C, with the lower range of Z-stacking from
40-60 m section (which is the core) has more fluorescence intensity than the periphery. Zstacking of the spheroid at different sections from 10-100m with CA IX targeted formulations
also shows superior fluorescence intensity from 40-60 µm sections representing organoid core.
Figure 5.4. E showed the overall merged view of CA IX-Rhod-B oligomer with bright field and
compared with untreated control. Figure 5.4 F shows the overall shape of the spheroid from along
the three dimensions (x, y, and z) as another way of representation to demonstrate spheroid core
penetration.

102

Figure 5.4. 3D spheroid uptake studies of hypoxia targeted-oligomer. Confocal microscope
images of ATZ-oligomer conjugated with rhodamine B and treated with hypoxic A498 RCC cells
-spheroid indicates tumor matrix penetration of CA IX targeted Oligomicelles. The untreated and
treated spheres were then photographed as noted in methods section. Z-stacking of the spheroid
(A-D) clearly indicates that fluorescence intensity is superior in 40-60 µm section. The highest
fluorescence intensity at the center (as indicated by arrow) of 3D- plot (E) suggests that CA IXRhoda oligomer is highly efficient to reach deep into the core of the tumor spheroid. (F) Z-stacking
of the spheroid at different sections from 10-100 m with CA IX targeted formulations also reveals
similar findings as noted for the 40-60 µm that had superior fluorescence intensity. Figure (G)
shows the untreated control experiments in comparison with CA IX-Rhoda oligomer and Figure
(H) shows the overall shape of the spheroid from along the three dimensions (x, y, and z).

5.4.6. C4.16 anti-cancer effect and Hypoxia targeting ability of CA IX NP
RCC is very difficult to treat as the cells are mostly resistant to many current therapies. Therefore,
newer treatments including better ways of drug delivery are urgently needed to fight this malignant
disease efficiently. Our previous work has demonstrated generation and characterization of RCC
cells that are resistant to Evr, a frontline mTOR-targeted therapy, and revealed that a class of
CARP-1 functional mimetic (CFM) compounds especially C-4.16 inhibited parental (WT) and
Evr-res RCCs157. In this study, we utilized C-4.16 and current clinical anti-RCC therapeutics Sor
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and Evr. First, we determined cytotoxicity of individual drugs C4.16, Sor, and Evr in both A498
as shown in Figure 5.5. Our results from Figure 5.5. A, B indicated that C4.16 was more effective
in inhibiting growth of WT and Evr-res A498 compared with Sor. Evr, however, did not inhibit
growth of Evr-res A498 RCC cells as previously published [14]. We then clarified whether a
combination of C4.16 and Sor were more effective when compared with individual treatment. In
vitro cytotoxicity assay of C4.16 and Sor on Figure 4 A, B indicates C4.16 was more potent than
FDA approved drug (Sor) and combining both drugs showed significantly lower the IC50 value.
All the results indicate C4.16 and Sor inhibited viabilities of WT and Evr-res RCC cells, and C4.16
when combined with sor was more effective than C4.16 or Sor alone. However, C4.16's poor water
solubility limits it’s in vivo testing and clinical translation. We addressed the solubility and
delivery concerns of C4.16 by utilizing a nanotechnology-based approach. Thus, encapsulation of
C4.16 in NP and conjugating them with CA IX targeting oligomer was considered as a functional
approach for resolving the challenges to deliver the compounds selectively to resistant RCC. The
results as noted in Figure 5.5 C show that CA IX-C4.16 was more effective in inhibiting growth
of A498 (WT and Evr-res) compared to Sor and Evr and supported that CA IX-C4.16 nanoformulation was more potent compared to FDA approved drugs. The table in Figure 5.5. D
summarizes IC50 values for all drugs with the WT and Evr-res RCC cell lines. The data in Figure
5.5. C, D showed that CA IX-C4.16 was more effective in inhibiting growth of A498 (WT and
Evr-res) compared to Sor and Evr and collectively indicate that CA IX-C4.16 was more potent
compared to other drug options. Furthermore, to confirm the synergism, we utilized CompoSyn®
software to evaluate the combination index (CI) value of C4.16 and Sor. As shown in Figure 5.5.
E, C4.16 and Sor had CI value (less than 1) of 0.531 for A498 WT and 0.654 for Evr-Res, which
indicated synergism between the two compounds. Figure 5.5. F also demonstrated a combination
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of CA IX-C4.16 with Sor is synergistic in RCC cell killing as obtained from isobologram analysis.
Thus, low dose of CA IX-C4.16 NP could potentially sensitize RCC cells for inhibition by Sor.
Moreover, as shown in Appendix Figure, a combination of 500 nM dose of CA IX-C4.16 with
various doses of Sor further support their synergistic inhibition of RCC cells. A 500 nM dose of
CA IX-C4.16 caused greater inhibition of RCC cell growth when combined with low doses of Sor
(100, 200, 500 nM).

Figure 5.5. C-4.16 inhibits growth of RCC cell lines derived from WT and Everolimusresistant cells. Cell cultures studies and in vitro cytotoxicity assay of C-4.16, sorafenib,
Everolimus on (WT and Evr-Res) A498 and UOK-262 RCC cell lines. (A, B, and C) Cytotoxicity
data indicates C-4.16 was more potent than FDA approved drugs (sorafenib and everolimus) in
WT A498 and (D, E, and F) WT UOK262. Also, cell cultures studies result on EV-res A498 RCC
cell lines (G and H) indicates that C-4.16 was more effective in inhibiting growth of Evr-res A498
RCC cell lines than sorafenib; however, Everolimus is not inhibiting the growth of Evr-res A498
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and UOK262 RCC cell lines as previously published. The data in the GI50 columns represent mean
of three independent experiments. Indicated parental and their respective drug resistant RCC cells
were either untreated (Control) or treated with noted doses of C-4.16 and sorafenib for 48h.

Figure 5.6. High synergistic CI value of C-4.16 with sorafenib combination supports the
hypothesis of selecting the combination to RCC treatment using hypoxia targeting OMs. (A)
Combining very low doses of both drugs will lower the IC50 value significantly as in (D) which
shows the combination index plot for C-4.16 plus sorafenib in the cells for both types A498 RCC
cell lines indicates very strong synergism between sorafenib and C-4.16. (B) The results also show
that CA IX-C-4.16 was more effective in inhibiting growth of A498 (WT and Ev-res) and to less
extent (C) UOK262 (WT and Ev-res) RCC cell lines than sorafenib and Ev and support that C4.16 was more potent than FDA approved drugs (sorafenib and everolimus). (D) We summarized
IC50 value table for all drugs with all the above mentioned RCC cell lines. (E) In vitro cytotoxicity
assay of CA IX-C4.16 (500 nM) in combination with different doses of sorafenib on Ev-res A498
RCC cell lines indicates that low dose of C-4.16-OMs sensitize sorafenib for inhibiting growth of
RCC cell line.
5.4.7. Mechanism of C4.16 for overcoming drug resistance
In this study, we determined how induction of apoptosis and inhibition of oncogenic
survival signaling would reinforce the synergistic cell killing and reversal of drug resistance in
WT and Evr-res A498 cells when treated with CA IX C4.16+Sor. As shown in Figure 5.7. A, we
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observed inhibition of AKT activation as indicated by downregulation of pAKT in C4.16 and Sor
treatment compared to untreated control. We found that Evr-res RCC cells that were treated with
C4.16 or Sor had a greater loss of AKT activities when compared with their WT cells treated with
respective agents. Interestingly though, a combination of C4.16 and Sor completely abolished
AKT activity (pAKT) in both the WT and resistant cells. Therefore, it is likely that superior RCC
growth inhibition by C4.16 and Sor is in part due to suppression of oncogenic AKT activity.
Moreover, C4.16 cytotoxicity was mediated by apoptosis induction (Figure 5.7 A) supporting our
prior studies that have shown activation of apoptosis in C4.16 treated cells. Although, C4.16 or
Sor induced caspase-3/7 activation, a significant upregulation of caspase-3/7 activity was noted in
RCC cells treated with C4.16+Sor as compared to control (Figure 5.7 B). This finding was further
supported by an increment of early and late apoptotic events in both WT and Evr-res A498 cells
treated with CA IX-C4.16+Sor as compared to untreated control or CA IX-C4.16 (Figure 5.7 C).
The fraction of cells that stained with Annexin V (+ve) or Annexin V (+ve) and 7-AAD (+ve) was
higher in combination treatment than singular treatments as shown in Figure 5.7 D. In all the cases;
combination always worked better than individual drugs in inhibiting RCC cells growth.
As shown previously, C4.16-dependent loss of RCC cell viability was due in part to
reduced cyclin B1 levels, activation of pro-apoptotic, stress-activated protein kinases (SAPKs),
and apoptosis

157

. Importantly, we also demonstrated that CARP-1 was a key player in inducing

apoptosis and cell cycle arrest in the breast, lung and renal cancer cells

139,140

. The up-regulation

of CARP-1 promotes activation of “apoptosis hallmarks,” such as caspase-mediated PARP
cleavage, downregulation of PI3K/AKT signaling and loss of cyclin B1 in RCC

157

. To identify

potent activators of CARP-1, a library of small molecules, namely CARP-1 functional mimetic
(CFM) compounds were developed. An NCI-60 screening, as well as high throughput screening
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using various cancer cell lines, including WT and drug-resistant Evr-res RCC, resulted in the
identification of several potent analogs. Our current results suggest that C4.16 is a superior
inhibitor of both WT and drug-resistant RCC even in comparison to the FDA approved drugs, such
as Ever and Sor. As RCC is highly vascularized, the use of drugs to inhibit RTK, such as VEGFR
or HGF signaling is used as first-line therapies. Alongside, mTOR inhibitors, such as Evr were
approved as second-line single agent therapy. All these kinase inhibitors are approved for single
agent therapy. However, tumors eventually become resistant to therapy including RKT/mTOR
inhibitors. Our findings suggest that the NPs formulations of the inhibitors will be a worthwhile
strategy to provide multiple benefits such as (i) amenable for i.v. injection leading to lowering of
drug dose; (ii) higher stability and bioavailability; (iii) sustain drug release and reduced toxicity.
Literature reports and clinical experience have revealed that inhibiting RCC proliferation with
drugs combination specific to different targets is superior to monotherapy approaches

228

.

However, such approaches tend to produce severe on-target and off-target toxicities 229. To achieve
the maximum therapeutic benefits and reduce the toxicity, we encapsulated anticancer drugs in
CA IX-C4.16 NPs. This i.v. administrable NPs in combination with currently approved drugs is
an excellent approach to precisely target the convergent pathways of RCC activity with resistant
and tumor stroma features 230.
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Figure 5.7. (A) Western Blot data indicates that C-4.16 stimulates apoptosis in WT and Evresistant RCC cells in part by upregulating pro-apoptotic CARP-1 and activating SAPKs as
previously shown in [14], and in here P-AKT is indicated as the a protein which is affected much
by combination of C4.16 and sorafenib. Indicated RCC cells were either untreated (Control,
denoted as C), treated with C-4.16, Sorafenib, or Everolimus with (+) means presence of the
combination and (-) indicates use only of single drug for noted dose and time. Cell lysates were
analyzed by Western blotting (WB) as in Methods for levels activation (phosphorylation) and
expression of both P-AKT and T-AKT in WT or Ev-res A498 RCC cells. (B) Up-regulation of
caspase 3/7 with (C-4.16+SOR) treatment in Evr-res A498 cells indicates the C-4.16 mediated
apoptosis to RCC cells as compared to sorafenib (SOR) treatment or combination (C-4.16+SOR).
The results support (C-4.16+SOR) combination is more effective for RCC cell lines growth
inhibition. (C) Free oligomer, CA IX-C-4.16 OMs and CA IX-C-4.16+ sorafenib with an
increasing apoptosis measured by FACs using staining of Annexin V-FITC and PI in (A) A498
RCC (WT and Ev-res) cells are shown. Free oligomer (vehicle) were used as negative controls.
Data represent mean SD, n=3 per group, **p<0.01 vs. control. (D) Histogram columns of both
viable cells and apoptotic cells indicates that CA IX-C4.16 + sorafenib has more % apoptotic cell
than CA IX- C4.16 alone which support our hypothesis of the synergism between these anticancer
agents.
5.4.8. Reprogramming macrophages to modulate combination treatment:
To overcome the critical problem of current RCC treatment, we developed a tumor-penetrating
nano-sized NP of spherical shape that can localize and penetrate tumor tissues efficiently and target
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tumor hypoxia to deliver the combination drug cocktail to shut down vital tumorigenic signaling
while simultaneously reprogramming macrophages for better therapeutic efficacy. Several studies
have identified the key players that are responsible for drug resistance and immune evasion leading
to the poor prognosis of RCC. These players are categorized based on their specific roles that
include (i) RTK-mTOR that regulates critical tumorigenic signaling for tumor survival, immune
suppression, and stroma formation, (ii) impairment of intrinsic and extrinsic apoptotic signaling is
an essential player of drug resistance. Induction of CARP-1 protein has been well documented to
induce apoptosis in cancer cells under the conditions of serum withdrawal or therapy stress. (iii)
CA IX is a tumor hypoxia marker for the maintenance of extracellular acidosis and cancer
stemness, thus facilitating tumor growth and metastases. More than seven clinical trials are
underway to target CA IX in RCC and other solid tumors [NCT00059735, NCT00884520]. The
delivery system we have engineered here will be a promising addition to clinical translation for
better RCC treatment. Figure 5.8. A shows a schematic diagram as Raw264.7 cells were placed
into the insert. Then, cells were polarized to M1-macrophage using IFN- and LPS, and to M2macrophage using IL-4 recombinant protein. The change of morphology of Raw264.7 as shown
in Figure 5.8. B supports the M1/M2 polarization of naïve Raw264.7 cells231 followed by
treatment with C4.16 and CA IX-C4.16+Sor for 24 h. The data in Figure 5.8. C clearly demonstrate
the up-modulation of the tumoricidal M1-macrophage marker (CD86, iNOS) and downmodulation of the tumorigenic M2-macrophage marker (CD206, Arginase I) compared to
untreated (UT) control and C4.16. The macrophage reprogramming ability of CA IX-targeting NP
builds a rational of using (CA IX-C4.16+Sor) as a potent antitumor immune-stimulatory agent of
RCC. The treatment of CA IX+Sor to Evr-res A498 cells cocultured with M1-macrophage resulted
in the growth inhibition and change of morphology that could be due to tumoricidal M-1
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macrophage mediated cell death of RCC cells as shown in Figure 5.8. D. Further to evaluate the
macrophage induced RCC cell death, we analyzed up-modulation of caspase 3/7 in Evr-res A498
cell co-cultured with Raw 264.7 cell and treated with CA IX-C4.16+Sor or other treatments. The
data from Figure 5.8. E clearly confirmed combination is significantly better in inducing apoptosis
as compared to control or individual treatments. All these results demonstrate hypoxia targeting
NP in combination with Sor is not only inducing chemotherapeutic effect but also reeducating
macrophages to function as a tumoricidal agent, which could prove excellent for a combination of
chemo-immune therapy to inhibit Evr-res RCC.
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Figure 5.8. Reprogramming macrophages with CA IX-C4.16+Sorafenib treatment. (A) Schematic
diagram of the procedure. Raw-264.7 cells were placed into the insert. Then, cells were polarized
to M1-macrophage using IFN- and LPS, and to M2- macrophage using IL-4 recombinant protein.
Scheme modified from the original protocol. (B) Change of morphology of M1 and M2
macrophages supports the polarization of Raw-264.7. (C) RT-PCR data clearly demonstrates the
up-modulation of the tumoricidal M1-macrophage marker (CD86, iNOS) and down-modulation
of the tumorigenic M2-macrophage marker (CD206, Arginase I) in CA IX-C4.16+Sor as
compared to control and C4.16. The macrophage reprogramming ability of CA IX targeting NP
builds a rational of using (CA IX-C-4.16+Sor) as a potent antitumor immune-stimulatory agent of
RCC. (D) Change of morphology and reduction of Evr-res A498 density in M1-macrophage and
Evr-res A498 co-cultured condition, treated with CA XI+Sor suggesting activated M1-
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macrophage mediated RCC cell death. (E) Treatment of CA IX+Sor educate the Raw-264.7 in
inducing caspase 3/7 mediated apoptosis of Evr-res A498.
5.4.9. Superior tumor core penetration and high tumor/liver uptake of CA IX oligomers in
xenograft RCC model.
After optimizing the anticancer effect of CA IX-C4.16 at the cellular level, we performed NIR
imaging in animals inoculated with RCC tumor model following administration of CA IX-S0456.
The idea of performing NIR-imaging with CA IX-oligomer will provide several advantages
including its use as (i) agent for tumor image guided RCC surgery in the clinic, as well as (ii)
meaningful insights into the therapeutic outcome and safety of nanoformulation in RCC model. It
is well known that clinically small molecule NIR imaging agents have excellent ability to
distinguish the tumor lesion from healthy tissue in imaging-guided surgery as noted in
NCT02317705 and NCT01778933
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. The results show CA IX-S0456 selectively home to the

orthotopic subcutaneous Evr-res A498 tumor as compared to control (Figure 5.9. A and C). The
bio-distribution (Bio-D) study in Figure 5.9. B validates the prominent tumor selectivity of CA
IX-S0456 as compared other healthy organs such as liver and spleen. Imaging of the patientderived RCC tumor xenograft (PDx) (Figure 5.9. C) showed favorable tumor localization of CA
IX-S0456. The tumor selectivity of CA IX-S0456 in both drug resistant and PDx RCC model
builds a foundation for widespread applicability of CA IX-S0456 in different RCC tumor model
that builds a rational platform for further investigation towards clinical translation of this
technology. In Figure 5.4, 3D spheroid uptake study of CA IX-rhodamine showed high localization
of rhodamine in the core of the hypoxic Evr-res A498 spheroid. To ascertain core penetrating
ability of CA IX-S0456 in a drug resistant tumor model, we performed a transverse section of the
isolated tumor after the bio-D study. Figure 5.9. D confirmed that CA IX-S0446 is very efficient
in penetrating the core of tumor that predominantly harbors hypoxia and drug resistant features.
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As shown in Figure 5.9. E, more than 3-fold tumor/liver ROI in CA IX-oligomer compared to
control demonstrates the feasibility of CA IX-S0456 in clinical translation as an image-guided
surgery tool. The findings in Figure 5.9. F suggest the ROI is >2 fold in CA IX-S0456 treated
tumor core as compared to tumor periphery. These results support a high binding affinity and
specific tumor uptake, faster normal tissue clearance, and low non-specific organ uptake of CA
IX-oligomer.
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Figure 5.9. Superior tumor specificity of CA IX-oligomer and antitumor efficacy study of
combination therapy in Evr-res A498 xenograft and RCC PDx model. (A and C) Superior tumor
accumulation of CAIX oligomer (CA IX-S0456) as compared to control (S0456) in Evr-res A498
tumor xenograft model. (B) Bio distribution (Bio-D) study of CA IX-S0456 showed superior
tumor specificity and low non-specific liver uptake in Evr-res A498 tumor bearing mice. The
control, S0456 showed poor tumor accumulation with high off-target activity. ((D) Further to
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demonstrate the tumor core penetration of NIR dye, isolated Evr-res A498 tumor was transversely
sectioned, and brightest fluorescence intensity at the middle section confirmed of CA IX-S0456
has an excellent hypoxic tumor core penetration ability as compared to control. (E) Significantly
high tumor/liver accumulation (more than 3-fold) of CA IX-oligomer solve the non-specificity
effect of the oligomer. (F) Quantification of fluorescent ROI indicates CA IX-oligomer is
significantly penetrating higher in tumor core contained as compared to its periphery. The results
suggest the importance of CA IX-oligomer in selective tumor targetability of RCC tumor model.
(G) Tumor growth inhibition of (CA IX-C4.16+Sor) is significantly higher compared to
vehicle(control), Sor, and CA IX-C4.16 in Evr-res A498 xenograft tumor. Significant tumor
growth suppression of combination therapy supports the rationale of using CA IX targeting nanoformulation as the delivery vehicle of potent drugs, C4.16. The data represented as average values
from whole four animals in the respective group, bars, SE, significant where *p<0.05 vs. Control.
(H) Histopathologic (H&E staining) examination to determine the toxicity of therapeutic drugs on
livers and kidneys at the end of the experiments. Images indicate there is no significant sign of
necrosis or loss of tissue architectural difference in vehicle control and CA IXC4.16+ Sor treated
tissues.

5.3.10. Tumor growth inhibition and excellent safety of CA IX-C4.16+Sor in Evr-res tumor.
After confirming the in vitro anticancer activity, we finally examined the antitumor effect of CA
IX-C4.16 NP in combination with Sor, to demonstrate the efficacy of combination regimen in
reversing Evr-resistance in RCC. The CA IX-C4.16 NPs formulation inhibited the viability of WT
and Evr-res A498 cells in vitro by stimulating various tumoricidal pathways including induction
of apoptosis, downregulation of pAKT and up-modulation and education of M1-macrophages. As
shown in Figure 5.9. G, CA IX-C4.16 significantly inhibited highly aggressive Evr-res A498 tumor
in combination with Sor. The greater tumor growth inhibitory effect of CA IX-C4.16+Sor
compared to control and individual treatments thus opens an avenue that CA IX-C4.16 nanotherapy can resurrect Sor as a more efficient anticancer therapeutic agent. Importantly, CA IXC4.16+Sor did not cause any necrosis or morphological changes in tissue architecture of normal
organs such as kidneys and liver (Figure 5.9. J). The superior tumor penetration of CAIXoligomer and efficient antitumor effect of CA IX-C4.16+Sor in different RCC tumor model
underscore a viable strategy for developing a smart therapy against drug resistant tumors
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with high safety profile. The current findings can support the claim that CA IX-NPs loaded
with anticancer payload can play a universal role in overcoming drug resistance and repurposing
current drugs in a more efficient way.
5.4.

Conclusions

In this study, we have demonstrated elevated expression of CA IX in RCC that qualifies its use as
an excellent biomarker for targeted therapy and imaging. The combination of C4.16 and Sor have
a superior synergistic cell killing in Evr-res RCC, which is due in part to activation of caspase 3/7
protein and complete eradication of oncogenic AKT activation. Combination of CA IX-C4.16 with
Sor showed targeted delivery of payload in hypoxic tumor resulting in induction of sequential
anticancer effects including, the resurrection of apoptosis, reversal of drug resistance, and
reprogramming of malfunction macrophages. This NP could have a direct impact on developing
newer therapies for treating RCC. We found that CA IX-C4.16 NP is suitable for intravenous
administration with superior tumor accumulation of CA IX-oligomer as compared to liver and
demonstrated effective antitumor response in Evr-res A498 tumor. Due to small molecular size
and ease of chemical functionalization, CA IX-oligomer can potentially be further explored for
selective CA IX tumor targeting for the diagnostic use and RCC image-guided surgery in the
clinical setting. The tumor spheroid uptake study has clearly demonstrated excellent tumor core
penetrating ability of CA IX-targeting oligomer, which is a critical indicator of tumor stromal
disruption leading to better therapy response and immune modulation. In conclusion, the
synergistic therapeutic potential of CA IX-C4.16 and Sor combination and selective NIR imaging
of the CA IX anchored oligomer portend their promising potential towards developing better
therapeutics and diagnostic tools for clinical translation against deadliest drug resistant RCC.
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6.

CHAPTER 6. SUMMARY AND KEY FINDINGS

6.1. Aim 1
6.1.1. Summary
Current treatments for Renal Cell Carcinoma (RCC) include a combination of surgery, targeted
therapy, and immunotherapy. Emergence of resistant RCCs contributes to failure of drugs and
poor prognosis, and thus warrants development of new and improved treatment options for RCCs.
Here we generated and characterized RCC cells that are resistant to Everolimus, a frontline mTORtargeted therapy, and tested whether our novel class of CARP-1 functional mimetic (CFM)
compounds inhibit parental and Everolimus-resistant RCC cells. CFMs inhibited RCC cell
viability in a dose-dependent manner that was comparable to Everolimus treatments. The GI50 dose
of Everolimus for parental A498 cells was ~1.2μM while it was <0.02μM for the parental UOK262
and UOK268 cells. The GI50 dose for Everolimus-resistant A498, UOK262, and UOK268 cells
were ≥10.0μM, 1.8-7.0μM, and 7.0-≥10.0μM, respectively. CFM-4 and its novel analog CFM4.16 inhibited viabilities of Everolimus resistant RCC cells albeit CFM-4.16 was more effective
than CFM-4. CFM-dependent loos of RCC cell viabilities was due in part to reduced cyclin B1
levels, activation of pro-apoptotic, stress-activated protein kinases (SAPKs), and apoptosis. CFM4.16 suppressed growth of resistant RCC cells in three-dimensional suspension cultures. These
findings portent promising therapeutic potential of CFM-4.16 in treatment of RCCs.
6.1.2. Key Findings:
(1) CARP-1 functional mimetics (CFM 4.16) are a novel small molecule inhibitor of triplenegative breast cancers, non-small cell lung cancers, and renal cell carcinoma.
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(2) CFMs induce Apoptosis by activating SAPKs and elevating CARP-1. CARP-1/CCAR1
interacts with RIPK1, pro-apoptotic adaptor protein FADD, cleaved caspase 8 and is likely a part
of an intracellular, apoptosis-transducing subcomplex.
(3) CFMs attenuate biological properties of cancer cell motility, migration, and invasion.
6.2. Aim 2
6.2.1. Summary:
CFMs are hydrophobic compounds and they have poor aqueous solubility and their dose escalation
for in-vivo studies remain challenging. In this study, we encapsulated CFM-4.16 in Vitamin-E
TPGS-based-micellar-nano-formulation that resulted in its higher loading (30% w/w). This CFM4.16 nanoformulations inhibited viability of parental and Everolimus-resistant RCC cells in vitro
and suppressed growth of parental A498 RCC-cell-derived xenografts in part by stimulating
apoptosis. These findings portent promising therapeutic potential of CFM-4.16 nanoformulations
in treatment of RCCs. Here we investigated whether the SMA-TPGS nano-formulation of CFM4.16 circumvents the solubility concerns of CFM compounds to permit its intravenous
administration in conducting in vivo studies. Also, the aim is to demonstrate if SMA-TPGS-CFM4.16 nanoformulation can produce cancer cells inhibition in different types of cancer. For this
purpose, we will optimize and characterize novel SMA-TPGS polymeric Nano micelles which
then will increase water solubility of drug loaded formulation; thus, it will allow intravenous (i.v.)
administration of the SMA-TPGS-CFM-4.16. Specifically, we aimed to achieve an increased
serum bioavailability of CFM-4.16 due to administration using nano-formulation, increased nanoformulation accumulation and retention within the tumor by the EPR effect and therefore an
increased localized CFM-4.16 concentration in tumor tissues relative to free drug and later
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producing a marked antitumor response. In this regard, NSCLC, TNBC, and RCC cell lines were
used to confirm the proof of concept for in-vitro effectiveness of nano micellar formulation of
CFM analog. The TPGS-based nano-formulation of CFM-4.16 inhibits viability of RCC cells in
vitro and their growth as xenografted tumors in immunocompromised mice.
6.2.2. Key Findings
CARP-1 functional mimetics (CFMs) are novel small molecule inhibitors of RCC. In
addition, CFMs induce apoptosis by activating SAPKs and elevating CARP-1. In this study, we
employed a nanotechnology to tackle the poor aqueous solubility of a potent CFM compound
(CFM-4.16) which restricts its in vivo therapeutic efficacy. This SMA-TPGS-CFM-4.16
formulation maintained its nanoparticulate nature, homogenous polydispersity and high drug
encapsulation efficacy. Since free CFM-4.16 or SMA-TPGS-CFM-4.16 elicited similar effects on
cell viability, and levels of apoptosis would indicate that the anti-cancer effects of CFM-4.16 are
retained in nanoformulation. Moreover, the physicochemical analyses indicate an optimum release
of CFM-4.16 from nanoformulation. Together the physicochemical characteristics and biological
activity of SMA-TPGS-CFM-4.16 seem promising for their use in future pre-clinical in vivo
studies for the RCC tumor models.
6.3. Aim 3
6.3.1. Summary:
Drug resistance is one of the significant clinical burden in renal cell carcinoma (RCC). The
development of drug resistance is attributed to many factors, including impairment of apoptosis,
elevation of carbonic anhydrase IX (CA IX, a marker of tumor hypoxia), and infiltration of
tumorigenic immune cells. To alleviate the drug resistance, we have used Sorafenib (Sor) in
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combination with tumor hypoxia directed nanoparticle (NP) loaded with a new class of apoptosis
inducer, CFM 4.16 (C4.16), namely CA IX-C4.16. The NP is designed to selectively deliver the
payload to the hypoxic tumor (core), provoke superior cell death in parental (WT) and Everolimusresistant (Evr-res) RCC and selectively downmodulate tumorigenic M2-macrophage. Copper-free
‘click’ chemistry was utilized for conjugating SMA-TPGS with Acetazolamide (ATZ, a CA IXspecific targeting ligand). The NP was further tagged with a clinically approved NIR dye (S0456)
for evaluating hypoxic tumor core penetration and organ distribution. Imaging of tumor spheroid
treated with NIR dye-labeled CA IX-SMA-TPGS revealed remarkable tumor core penetration that
was modulated by CA IX-mediated targeting in hypoxic-A498 RCC cells. The significant cell
killing effect with synergistic combination index (CI) of CA IX-C4.16 and Sor for Evr-Resistant
A498 RCC cells suggests efficient reversal of Evr-resistance. The CA IX directed nanoplatform
in combination with Sor has shown multiple benefits in overcoming drug resistance through (i)
inhibition of p-AKT, (ii) upregulation of tumoricidal M1 macrophages resulting in induction of
caspase 3/7 mediated apoptosis of Evr-res A498 cells in macrophage-RCC co-culturing condition,
(iii) significant in vitro and in vivo Evr-res A498 tumor growth inhibition as compared to
individual therapy, and (iv) untraceable liver and kidney toxicity in mice. Near-infrared (NIR)
imaging of CA IX-SMA-TPGS-S0456 in Evr-res A498 and patient derived tumor xenograft (PDx)
RCC model exhibited significant accumulation of NP in tumor core with >3-fold higher
tumor/liver uptake as compared to control. In conclusion, this proof-of-concept study demonstrates
versatile tumor hypoxia directed nanoplatform that can work in synergy with existing drugs for
reversing drug-resistance in RCC accompanied with re-education of tumor-associated
macrophages.
6.3.2. Key Findings
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In this study, we have demonstrated elevated expression of CA IX in RCC that qualifies its use as
an excellent biomarker for targeted therapy and imaging. The combination of C4.16 and Sor have
a superior synergistic cell killing in Evr-res RCC, which is due in part to activation of caspase 3/7
protein and complete eradication of oncogenic AKT activation. Combination of CA IX-C4.16 with
Sor showed targeted delivery of payload in hypoxic tumor resulting in induction of sequential
anticancer effects including, the resurrection of apoptosis, reversal of drug resistance, and
reprogramming of malfunction macrophages. This NP could have a direct impact on developing
newer therapies for treating RCC. We found that CA IX-C4.16 NP is suitable for intravenous
administration with superior tumor accumulation of CA IX-oligomer as compared to liver and
demonstrated effective antitumor response in Evr-res A498 tumor. The tumor spheroid uptake
study has clearly demonstrated excellent tumor core penetrating ability of CA IX-targeting
oligomer, which is a critical indicator of tumor stromal disruption leading to better therapy
response and immune modulation against deadliest drug resistant RCC.
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APPENDIX

A

B

UOK 262 HLRCC Cells

UOK 268 HLRCC Cells

Appendix Figure 7.1. CFMs inhibit RCC cell growth. We treated noted cell lines either with DMSO
(Control), with various CFMs (A, B) for indicated dose and time. We determined cell viability by MTT
assay. The data in the histograms represent means of three independent experiments with 4-6 replicates for
each treatment; bars, S.E. A-D, @,#,&,*, E-F, α,β,γ,δ, statistically significant inhibition (p = <0.05) relative
to DMSO-treated respective controls. Adapted from 1.
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Appendix Figure 7.2. CFM-4. 16 stimulates apoptosis in parental and Everolimus-resistant
RCC cells in part by upregulating pro-apoptotic CARP-1 and activating SAPKs. (A, B) Indicated
RCC cells were either untreated (Control, denoted as 0), treated with CFM-4, or CFM-4.16 for noted dose
and time. Cell lysates were analyzed by western blotting (WB) as in Methods for levels of CARP-1, cyclin
B1, cleaved PARP and caspase-8, and activation (phosphorylation) of pro-apoptotic p38 and JNK1/2
SAPKs. The western blot membranes were probed with anti-actin antibodies to assess protein loading.
Adapted from 1.
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Appendix Figure 7.2. (continued) CFM-4. 16 stimulates apoptosis in parental and Everolimusresistant RCC cells in part by upregulating pro-apoptotic CARP-1 and activating SAPKs. (C-E)
Parental or Everolimus-resistant RCC cells were either untreated (Control), treated with Everolimus, CFM4, or CFM-4.16 for noted dose and time. Cell lysates were analyzed by Western blotting (WB) for
expression and/or activation of Akt, SAPKs, Cyclin B1, PARP, and CARP-1. The western blot membranes
in panels C-E were probed with anti-actin antibodies to assess protein loading. Adapted from 1.
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Appendix Figure 7.3. Knockdown of CARP-1 blocks CFM-4.16 effects. (A) Cells were either
untransfected, transfected with the pcDNA3/Hygro vector plasmid or plasmid expressing CARP-1
antisense, and stable, hygromycin-resistant cells were generated and characterized as detailed in methods.
Cell lysates from indicated stable cell lines were subjected to WB analysis as in figure 3 for levels of CARP1 and α-tubulin. (B) The Indicated vector or CARP-1 antisense expressing RCC sublines were either
untreated (Control) or treated with noted doses of CFM-4, or CFM-4.16 for 24h. Cell viability was
determined by MTT assay. The histogram columns represent means of three independent experiments; bars,
S.E. α, β, , , p = <0.05 relative to the vector expressing subline treated with CFM-4.16 only. Adapted
from 1.
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Appendix Figure 7.4. Triple negative cancer cells (MDA-MB468), lung cancer cells (A549) and

renal cancer cells (A 498 and UOK 262) were treated with the indicated doses for 24 hours. The
number of viable cells were then determined by MTT assay as described.
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Appendix Figure 7.5. Scheme 1 and 2 indicate the general procedure for acetazolamide-oligomer
fragment synthesis. Scheme 3 indicates the preparation of OMs with C-4.16 and mechanism of
CA IX receptor mediated internalization of OMs in RCC.
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Appendix Figure 7.6. Oligomicelles formulation and characterization. (A) Hydrodynamic size of
targeted CA IX-C4.16 OMs and non-targeted SMA-TPGS-C-4.16 OMs and (B) Zeta potential by
Dynamic Light Scattering (DLS) are shown. (C) The morphology of representative OMs is
characterized by TEM as shown. Scale bar = 100 nm. (D and E) MALDI-MS analysis of ATZSMA-TPGS and SMA-TPGS are shown. The increment of m/z value in ATZ-SMA-TPGS (m/z
2239.1) compared to SMA-TPGS(m/z1565.6) oligomers indicates the successful conjugation of
ATZ to the SMA-TPGS polymers.
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IHC FOR CA-IX Expression of A498 Tumor-confocal microscopy

Appendix Figure 7.7. Overexpression of CA IX protein in A498 RCC cells and xenograft
model. (A) Immunohistochemistry of CA IX positive A498 renal cell carcinoma tumor xenografts
collected from tumor tissue section is shown. The intense bright green fluorescence indicates the
rationale of choosing CA IX as an excellent RCC targeted therapy. (B) Western blot detection of
CA IX protein in A498 and EV-A498 RCC cells lysates after normoxia (no cobalt chloride
treatment) and hypoxia (treated with cobalt chloride for 72 hrs to induce hypoxia) are shown. The
fold up-regulation of CA IX expression in hypoxic WT and EV-res A498 RCC cells than normoxia
provides a solid foundation for delivering the payload into oxygen deprived regions and hypoxic
core of RCC tumor.
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Appendix Figure 7.8. 3D spheroid uptake studies of hypoxia targeted-oligomer. Confocal
microscope images of ATZ-oligomer conjugated with rhodamine B and treated with hypoxic A498
RCC cells -spheroid indicates tumor matrix penetration of CA IX targeted oligomicelles. The
untreated and treated spheres were then photographed as noted in methods section. Z-stacking
of the spheroid (A-D) clearly indicates that fluorescence intensity is superior in 40-60 µm section.
The highest fluorescence intensity at the center (as indicated by arrow) of 3D- plot (E) suggests
that CA IX-Rhod oligomer is highly efficient to reach deep into the core of the tumor spheroid. (F)
Z-stacking of the spheroid at different sections from 10-100 m with CA IX targeted formulations
also reveals similar findings as noted for the 40-60 µm that had superior fluorescence intensity.
Figure (G) shows the untreated control experiments in comparison with CA IX-Rhod oligomer and
Figure (H) shows the overall shape of the spheroid from along the three dimensions (x, y, and z).
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Appendix Figure 7.9. C-4.16 inhibits growth of RCC cell lines derived from WT and Everolimusresistant cells. Cell cultures studies and in vitro cytotoxicity assay of C-4.16, sorafenib, Everolimus on
(WT and Evr-Res) A498 and UOK-262 RCC cell lines. (A, B, and C) Cytotoxicity data indicates C-4.16
was more potent than FDA approved drugs (sorafenib and everolimus) in WT A498 and (D, E, and F) WT
UOK262. Also, cell cultures studies results on EV-res A498 RCC cell lines (G and H) indicates that C4.16 was more effective in inhibiting growth of Evr-res A498 RCC cell lines than sorafenib; however,
Everolimus is not inhibiting the growth of Evr-res A498 and UOK262 RCC cell lines as previously
published [14]. The data in the GI50 columns represent mean of three independent experiments. Indicated
parental and their respective drug resistant RCC cells were either untreated (Control) or treated with noted
doses of C-4.16 and sorafenib for 48h.
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Appendix Figure 7.10. High synergistic CI value of C-4.16 with sorafenib combination
supports the hypothesis of selecting the combination to RCC treatment using hypoxia
targeting OMs. (A) Combining very low doses of both drugs will lower the IC50 value significantly
as in (D) which shows the combination index plot for C-4.16 plus sorafenib in the cells for both
types A498 RCC cell lines indicates very strong synergism between sorafenib and C-4.16. (B)
The results also show that CA IX-C-4.16 was more effective in inhibiting growth of A498 (WT and
Ev-res) and to less extent (C) UOK262 (WT and Ev-res) RCC cell lines than sorafenib and Ev
and support that C-4.16 was more potent than FDA approved drugs (sorafenib and everolimus).
(D) We summarized IC50 value table for all drugs with all the above mentioned RCC cell lines. (E)
In vitro cytotoxicity assay of CA IX-C4.16 (500 nM) in combination with different doses of sorafenib
on Ev-res A498 RCC cell lines indicates that low dose of C-4.16-OMs sensitize sorafenib for
inhibiting growth of RCC cell line.
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Appendix Figure 7.11. Antitumor efficacy study of combination therapy and NIR imaging of CA IX
targeted oligomer in RCC xenografts tumor. (A) Tumor growth inhibition effect of (CA IX-C4.16+SOR) is significantly higher compared to vehicle(control), SOR, and CA IX-C-4.16 in A498
xenograft tumor. Significant tumor growth suppression of combination therapy supports the rational of
using CA IX targeting nano-formulation as delivery vehicle of potent drugs, C-4.16. The data represent as
average values from total four animals in respective group, bars, SE, significant where *p<0.05 vs Control.
(B) Histopathologic (H&E staining) examination to determine the toxicity of therapeutic drugs on livers
and kidneys at the end of the experiments. Images indicate there is no significant sign of necrosis, or loss
of tissue architectural difference in vehicle control and CA IX-C-4.16 treated tissues. (C-F) CA IX negative
(UOK262) tumor treated with CA IX-S0456 oligomers shows high off-target effect and low tumor
specificity. (E) UOK 262 and A498 tumor were inoculated on the circled parts. (F-I) CA IX positive (A498)
tumor treated with hypoxia targeted-NIR oligomer shows high tumor targetability and low non-specific
healthy organ uptake after 24 hrs of post injection suggesting the importance of CA IX for selective tumor
imaging for RCC tumor model after 24 hrs indicates high fluorescence intensity at the tumor compared to
liver and other organs.
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Appendix Figure 7.12. Compounds were characterized by 1H-NMR to assure chemical identity
(Supplementary, S1 A-C). SMA-TPGS-PEG-Azid and ATZ-DBCO conjugates indicates the successful
conjugation of ATZ to the SMA-TPGS polymers. 1H-NMR results confirmed the triazole ring formation as
some characteristic peaks were found such as H-triazole ring around 7.9 ppm, O-CH2 of triazole ring around
5.2 ppm, and CH2-N3 peak around 4.2 ppm.
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Appendix Figure 7.13. In vitro cytotoxicity assay of CA IX-C4.16 (500 nM) in combination with different
doses of sorafenib on Ev-res A498 RCC cell lines indicates that low dose of CA IX-C4.16 NPs sensitize
sorafenib for inhibiting growth of RCC cell line.
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PARTICLE SIZE DISTRIBUTION

Appendix Figure 7.14. Particle size of NFs and the particle size distribution from DLS.
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Appendix Figure 7.15. M1/M2 Activation procedure.
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ABSTRACT
TUMOR MULTICOMPONENT TARGETING POLYMER-LIPID HYBRID
NANOPARTICLES TO OVERCOME DRUG RESISTANCE IN RENAL CELL
CARCINOMA
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Renal Cell Carcinoma (RCC) contributes to more than 90% of the most common form of
kidney tumor and remains one of the ten leading causes of cancer death in the United States.
Although surgery remains an option for operable tumors, high metastatic index and resistance to
radiation and chemotherapies prompted recent development of therapeutics that target the RCC
angiogenesis and cell proliferation pathways. Eventually, new strategies with encouraging results
have emerged that include immunotherapy, such as the programmed death-1 inhibitor
(Nivolumab), cytokines, and a combination of chemo-immune therapy. Thus, developing
alternative strategies with effective treatment options remains an urgent unmet need for therapyresistant RCC. In this regard, combination treatment targeting different cancer survival pathway
of tumor microenvironment can be advantageous. Along these lines, we have pursued different
combination drug regimens, including inhibitors that target mTOR (everolimus) and RTK or
VEGFR (cabozantinib or sorafenib), as possible treatment strategies. In addition, we explored the
rational design of nanoparticles to selectively deliver a variety of therapeutic payloads to target
hypoxic tumor microenvironment overexpressing carbonic anhydrase-IX (CA IX). Our strategy
involved establishing a library of tumor penetrating nanocarriers carrying combination drug
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payload of RTK-inhibitor with our own apoptosis inducer/CARP-1 protein functional mimetics
(CFM-4.16). Nano-carriers were tailored to have varying composition and size that could: (i)
efficiently reach the tumor core; (ii) target tumor multi-components including cancer epithelial
cells and tumor-associated macrophages (TAM) for overcoming drug resistance in RCC.
Specifically, the current work was focused on multimodal approaches, including (a) Optimization
of hypoxia marker (CA IX) targeted polymer-lipid nano-formulation (PLNP) using copper-free
‘click’ chemistry; (b) In vitro and in vivo pre-clinical imaging and therapy of PLNP loaded with
multiple drugs in inhibiting RCCs using mice bearing resistant RCCs and human cancer mimicking
patient-derived xenografts (PDx). The results of antitumor efficacy and biodistribution of targeted
PLNPs in animals bearing RCC xenograft and PDx models revealed selective accumulation of
drugs at tumor sites resulting in greater tumor growth inhibition with reduced side effects. These
findings portent promising therapeutic potentials for our newly developed hypoxia-targetedPLNPs loaded with CFM-4.16 in combination with RTK-inhibitor for effective RCC therapy in
the clinic.
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